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Already in ancient times, semisolid preparations for cutaneous application, popularly known
as ointments, played an important role in human society. An advanced scientific investigation of
“ointments” as dosage forms was set off in the late fifties of the previous century. It was only from
then on that the intensive physico-chemical characterization of ointments as well as the inclusion of
dermatological aspects led to a comprehensive understanding of the various interactions between the
vehicle, the active ingredient, and the skin.
In the meantime, many researchers have been involved in optimizing semisolid formulations with
respect to continuously changing therapeutic and patient needs. Aspects that have been dealt with
are the optimization of dermato-biopharmaceutical properties and many different issues related to
patient’s compliance, such as skin tolerance, applicability, and cosmetic appeal. Moreover, processing
technology has been improved and analytical techniques developed and refined in order to enable
improved characterization of the formulation itself as well as its interaction with the skin.
This Special Issue serves to highlight and capture the contemporary progress and current research
on semisolid formulations such as dermal drug delivery systems. We gathered articles on different
aspects of semisolid formulations highlighting the research currently undertaken to improve and better
understand these complex drug delivery systems, in particular with respect to formulation, processing,
and characterization issues.
This Special Issue comprises 12 articles featuring the various aspects of semisolids, which mainly
comprise but are not limited to cutaneous application.
Three papers in this Special Issue deal with formulations intended to treat wounds. In particular,
the paper by Ghaffar et al. describes a concept to enhance the gelling ability of an oleogel consisting of
sunflower oil and a birch bark extract where the triterpene extract functions as the active substance as
well as the gelling agent [1]. In order to save the extract, the authors studied several additives, which
can act as linkers between the extract particles and thereby enhance the formation of a particulate
network. The most pronounced effect was observed in diols with terminal hydroxyl groups, e.g.,
1,6-Hexanediol. In contrast, 1,2-diols impaired gel formation by blocking superficial OH groups on the
extract particles.
The contribution of Ternullo et al. describes ‘’Curcumin-In-Deformable Liposomes-In-Chitosan-
Hydrogel as a Novel Wound Dressing” that utilizes the wound-healing potential of both curcumin and
chitosan [2]. Most promising results were achieved with positively charged deformable liposomes.
They proved to stabilize the formulation’s bioadhesiveness and allowed sustained permeation of
curcumin through ex-vivo fullthickness-human skin. The developed advanced dermal delivery system
therefore seems to be a promising candidate as a wound dressing.
As third article on wound healing, Lee et al. present results of ‘’In-Situ Hydrogel-Forming/Nitric
Oxide-Releasing Wound Dressing for Enhanced Antibacterial Activity and Healing in Mice with
Infected Wounds” [3]. The formulation is a dry powder consisting of alginate, pectin, PEG, and
S-nitrosoglutathione, which shows good storage stability. When applied to wounds, it absorbs wound
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fluid and transforms it into an adhesive hydrogel that enables a controlled NO release property for the
effective treatment of infected wounds.
The paper of Liu et al. is entitled “Systematic Investigation of the Effect of Non-Ionic Emulsifiers
on Skin by Confocal Raman Spectroscopy—A Comprehensive Lipid Analysis” [4]. The article deals
with the effect of topically applied emulsifiers on the qualitative and quantitative composition of the
stratum corneum lipids. Using confocal Raman spectroscopy (CRS), the authors could demonstrate that
polyethylene glycol (PEG) sorbitan esters revealed no alteration of intercellular lipid properties, while
PEG-20-ethers appeared to have the most significant effects on reducing lipid content and interrupting
lipid organization. Thus, CRS was shown to be a valuable tool to characterize the molecular effects
of nonionic emulsifiers on skin lipids and further deepen the understanding of enhancing substance
penetration with reduced skin barrier properties and increased lipid fluidity.
Formulation development for treatment of various skin diseases is the topic of the following
three papers.
Schmidberger et al. present a study dealing with the ”Optimization of Rheological Behaviour and
Skin Penetration of Thermogelling Emulsions with Enhanced Substantivity for Potential Application in
Treatment of Chronic Skin Diseases” [5]. The aim of this study was to find an innovative formulation
with increased substantivity allowing for a controlled cutaneous drug release, reduced application
frequency, and diminished contamination of patients’ environment with the active ingredients. This
was achieved by adding high amounts of methyl cellulose to a cream, which changes the formulation
into a predominantly elastic body at skin surface temperature.
Berenguer and coworkers present results on a ‘’Topical Amphotericin B (AmB) Semisolid Dosage
Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex-Vivo Skin Permeation
and Biological Activity” [6]. The study describes an AmB gel that proved to be stable for 60 days
at 4 ◦C and showed characteristics that made it favorable for cutaneous application. As desired,
ex-vivo permeation experiments revealed that neither application to damaged nor to nondamaged
skin produced detectable concentration of AmB in the receptor fluid. Furthermore, no cytotoxic effects
were observed in the macrophage or in the keratinocyte cell lines. This makes the AmB gel a promising
candidate for further evaluation of its activity and efficacy in the treatment of cutaneous leishmaniasis.
Finally, the article of Rancan and coworkers deals with ‘’Dermal Delivery of the
High-Molecular-Weight Drug Tacrolimus by Means of Polyglycerol-Based Nanogels” [7]. The authors
show that tacrolimus formulated as ointment or nanogel suspension penetrates skin with different
efficiency in dependence on SC thickness and integrity. Irritation effects of tacrolimus ointment
and nanogel formulations, reflected by the released inflammatory cytokines IL-6 and IL-8, were
more pronounced in barrier-disrupted and immuno-activated skin. The results support the key
role of the SC as barrier for drug and nanocarrier penetration and underline the critical balance
of penetration enhancement and potential increase of side effects. All in all, the results suggest
that nanogel suspensions are valuable dermal delivery systems for high molecular weight, poorly
water-soluble drugs like tacrolimus.
Four of the remaining articles deal with the investigation of skin penetration and permeation.
Zsikó et al. provide a “Comparison of Skin Penetration Testing Methods based on a Nanostructured
Lipid Carrier (NLC) Gel for the Dermal Application of Lidocaine” [8]. As expected, drug release
profiles of the Lidocaine-NLC gel obtained with the different techniques were not fully equivalent. The
various tested synthetic membranes were shown to be useful tools to examine the permeation/release
of an active from a dermal formulation. The presented results can be used to guide formulators in
selecting appropriate vehicles. However, no general recommendation can be made and it is still a
challenging task for researchers to select the most suitable membrane to be used with Franz cells for
topical product testing.
Rath et al. present in their article ‘’A Validated In-Vitro Release Test (IVRT) Method to Assess
Topical Creams Containing Metronidazole Using a Novel Approach” [9]. The reported IVRT method
was carefully developed and comprehensively validated to assess the release of metronidazole from
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cream products, taking into account the various parameters that may affect the API release rate. The
presented data indicate that the developed IVRT method can be applied to accurately and precisely
assess “sameness” and differences between various metronidazole cream products as a valuable
procedure in formulation development.
Zhang et al. summarize in their article results on the ‘’Influence of Binary and Ternary Solvent
Systems on the Topical Delivery of Niacinamide” [10]. Binary systems consisting of propylene glycol
(PG) and some fatty acids showed enhanced skin penetration. However, the correlation for the
permeation data of binary and ternary systems in Skin (Parallel Artificial Membrane Permeability
Assay) PAMPA and in porcine skin was limited. It could be clearly improved by excluding the PG-Oleic
Acid and PG-Linoleic Acid systems, indicating that there is still a lack of knowledge concerning specific
interactions between the Skin PAMPA model and penetration-enhancing excipients.
“Preparation, Characterization and Dermal Delivery of Methadone” is the title of the article
by Kung et al. [11]. They tested a range of solvents using ex-vivo permeation and mass balance
method in porcine skin. Their data identified octyl salicylate, d-limonene, Transcutol®, and ethyl
oleate as the most promising penetration enhancer for methadone base. Furthermore, maximum skin
flux was estimated. Although the study confirms skin permeation of methadone base, the outcome
was suboptimal as the majority of the active remained on the skin surface after 24 h under finite
dose conditions.
Last but not least, the article that does not deal with dermal application describes a ‘’Mucoadhesive
Budesonide Formulation for the Treatment of Eosinophilic Esophagitis (EE)” [12]. The authors present
results from a study that revealed a standardized budesonide oral formulation intended to improve the
resistance time of the drug on the esophageal mucosa for EE treatment. The development focused on
the formulation’s physicochemical stability and the main critical quality attributes of the formulation,
e.g., rheological properties, syringeability, mucoadhesiveness, and in-vitro penetration of budesonide
in porcine esophageal tissue. The optimized formula demonstrated that the used gums enable a
prolonged residence time in the esophagus.
The purpose of this Special Issue was to provide an overview of recent advances in the field of
semisolid formulations. Following the results of the interesting articles collected for this Special Issue,
we can conclude that although semisolids already played an important role in human society in ancient
times there is still innovative research in this field adding new pieces to the jigsaw puzzle.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: Non-ionic emulsifiers are commonly found in existing pharmaceutical and cosmetic
formulations and have been widely employed to enhance the penetration and permeation of active
ingredients into the skin. With the potential of disrupting skin barrier function and increasing fluidity
of stratum corneum (SC) lipids, we herein examined the effects of two kinds of non-ionic emulsifiers
on intercellular lipids of skin, using confocal Raman spectroscopy (CRS) with lipid signals on skin
CRS spectrum. Non-ionic emulsifiers of polyethylene glycol alkyl ethers and sorbitan fatty acid esters
were studied to obtain a deep understanding of the mechanism between non-ionic emulsifiers and
SC lipids. Emulsifier solutions and dispersions were prepared and applied onto excised porcine
skin. Water and sodium laureth sulfate solution (SLS) served as controls. SC lipid signals were
analysed by CRS regarding lipid content, conformation and lateral packing order. Polyethylene
glycol (PEG) sorbitan esters revealed no alteration of intercellular lipid properties while PEG-20
ethers appeared to have the most significant effects on reducing lipid content and interrupting lipid
organization. In general, the polyoxyethylene chain and alkyl chain of PEG derivative emulsifiers
might indicate their ability of interaction with SC components. HLB values remained critical for
complete explanation of emulsifier effects on skin lipids. With this study, it is possible to characterize
the molecular effects of non-ionic emulsifiers on skin lipids and further deepen the understanding of
enhancing substance penetration with reduced skin barrier properties and increased lipid fluidity.
Keywords: non-ionic emulsifiers; intercellular lipids; confocal Raman spectroscopy (CRS);
polyethylene glycol alkyl ethers; polyethylene glycol sorbitan fatty acid esters
1. Introduction
Skin represents the largest organ of the human organism and forms the outermost barrier film
that protects the human body from external environment impacts and exogenous irritations and
corrosions. Stratum corneum (SC) is the uppermost layer of the skin, composed of a highly ordered,
multilamellar lipid matrix with embedded flattened, keratin-filled corneocytes [1,2]. The particular
intercellular lipids in SC consist of ceramides, free fatty acids and cholesterol in an approximately
equimolar ratio [3,4]. It has been well accepted that intercellular lipids in SC play an important role in
maintaining skin barrier function and keeping the skin in a proper hydration state [5]. The removal
and organizational alteration of intercellular lipids would disrupt the barrier function from multiple
aspects and deteriorate into some chronic skin diseases [6,7]. With the importance of assuring the
solid structures and ordered properties of skin lipids, it is essential to monitor the molecular lipid
interactions with exposed substances and maintain the protective barrier state for further optimization
of dermatological treatments.
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In everyday life, the skin is exposed to different environments and mostly exposed to various
sanitary and cosmetic products and cleansers. Among the main components of them, non-ionic
emulsifiers have been widely used and become the potential class to be exposed on the skin and may
simultaneously interact with molecular skin components [8,9]. Although non-ionic emulsifiers are
usually considered to be relatively safe and better tolerated in comparison to cationic and anionic
emulsifiers, they have been proved having the potential to interact with biological membranes,
especially skin, with their increasing applications [10–12]. In particular, recent studies from our group
found that polyethylene glycol (PEG)-20 glycerol monostearate displayed negative effects on skin lipid
extraction and structural disruption while polysorbate 80 reflected no such effects [13,14]. For this
reason, the selection and usage of non-ionic emulsifiers in pharmaceutical and cosmetic formulations
are currently of high interest. In order to gain mechanistic insights into their skin effects, PEG alkyl
ethers and sorbitan fatty acid esters (e.g., polysorbate or Tween) were taken into consideration which
are both non-ionic PEG derivatives. They are composed of a hydrophilic polyoxyethylene head group
and a lipophilic alkyl chain. Keeping constant either of these two parts, the other part of size and chain
length etc. would be potential parameters to monitor the governing rules [15]. Furthermore, these
two groups of emulsifiers are widely applied in cosmetic and dermal products due to their solubility
and viscosity properties with low toxicity according to the existing safety assessments identified in
previous studies [16,17]. We therefore chose to further investigate these two groups of emulsifiers in a
systematic approach and evaluate their possibilities for prospective development of skin products
with relatively mild effects on skin lipids [18].
Up to now, considerable number of studies have made efforts on obtaining more information
about the quantitative and structural properties of skin lipids [19–21]. The means of small- and
wide-angle X-ray scattering, neutron scattering, and liquid chromatography coupled with mass
spectrometry have been intensively applied. However, those methodologies have potential risks of
sample contamination, being time-consuming and sample destruction [22,23]. In this area confocal
Raman spectroscopy (CRS) has emerged as a promising non-invasive tool in skin research and caught
increasing attention for skin characterizations such as skin penetration and permeation of topically
applied materials [24,25]. CRS is also an efficient and label-free method and has been increasingly used
to study the macroscopic alterations of skin properties with humidity changes, age difference and hair
removal comparisons [26–28]. Detailed information about biochemical molecules can be obtained from
CRS, including the chemical structure, phase and molecular interactions. Recent findings from our
group have demonstrated that CRS could be used as an alternative method to analyze lipid extraction
and conformation in SC [13,14]. Based on this proof and listed advantages, CRS was used in this study
as a useful and convenient approach for lipid analysis.
For studying the physiological parameters of SC lipids, many researchers have focused on finding
spectral signals in CRS for skin research [29,30]. Those spectral signals in this study are the identified
Raman bands associated with molecular vibrations of lipids inside the skin. They are originated
from the methylene (−CH2−) and methyl (−CH3) groups in lipid molecular structures. Using them a
comprehensive study measuring lipid content, conformational order, lateral packing order and SC
thickness could be conducted at the same time. However, the skin CRS spectrum is extremely complex
and the lipid-derived Raman bands usually overlap with bands originating from molecular vibrations
of proteins [19,31]. In order to track the individual lipid-related spectral signals, a Gaussian-function
based mathematical procedure could be applied on account of a previous report from Choe et al. [32].
As we know, many hypotheses regarding the interactions between emulsifiers and skin are
still not well grounded [33], making it essential to perform a systematic investigation of non-ionic
emulsifiers. Therefore, the aim of this study is to use different lipid-related spectral signals to analyse
the interactions between non-ionic emulsifiers and intercellular lipids. PEG alkyl ethers and sorbitan
fatty acid esters were selected. To the best of our knowledge, this is the first systematic report
considering PEG derivatives with different number of oxyethylene groups and different hydrophobic
alkyl chain lengths using CRS to better understand their mechanism of influence on skin components.
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Results should be helpful to find a rule for further selections of non-ionic emulsifiers which is beneficial
to the development of skin products.
2. Materials and Methods
2.1. Materials
PEG alkyl ethers including PEG-2 oleyl ether (O2), PEG-10 oleyl ether (O10), PEG-20 oleyl
ether (O20), PEG-2 stearyl ether (S2), PEG-10 stearyl ether (S10), PEG-20 stearyl ether (S20),
PEG-2 cetyl ether (C2), PEG-10 cetyl ether (C10), PEG-20 cetyl ether (C20) were purchased from
Croda GmbH, (Nettetal, Germany). PEG sorbitan fatty acid esters containing PEG-20 sorbitan
monopalmitate (Polysorbate 40, PS40), PEG-20 sorbitan monostearate (Polysorbate 60, PS60), PEG-20
sorbitan monooleate (Polysorbate 80, PS80) were obtained from Caesar & Loretz GmbH (Hilden,
Germany). Sodium lauryl sulfate (SLS) was obtained from Cognis GmbH & Co. KG (Düsseldorf,
Germany). Trypsin type II- S (lyophilized powder) and trypsin inhibitor (lyophilized powder) were
obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Parafilm® was from Bemis
Company Inc., (Oshkosh, WI, USA). Sodium chloride, disodium hydrogen phosphate, potassium
dihydrogen phosphate, and potassium chloride were of European Pharmacopoeia grade. All aqueous
solutions were prepared with ultra-pure water (Elga Maxima, High Wycombe, UK). Porcine ear
skins (German land race; age: 15 to 30 weeks; weight: 40 to 65 kg) were provided by Department of
Experimental Medicine at the University of Tuebingen. The Department of Pharmaceutical Technology
at the University of Tuebingen has been registered for the use of animal products [13].
2.2. Preparation of Dermatomed Porcine Ear Skin
Porcine ear skin was selected as substitute for human skin in this study due to their histologically
and morphologically similarity with human skin [34,35]. Porcine ears used in this study were achieved
from the Department of Experimental Medicine of the University Hospital Tuebingen. The live animals
used were kept at the Department of Experimental Medicine and sacrificed in the course of their
experiments, which are approved by the ethics committee of the University Hospital Tuebingen. Those
ears were received directly after the death of the animals. Prior to study start, the Department of
Pharmaceutical Technology has registered for the use of animal products at the District Office of
Tuebingen (registration number: DE 08 416 1052 21). Fresh porcine ears were cleaned with isotonic
saline. Full-thickness skin was removed from cartilage and gently cleaned from blood with cotton
swabs and isotonic saline. The obtained postauricular skin sheets were then dried with soft tissue,
wrapped with aluminium foil and stored in freezer at −30 ◦C. On the day of experiment, skin sheet
was thawed to room temperature, cut into strips of approximately 3 cm width and stretched onto a
Styrofoam plate (wrapped with aluminium foil) with pins to minimize the effect of furrows. Skin hairs
were trimmed to approximately 0.5 mm with electric hair clippers (QC5115/15, Philips, Netherlands).
Subsequently, the skin was dermatomed to a thickness of 0.8 mm (Dermatom GA 630, Aesculap AG &
Co. KG, Tuttlingen, Germany) and punched out for circles to a diameter of 25 mm.
2.3. Incubation of Porcine Ear Skin in Franz Diffusion Cells
Franz diffusion cells have been commonly used as a specific analytical setup for ex vivo
determination of skin absorption. Here, degassed, prewarmed (32 ◦C) phosphate buffered saline
(PBS) was used as receptor fluid and filled in the Franz diffusion cells of 12 mL. The stirring speed
of the receptor fluid was 500 rpm. The dermatomed skin circles were mounted onto the cells with
donor compartment on above. The equipped Franz diffusion cells were put into water bath with
temperature of 32 ◦C. After a short equilibrium of 30 min, 1 mL of each emulsifier solution/dispersion
was applied to each skin sample (all non-ionic emulsifiers used in this study are listed in Table 1 with
detailed information). Then, a piece of parafilm was capped onto each donor compartment to prevent
evaporation. After 4 h incubation, skin samples were removed from cells and each skin surface was
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gently washed and cleaned with isotonic saline and cotton swabs for 30 times in order to remove the
remaining samples and avoid erroneous measuring result. Finally, the actual application area (15 mm
in diameter) was punched out and patted dry with cotton swabs. This part of the method has been
detailly described by our group [13].
Table 1. Characteristics of non-ionic emulsifiers including polyethylene glycol (PEG) alkyl ethers and










PEG-2 oleyl ether Oleyl alcohol C18, C9–C10 unsaturated 2 O2 5.0
PEG-10 oleyl ether Oleyl alcohol C18, C9–C10 unsaturated 10 O10 12.4
PEG-20 oleyl ether Oleyl alcohol C18, C9–C10 unsaturated 20 O20 15.3
PEG-2 stearyl ether Stearyl alcohol C18 2 S2 4.9
PEG-10 stearyl ether Stearyl alcohol C18 10 S10 12.4
PEG-20 stearyl ether Stearyl alcohol C18 20 S20 15.3
PEG-2 cetyl ether Cetyl alcohol C16 2 C2 5.3
PEG-10 cetyl ether Cetyl alcohol C16 10 C10 12.9
PEG-20 cetyl ether Cetyl alcohol C16 20 C20 15.7
PEG-20 sorbitan
monopalmitate Palmitic acid C16 20 PS40 15.6
PEG-20 sorbitan
monostearate Stearic acid C18 20 PS60 14.9
PEG-20 sorbitan
monooleate Oleic acid C18, C9–C10 unsaturated 20 PS80 15
2.4. Isolation of Stratum Corneum
The stratum corneum was isolated following the trypsin digestion process as described by
Kligman et al. and Zhang [14,36]. This isolation procedure has been proved to have no influence on
the lamellar lipid organization [37]. The obtained skin circles (with diameter of 15 mm) from last step
were placed dermal side down on filter paper soaked with a 0.2% trypsin and PBS solution. After the
incubation of skin sample for overnight at room temperature, digested SC was peeled off gently and
immersed into 0.05% trypsin inhibitor solution for 1 min. Afterwards, the isolated SC was washed
with fresh purified water for min. five times to remove the underlayer tissues. The final obtained SC
sheet was then placed onto glass slide and stored in desiccator to dry for min. three days.
2.5. Confocal Raman Spectroscopy (CRS)
In order to investigate the effects of different non-ionic emulsifiers on SC, CRS served as the
primary instrument to detect their differences. After drying, the SC sheets were taken out of the
desiccator and fitted onto the scan table of alpha 500 R confocal Raman microscope (WITec GmbH,
Ulm, Germany). This CRS device was equipped with a 532-nm excitation laser, UHTS 300 spectrometer
and DV401-BV CCD camera. To avoid the damage of skin sample due to higher laser intensity, the laser
power used was 10 mW, which could be adjusted using the optimal power meter (PM100D, Thorlabs
GmbH, Dachau, Germany). A 100× objective with numerical aperture of 0.9 (EC Epiplan-neofluor,
Carl Zeiss, Jena, Germany) was used to focus the light on skin surface. The backscattered light from
the skin was then dispersed by an optical grating (600 g/mm) to achieve the spectral range from
400–3800 cm−1. Collected scattered light was analysed on a charge-coupled device (DV401-BV CCD
detector) which had been cooled down to −60 ◦C in advance. The CRS measurements were performed
based on a method developed by Zhang et al. [13,14].
2.6. Determination of Skin Surface and Thickness
In order to achieve spectral signals of lipids from skin surface and measure SC thickness at the
same time, the spectra were detected with the focus point moving from −50 μm beneath the skin to
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50 μm above the skin. The spectra were recorded with the step size of 1 μm. The skin surface was
determined using the intensity difference of keratin signal (ν (CH3), 2920–2960 cm−1). The area under
the curve (AUC) of the keratin peak was calculated and plotted against depth. While the intensity of
the keratin signal reaches the half maximum, the laser spot would be located at the boundary between
glass slide and skin bottom or the boundary between skin surface and air [13,38]. So that the spectrum
extracted from the boundary between skin surface and air was regarded as skin surface and used for
lipid signal analysis. Moreover, with the description above, the full width of half maximum (FWHM)
could serve as the thickness of skin sample.
2.7. Lipid Signals in Fingerprint Region
2.7.1. C–C Skeleton Vibration Mode
The first three small peaks in Figure 1 highlighted in red are assigned to the vibration of C–C
skeleton. They are sensitive to the trans–gauche conformational order of long chain hydrocarbons
which exist mostly in intercellular lipids [39,40]. The peaks located at 1060 cm−1 and 1130 cm−1 arise
from all-trans conformation which stand for a more ordered state of lipids. The peak at 1080 cm-1
corresponds to the gauche conformation which represents a more disordered state of lipids [41,42].
In this case, PCA analysis and polynomial background subtraction are needed to remove the noise
and obtain a more precise result. On the other hand, the band at 1130 cm−1 contains part of the
contribution of keratin at 1125 cm−1. As a result, an adequate integration area is selected to eliminate
the influence of keratin peak. Then, the conformational order could be calculated with the ratio of AUC
of those three peaks: conformational order = AUC1080 / (AUC1060 + AUC1130) as originally described
by Snyder, et al. [43]. Thus, a higher value of conformational order represents an indication to the
gauche conformation and disordered state of lipids.
Figure 1. Major band assignments of CRS spectrum obtained from skin sample. The red/blue areas
represent the specific peak referring to different molecular vibrations. The break on the axis of
wavenumber separates the fingerprint region (left side) and high wavenumber region (right side).
The peaks assigned to trans and gauche conformations are both originated from C–C skeleton vibration.
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2.7.2. CH2 Twisting and Scissoring Mode
The peak located at about 1300 cm−1 in Figure 1 is assigned to the CH2 twisting mode. The shift
of this peak could also indicate the order or disorder of lipid conformations because of the sensitivity
of this peak to hydrocarbon chains [44]. The broadening and shift to a higher wavenumber of
this peak indicates a tendency of intercellular lipids turning into a more disordered and gauche
conformation state.
Apart from the detection of conformational order on Raman spectra, vibrational characteristics
are also convenient to determine the lateral packing state (orthorhombic order, hexagonal order,
and liquid-like chain packing) influenced by the intramolecular interactions [44]. The CH2 scissoring
band at 1430–1470 cm−1 reflects the nature of lateral packing between ceramide molecules. The shift of
this peak to a higher wavenumber in the Raman spectrum stands for a more hexagonal or even liquid
like packing state.
2.7.3. CH2 and CH3 Stretching and C=O Vibration Mode
The last two bands marked in fingerprint region of Figure 1 are assigned to δ (CH2, CH3)– mode
at 1425–1490 cm−1 and ν (C=O)– mode at 1630–1710 cm−1 respectively. The band at 1630–1710 cm−1
arises from the Amide I mode which showed the least variation within one donor or among different
donors. Thus, this band has been often used in the normalization of other Raman peaks derived
from SC [30,42]. The band at 1425–1490 cm−1 originates from both keratins and lipids. In this study,
this band was regarded as “lipids-peak” for calculation of lipid content.
Based on the equation of Normalized lipids = AUC1425–1490/AUC1630–1710, the lipid-keratin peak
was normalized by the amide I peak. The final calculated result would indicate the content variation of
lipids. Therefore, the lipid content in fingerprint region in this study was calculated as equation above.
2.8. Lipid Signals in High Wavenumber Region
In order to achieve further information about lipid content and lateral packing order state for a
more precise and forceful result, the lipid-keratin peak (2800–3030 cm−1) in the HWN region was taken
into consideration. This band is also derived from the CH2 and CH3 vibrations.
2.8.1. Gaussian Deconvolution Process
As depicted in Figure 1, it is obvious that the peaks originated from lipids and keratins overlapped
and formed a peak with higher intensity and broad width. In order to track the information of each
peak individually, a mathematical process based on Gaussian functions was employed. As described
by Choe, the Gaussian function type exhibited the least fitting error and demonstrated to be the best
fitting function for Raman spectra of the skin [32].
In this study, the obtained spectrum of SC was deconvoluted into four Gaussian peaks automatically
with the application of curve fitting toolbox on Matlab software (version R2019a, MathWorks GmbH,
Natick, MA, USA). The summation of four Gaussian functions was used as the fitting formula. In order
to achieve reproducible result and reduce the fitting error, the Gaussian peak maximum positions and
FWHMs were allowed to vary in defined intervals only. Afterwards, a non-linear iteration process was
applied. It can be seen from Figure 2 that each fitted peak was labelled in different colour. The goodness
of fitting results could also be generated automatically with all R2 above than 0.98.
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Figure 2. Deconvolution of lipid-keratin peak from skin spectrum by using four Gaussian peaks in
high wavenumber region. The assignments were labelled with different colours.
2.8.2. ν (C–H) Symmetric and Asymmetric Stretching
As illustrated in Figure 2, peaks located at 2850 cm−1 and 2880 cm−1 stand for the ν (C–H)
symmetric and ν (C–H) asymmetric stretching mode respectively which are both derived from the
vibration of lipids. These two peaks are sensitive to the packing order of alkyl chains of lipids. Based
on some research, the ratio of the intensities of these two peaks could be used as a sign of crystalline
phase of intercellular lipids [39,45]. In this study, peak areas after deconvolution were applied for the
calculation of lateral packings Ratiolat = AUC2880/AUC2850 according to ref. [46]. This procedure has
effectively eliminated the influence of multi-peak overlap phenomenon. Hereby, the higher Ratiolat
represents a prevalence towards highly crystalline and orthorhombic phase. The lower Ratiolat reveals
a tendency towards disordered and liquid-like phase.
2.8.3. ν (CH3) Symmetric and Asymmetric Stretching
As is shown in Figure 2, the blue and orange peaks at 2930 cm−1 and 2980 cm−1 arise from
the contribution of keratins and originated from the ν (CH3) symmetric and ν (CH3) asymmetric
stretching separately. Previous studies often use the area of these two keratin related peaks to
normalize lipid related peaks in order to determine the lipid content [47,48]. As described in this
study, the AUC extracted directly in high wavenumber would contain the contribution of adjacent
peaks. The deconvolution process would exclude the influence of peak superposition. As a result,
the Gaussian areas after deconvolution were employed for calculation of lipid content: Normalized
lipid = (AUC2880 + AUC2850)/(AUC2930 + AUC2980).
2.9. Data Analysis
2.9.1. Raman Spectra Pre-Processing
The initial processing step of Raman spectra usually included the spectral cosmic ray removal,
smoothing as well as background subtraction which were all performed by the WITec Project Software
(WITec GmbH). Referring to the smoothing process, Savitzky-Golay (SG) filter was applied with third
polynomial order and nine smoothing point. For the type of background subtraction, an automatic
polynomial function was fitted to the spectrum and subtracted. Furthermore, the AUC extracted in
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this study is the integrated area under a specified peak of the spectrum and could be calculated using
trapezoidal method on WITec Project Software or MatLab software.
2.9.2. Principle Component Analysis
Multivariate data analysis was also performed on the WITec Project Software. For the study,
Principle component analysis (PCA) was employed to further analysis the grouped spectra and reduce
minor variations. PCA is the underlying method for many multivariate methods and could effectively
obtain a reduced data set from multiple dimensions. Among the grouped Raman spectra, the first
three principle components (PCs) are selected for reconstruction since they have contained most of
essential information. In this study, PCA was applied for lipid conformation analysis.
2.9.3. Statistical Analysis
Spectra data were obtained from repeated measurements (n ≥ 18). The graphs were shown
with mean values ± standard deviations (mean ± SD). Statistical differences were determined using
one-way or two-way analysis of variance (ANOVA) followed by Student-Newman-Keuls (SNK) which
were employed by GraphPad Prism 7.0 (GraphPad Software Inc., La Jolla, CA, USA). Diagrams and
statistical differences were ultimately generated. Significant differences were marked with different
number of asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001.
3. Results
3.1. Lipid Content Analysis with Normalized Lipid Signal
Lipid content in SC was analysed in the fingerprint and HWN regions by using lipid signals
normalized by keratin signals. With the aim of detecting their impacts on lipids, different non-ionic
emulsifiers were used to treat the SC, respectively. The alterations of lipid content are shown in
Figure 3a,b. As can be seen, the red bars indicate the relative lipid content in fingerprint region while
the blue bars represent the content in HWN region. It is evident that most of the PEG ethers cause
a reduction of lipid content (Figure 3a) while all the polysorbate emulsifiers show no effects on SC
lipid content (Figure 3b). Specifically speaking, the group of PEG ethers treated SC shows different
extent of lipid reduction. Among them, only O2 and S2 treated SCs indicate no effects on SC lipid
content. Focusing on the rest of the emulsifiers, all the PEG-20 alkyl ethers display to dramatically
reduce lipid content. Regarding the PEG-10 alkyl ethers, O10 shows a relatively smaller difference
compared to S10 and C10 which both indicate a greater reduction of skin lipid content. Interestingly,
only C2 in PEG-2 alkyl ethers shows a slight impact on reducing lipid content. In contrast, polysorbate
emulsifiers reflect completely no extraction of lipids. It turns out a part of this outcome is correlated
with a previous result in our group that showed 5% of polysorbate 60 had no effects on lipids [13].
In general, the result of lipid content analysis in fingerprint region is complementary to that in HWN
region and exhibited the same tendency of emulsifier effects.
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Figure 3. Normalized lipid signals in fingerprint and HWN region for lipid composition analysis of
(a) PEG alkyl ethers treated SC and (b) PEG sorbitan esters treated SC. Mean ± SD, n = 18. * p < 0.05;
** p < 0.01; *** p < 0.001.
3.2. CH2 Twisting and Scissoring Mode Analysis
CH2 twisting mode in fingerprint region was selected in this study. It is also feasible to analyse the
lipid conformational order. The band derived from CH2 twisting mode is located at about 1300 cm−1.
The band shift is sensible to the conformation of hydrocarbon chains of lipids, so that it could be used
as another conformational signal. Figure 4 shows the comparison of twisting mode between emulsifier
treated and water treated skin samples. The peak location is in between 1285–1303 cm−1. It can be
clearly seen that SLS has the most significant effect on SC lipid as the band shifts from about 1293 cm−1
to about 1299 cm−1. Among PEG ethers, relatively higher effects on lipids are caused by the PEG ether
emulsifiers with the average number of oxyethylene groups of 20 as well as O10 and S10. Interestingly,
C10 only shows small effects on lipid conformation. Nevertheless, in lipid content and C–C skeleton
conformation analysis presented above, C10 has been determined to strikingly extract lipids and
change conformational order. Apart from this slight discordance, the result is still a confirmation of
emulsifier effects on lipid signals. Further, no significant effects are noted in polysorbate emulsifier
treated SCs.
Figure 4. Lipid signals of CH2 twisting and scissoring mode for analyzing (a) PEG alkyl ethers treated
SC and (b) PEG sorbitan esters treated SC. Mean ± SD, n = 18. * p < 0.05; ** p < 0.01; *** p < 0.001.
Except for the detailed information of hydrocarbon chains of lipids, CRS is also available to
determine the lateral packing of lipids with CH2 scissoring mode in fingerprint region. Using the
peak at 1434–1452 cm−1, Figure 4 shows the differences of scissoring mode when comparing emulsifier
treated and water treated skin samples. It can be observed that some bands strikingly shift to higher
wavenumbers after treatment with emulsifiers such as PEG-20 alkyl ethers and SLS. It means that the
lateral packing tends to be transformed from orthorhombic phase to hexagonal or liquid-like phase.
C10 and S10 shows to moderately lower the lateral packing density. However, the influence of O10
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on SC is slightly lower than what we expected but similar to the impact of C10 on SC. In line with
results from C–C skeleton vibration mode analysis, the results from scissoring mode analysis show no
significant difference for polysorbate emulsifiers treated SCs.
3.3. C–C Skeleton Conformation Analysis
C–C skeleton vibrations in fingerprint region contain the all-trans signal (1060 cm−1 and 1130 cm−1)
and gauche signal (1080 cm−1) of SC lipids. With the application of non-ionic emulsifiers, lipid
conformation in SC was influenced to different degree. As displayed in Figure 5a, most of the PEG
ethers show significant effects on lipid conformation when compared with water treated SC. Especially
S10 and S20 as well as C10 and C20 present huge effects on SC lipid conformation, indicating the
intercellular lipids have more gauche conformation (more disorder state). Surprisingly, O10 and O20
only show small influence on altering lipid conformation which is even less than the impact of C2.
Whereas O2 and S2 show no effects on turning lipids into a more gauche conformation. Focusing on the
investigation of the polysorbate group, it can be seen from Figure 5b that no significant difference has
been found in polysorbate emulsifiers-treated SCs. It turns out that, with the application of polysorbate
emulsifiers, lipid conformation remains in a more trans and ordered state.
Figure 5. C–C skeleton vibration mode for lipid conformation analysis of (a) PEG alkyl ethers treated SC
and (b) PEG sorbitan esters treated SC; lateral packing order analysis by AUC ratio of band 2850 cm−1
and 2880 cm−1: (c) PEG alkyl ethers treated SC and (d) PEG sorbitan esters treated SC. Mean ± SD,
n = 18. * p < 0.05; ** p < 0.01; *** p < 0.001.
3.4. Lateral Packing Analysis in HWN Region
Commonly, the broad shaped lipid-keratin peak originated from C–H vibration in HWN region is
used to calculate lipid content and lipid lateral packing. The ratio of AUCs of 2880/2850 cm−1 has been
defined to evaluate the lateral packing density of intercellular lipids. In this spectral region, peaks
reflecting vibrations of SC lipids overlap with peaks derived from keratin. After the deconvolution
process of lipids-keratin signals, the calculation of lateral packing in HWN is more precise owing to
the exclusion of keratin peak influences.
As the results shown in Figure 5c, O20 and C20 have the highest effects on decreasing the lateral
packing density which are nearly the same as the effect of SLS. C10 tends to transform the lipid structure
to hexagonal phase (more disordered structure). In addition, O10, S20 as well as C2 treated SC only
indicate relatively lower effects. Whereas S10 treated SC unexpectedly presents no statistical difference
which is unlike the lateral packing result shown in the scissoring mode analysis. The results depicted
in Figure 5d reconfirmed that polysorbate emulsifiers appeared to exert no significant effects on SC
lipids and maintained the orthorhombic structure of intercellular lipids.
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3.5. Skin Thickness Measurement
The thickness of skin samples was measured after the treatment with different emulsifiers. It has
to be noted that SC thickness was measured on dried SC sheets and will thus give lower values
as in (hydrated) full thickness skins. With the comparison to references, the results are shown in
Figure 6. It is apparent from Figure 6a that the water treated SC was measured to be the thickest
with the average thickness of 4.50 ± 0.64 μm. In contrast, SLS treated SC exhibited the thinnest skin
samples (2.55 ± 0.54 μm), followed by the C20 and C10 treated SC with thickness of 2.84 ± 0.69 μm and
3.27 ± 1.20 μm respectively. O10 and O20 treated SC showed a tendency towards a reduced thickness
as well. Unexpectedly, no indication was found of reduction of SC thickness after treatment with S10.
In another experiment depicted in Figure 6b, the water treated SC was measured to have the thickness
of 4.04 ± 1.16 μm, while the polysorbate emulsifiers treated SCs showed no significant difference when
compared with water treated SC.
(a) (b) 
Figure 6. Thickness of SC after treatment with (a) PEG alkyl ethers treated SC and (b) PEG sorbitan
esters treated SC. Mean ± SD, n = 18. * p < 0.05; ** p < 0.01; *** p < 0.001.
4. Discussion
Throughout this study, different spectral signals were utilized to analyse the effects of non-ionic
emulsifiers on SC lipids. The result of lipid content analysis was achieved with the combination of lipid
spectral signals from fingerprint region and HWN region. We could clearly see that PEG ethers were
more capable to extract the lipids from SC than polysorbate emulsifiers. Meanwhile, both results of
lipid content analysis were in good correlation with each other. It proved that after curve fitting process,
the lipid-keratin peak ratio could serve as a sensitive lipid signal to calculate the lipid content. As an
alternative, the lipid-keratin peak ratio in fingerprint region may be used and gives similar results.
The conformational analysis was evaluated in this study with the band shift of the twisting
mode and calculated by the ratio of three small peaks related to gauche/trans conformation which
originated from the C–C skeleton vibration bands. In view of the same tendency of detected
emulsifier effects, both of the lipid spectral signals are capable to analyse lipid conformation accurately.
However, comparing a series of complicated data processing steps in C–C skeleton vibration features,
the prominent peak shift related to CH2 twisting mode at about 1300 cm−1 would be a better choice
and less time-consuming.
There was a slightly difference in lipid analysis of lateral packing density. The ratio calculated by
2880/2850 cm−1 revealed that S10 had no significant effect. Whereas the results of scissoring mode
indicated significant difference (p < 0.01). Although the deconvolution process has eliminated the
influence of the keratin signal in the HWN region, the differences between results from S10 treated SC
and water treated SC are not large enough to reach statistical significance. With the consideration of
minor errors may result from the curve fitting process, the signal of scissoring mode might provide a
more sensitive and efficient detection in our further study.
As the preliminary study of our group presented, the thinning of SC was assumptively caused by
the extraction of lipids, subsequently leading to a loosened cohesion of SC and thereby fascinating
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keratinocytes removal [13]. In the skin thickness analysis of present work, most results complied
with expectations and previous findings although the results of S10 and C2 reflected inconsistent with
former lipid signals which may be triggered by the influence of different donors. The thinner the SC
thickness originally, the less accurate the measuring result. Besides, the isolation of SC may also induce
measurement errors.
Since this systematic study has proved that non-ionic emulsifiers have the potential to interact
with SC lipids, we may find some rules or mechanisms to explain the ability of them to extract lipid
components and decrease lipid order of SC. First, their capability to affect SC lipids might be governed
by their structural properties as they contain both polar head region of hydrophilic chain and nonpolar
tail region of hydrophobic chain. The characteristics of non-ionic emulsifiers used in this study has
been listed in Table 1. As the influence of PEG ethers on SC shown, we may suggest that the higher
the average number of oxyethylene groups, the stronger the interaction between PEG ethers and SC
lipids. Meanwhile, the alkyl chain was highlighted in the potency of emulsifier interaction with SC
lipid as well. With the results shown in this study, C2 appeared to be the only emulsifier to reduce lipid
content and increase lipid disorder compared to other PEG-2 ethers. As they own the same number of
oxyethylene groups, we may speculate that PEG derivatives with less carbon numbers of alkyl chain
present higher ability to disturb SC lipid properties. Furthermore, keeping constant the number of
carbon atoms in hydrophobic chain, similar effects of PEG oleyl ethers (unsaturated alkyl chain, C18)
and PEG stearyl ethers (saturated alkyl chain, C18) on SC lipids were observed. We might then assume
that with the same length of alkyl chain, the double bound only show little impact on SC lipids.
In the present study of polysorbate emulsifiers, they have been confirmed to have no influence on
SC lipids, although they have longer polyoxyethylene chain (n = 20) and different length of alkyl chain.
In this case, the molecular weight and structures could also serve as underlying factors for explaining
the effects of polysorbate emulsifiers. The molecular structures of PEG ethers and esters used in this
study are given in Table 2. It is apparent that polysorbate emulsifiers have larger molecular structure
sizes which are expected to make it difficult for them to penetrate the skin and interact with SC lipids.
Furthermore, although a recent finding from another group revealed a slight toxicity of polysorbate
emulsifiers towards skin cells, it is not contradictory to our results that presented more friendly effects
of them on skin lipids [49]. Our investigation suggests that polysorbates do not penetrate the skin and
thus do not reach the deeper levels of the skin where living cells are located. Thus, it can be concluded
that they may be regarded as safe excipients as long as they are not taken up into viable cell layers.
Meanwhile, the emulsifier incorporated in various formulations may also display different influence
on skin properties [13,49].
Last, according to the HLB values listed in Table 1, we first expect that the HLB values of non-ionic
emulsifiers correlate to their effects on SC lipids. We could suggest from the result of PEG ethers that
the higher the HLB value, the more intensive effects of emulsifiers on SC lipids. However, C2 with
HLB value of 5.3 sometimes revealed relatively similar influence with O10 and S10 (HLB value 12.4).
More strikingly is that all polysorbate emulsifiers present no effects on SC lipids with HLB values all
around 15. Therefore, we may conclude that HLB value alone is not a reliable predictor of interactions
between non-ionic emulsifiers and SC lipids. On the other hand, the molecular weight and structures
may be the main factor of polysorbate emulsifiers to interact with skin lipids. Concerning these
debatable factors, further research needs to be done for deeper understandings of possible mechanisms
to describe how non-ionic emulsifiers penetrate the skin and interact with skin components.
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5. Conclusions
This study systematically examined the effects of non-ionic emulsifiers, including PEG alkyl ethers
and PEG sorbitan fatty acid esters, on SC lipids. CRS was employed in this study as a non-invasive,
efficient and versatile instrument. Different spectral signals of CRS in both fingerprint and HWN
regions were applied to assess the alteration of lipid content, conformation, lateral packing order
and SC thickness which caused by the interaction of non-ionic emulsifiers with SC. To sum up, it has
been demonstrated that the results of conformation and lateral packing order analysis were basically
correlated with the results of content analysis, indicating that the extraction of lipids from SC may
disturb the lipid structures in SC, and to some extent weaken the skin structural integrity. Furthermore,
our results so far implied that non-ionic emulsifiers of polysorbates as well as PEG ethers with a smaller
number of oxyethylene groups would be better choices to incorporate into topical formulations due
to their lower effects regarding extraction of lipids, interruption of lipid organizations and further
damage of skin barrier functions.
Overall, based on these findings, the assessment of different lipid signals played a meaningful
role to filtrate more effective spectral features for deeper differentiations. This research on non-ionic
emulsifiers could also serve as a basis and be helpful to screen suitable emulsifiers for further
formulation development.
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33. Savić, S.; Weber, C.; Savić, M.M.; Müller-Goymann, C. Natural surfactant-based topical vehicles for two
model drugs: Influence of different lipophilic excipients on in vitro/in vivo skin performance. Int. J. Pharm.
2009, 381, 220–230. [CrossRef] [PubMed]
34. Jacobi, U.; Kaiser, M.; Toll, R.; Mangelsdorf, S.; Audring, H.; Otberg, N.; Sterry, W.; Lademann, J. Porcine ear
skin: An in vitro model for human skin. Ski. Res. Technol. 2007, 13, 19–24. [CrossRef] [PubMed]
35. Tfaili, S.; Gobinet, C.; Josse, G.; Angiboust, J.F.; Manfait, M.; Piot, O. Confocal Raman microspectroscopy for
skin characterization: A comparative study between human skin and pig skin. Analyst 2012, 137, 3673–3682.
[CrossRef] [PubMed]
36. Kligman, A.M. Preparation of Isolated Sheets of Human Stratum Corneum. Arch. Dermatol. 2011, 88, 702.
[CrossRef] [PubMed]
37. Van Smeden, J.; Janssens, M.; Gooris, G.S.; Bouwstra, J.A. The important role of stratum corneum lipids for
the cutaneous barrier function. Biochim. Biophys. Acta-Mol. Cell Biol. Lipids 2014, 1841, 295–313. [CrossRef]
38. Bridges, T.E.; Houlne, M.P.; Harris, J.M. Spatially Resolved Analysis of Small Particles by Confocal Raman
Microscopy: Depth Profiling and Optical Trapping. Anal. Chem. 2004, 76, 576–584. [CrossRef]
39. Hathout, R.M.; Mansour, S.; Mortada, N.D.; Geneidi, A.S.; Guy, R.H. Uptake of microemulsion components
into the stratum corneum and their molecular effects on skin barrier function. Mol. Pharm. 2010, 7, 1266–1273.
[CrossRef]
40. Hoppel, M.; Baurecht, D.; Holper, E.; Mahrhauser, D.; Valenta, C. Validation of the combined ATR-FTIR/tape
stripping technique for monitoring the distribution of surfactants in the stratum corneum. Int. J. Pharm.
2014, 472, 88–93. [CrossRef]
41. Choe, C.; Lademann, J.; Darvin, M.E. A depth-dependent profile of the lipid conformation and lateral packing
order of the stratum corneum in vivo measured using Raman microscopy. Analyst 2016, 141, 1981–1987.
[CrossRef]
42. Williams, A.C.; Edwards, H.G.M.; Barry, B.W. Raman spectra of human keratotic biopolymers: Skin, callus,
hair and nail. J. Raman Spectrosc. 1994, 25, 95–98. [CrossRef]
43. Snyder, R.G.; Hsu, S.L.; Krimm, S. Vibrational spectra in the CH stretching region and the structure of the
polymethylene chain. Spectrochim. Acta Part A Mol. Spectrosc. 1978, 34, 395–406. [CrossRef]
44. Tfayli, A.; Guillard, E.; Manfait, M.; Baillet-Guffroy, A. Thermal dependence of Raman descriptors of
ceramides. Part I: Effect of double bonds in hydrocarbon chains. Anal. Bioanal. Chem. 2010, 397, 1281–1296.
[CrossRef] [PubMed]
45. Schwarz, J.C.; Klang, V.; Hoppel, M.; Mahrhauser, D.; Valenta, C. Natural microemulsions: Formulation
design and skin interaction. Eur. J. Pharm. Biopharm. 2012, 81, 557–562. [CrossRef]
46. Wallach, D.F.H.; Verma, S.P.; Jeffrey, F. Application of laser Raman and infrared spectroscopy to the analysis
of membrane structure. Biochim. Biophys. Acta-Rev. Biomembr. 1978, 559, 153–208. [CrossRef]
47. Choe, C.; Lademann, J.; Darvin, M.E. Analysis of Human and Porcine Skin in vivo/ex vivo for Penetration of
Selected Oils by Confocal Raman Microscopy. Ski. Pharmacol. Physiol. 2015, 28, 318–330. [CrossRef]
48. Choe, C.; Lademann, J.; Darvin, M.E. Confocal Raman microscopy for investigating the penetration of
various oils into the human skin in vivo. J. Dermatol. Sci. 2015, 79, 176–178. [CrossRef]
49. Vater, C.; Adamovic, A.; Ruttensteiner, L.; Steiner, K.; Tajpara, P.; Klang, V.; Elbe-Bürger, A.; Wirth, M.;
Valenta, C. Cytotoxicity of lecithin-based nanoemulsions on human skin cells and ex vivo skin permeation:
Comparison to conventional surfactant types. Int. J. Pharm. 2019, 566, 383–390. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Mucoadhesive Budesonide Formulation for the
Treatment of Eosinophilic Esophagitis
Antonella Casiraghi 1,*, Chiara Grazia Gennari 1, Umberto Maria Musazzi 1,
Marco Aldo Ortenzi 2,3, Susanna Bordignon 4 and Paola Minghetti 1
1 Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via G. Colombo 71-20133 Milan,
Italy; chiara.gennari@unimi.it (C.G.G.); umberto.musazzi@unimi.it (U.M.M.);
paola.minghetti@unimi.it (P.M.)
2 CRC Materiali Polimerici (LaMPo), Department of Chemistry, Università degli Studi di Milano, Via Golgi
19-20133 Milan, Italy; marco.ortenzi@unimi.it
3 Department of Chemistry, Università degli Studi di Milano, Via Golgi 19-20133 Milan, Italy
4 Student of Specialization School in Pharmacy, Department of Pharmaceutical Sciences, Università degli
Studi di Milano, Via G. Colombo 71-20133 Milan, Italy; susanna.bordignon@gmail.com
* Correspondence: antonella.casiraghi@unimi.it
Received: 20 December 2019; Accepted: 23 February 2020; Published: 1 March 2020
Abstract: Eosinophilic esophagitis (EE) is a chronic immune/antigen-mediated esophageal
inflammatory disease for which off-label topical corticosteroids (e.g., budesonide) are widely used in
clinic. In general, thickening excipients are mixed with industrial products to improve the residence
time of the drug on the esophageal mucosa. The compounding procedures are empirical and the
composition is not supported by real physicochemical and technological characterization. The
current study aimed to propose a standardized budesonide oral formulation intended to improve
the resistance time of the drug on the esophageal mucosa for EE treatment. Different placebo
and drug-loaded (0.025% w/w) formulations were prepared by changing the percentage of xanthan
gum alone or in ratio 1:1 with guar gum. Both excipients were added in the composition for their
mucoadhesive properties. The formulative space was rationalized based on the drug physicochemical
stability and the main critical quality attributes of the formulation, e.g., rheological properties,
syringeability, mucoadhesiveness and in vitro penetration of budesonide in porcine esophageal
tissue. The obtained results demonstrated that gums allowed a prolonged residence time. However,
the concentration of the mucoadhesive polymer has to be rationalized appropriately to permit the
syringeability of the formulation and, therefore, easy dosing by the patient/caregiver.
Keywords: eosinophilic esophagitis; budesonide; xanthan gum; guar gum; mucoadhesion; esophagus
permeability; rheological characterization; pediatric medicine; compounded preparation
1. Introduction
Eosinophilic esophagitis (EE) is a chronic immune/antigen-mediated esophageal inflammatory
disease associated with esophageal dysfunction resulting from severe eosinophil-predominant
inflammation [1,2]. EE treatment is mainly based on dietary and pharmacological interventions.
The diet of patients having EE is a highly restricted regimen based on the elimination of specific allergen
components for a limited number of weeks. Removal of harmful food allergens results in clinical
remission of EE. After the elimination period, foods can be reintroduced in the diet sequentially in
order to identify food triggers of esophageal eosinophilia and to establish a less restrictive, long-term,
therapeutic diet for the effective disease management [3]. Elemental formulas and other types of
elimination diets are safe and efficacious approaches for EE treatment [4], but the severe restrictions
markedly reduce patient compliance [5]. The main drawbacks are the scant palatability of the highly
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restricted diet regimen, the marked weight loss and the high costs for the patient [6]. Therefore,
pharmacological treatments are often necessary. First line therapy is based on oral proton pump
inhibitors (PPIs) [7], which are effective, safe and not so expensive for the patients. If the patient does
not respond to PPIs, corticosteroids are useful alternative therapeutics, since they can inhibit maturation
and activation of eosinophils through suppression of the release of their stimulating cytokines. Inhaled
budesonide (BU) and fluticasone are the most investigated drugs of this class [8–10]. However, the
benefit-risk balance of such medicinal products may be affected by significant secondary side effects due
to systemic drug absorption after pulmonary administration. It may also be affected by a low patient
adherence, due to the complexity of the administration devices (e.g., metered-dose inhaler). Therefore,
the interest in developing topically applied therapeutics is increasing [11,12]. In this context, off-label
topical corticosteroids are frequently used in clinic: patients are trained to swallow asthma medicinal
products designed initially to be inhaled or viscous oral formulations extemporaneously compounded
in pharmacies. Recently, European regulatory authorities have authorized an orodispersible tablet
loaded with BU indicated for the treatment of EE in adults older than 18 years of age. This medicinal
product is not suitable for pediatric patients since they require adjustments in strength and dosage
form in comparison to adults [13–15].
When an authorized medicinal product is not available on the market, the compounding of
extemporaneous preparations by the community and hospital pharmacists is crucial to meet the special
needs of patients [16,17]. The compounding activities should be based on the provisions of the Good
Compounding Practice and other available technical guidelines to assure the required quality of the
magistral preparation [18].
In the case of the BU for EE, a certain number of studies in the literature suggested the clinical
efficacy of viscous preparations. Frequently, they have been prepared by mixing a commercial sterile
suspension of BU to be nebulized, which is indicated in the treatment of bronchial asthma and in
infants and children with croup, with a thickening agent (e.g., sucralose) [19–21]. Alternatively,
cellulose derivatives [22] or gums [23,24] have also been added. Hefner et al. [25] compared the
technological performances of different types of thickening agents like sucralose, xanthan gum or honey,
demonstrating that the gum permitted a better residence time of the active pharmaceutical ingredients
(API) on the esophageal mucosa. However, such pieces of evidence have been obtained using a
medicinal product as an API source instead of the API. Although such an approach seems practical
to meet patient’s needs, the use of a medicinal product can determine the presence of unnecessary
excipients in the final preparation and can cause problems of physical compatibility to arise with all
the adopted substances. Moreover, the exact quantitative composition of the medicinal product is
generally unknown. In this light, it is preferable that compounding starts from the raw materials
(pure active principle and excipients). Alternatively, a proprietary excipient mixture can be used as a
formulation base (e.g., Mucolox™) [26].
The development of standardized formulations can be a valid strategy to support pharmacists in
their activities, reducing heterogenicity and uncertainty in compounding procedures, improving the
quality of the final preparation, at the same time. Indeed, the availability of well set up and validated
operating procedures is instrumental in assuring the quality of the magistral preparation.
The aim of this work is to propose a standardized BU oral formulation to improve the residence
time of the drug on the esophageal mucosa. Starting from a formulation already in use in hospital
pharmacies, based on xanthan gum, six pharmacists were enrolled in the compounding process to verify
its reproducibility. On the bases of these results, the formulation and the compounding procedures
were optimized. Considering the evidence, reported in the literature, on the combined use with
galactomannans, guar gum was selected to compare its performances, when in ratio 1:1, as opposed
to xanthan gum alone. The formulative space was rationalized based on the drug’s physicochemical
stability and the main critical quality attributes of the formulation, such as rheological properties,
mucoadhesiveness and in vitro penetration of BU in porcine esophageal tissue.
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2. Materials and Methods
2.1. Materials
Micronized Budesonide (BU) was obtained from Farmabios, Gropello Cairoli, PV, Italy. Guar
Gum (GG, viscosity min 5000 mPas) was kindly gifted by Lamberti spa, Albizzate, VA, Italy. All other
materials were obtained from the named supplier: Xanthan Gum (XG, viscosity more than 1200 mPas),
(ethylenedinitrilo)tetraacetic acid disodium salt dihydrate (EDTA), sodium benzoate, sodium saccharin
(Farmalabor, Canosa di Puglia, BAT, Italy), glycerin, sodium dihydrogen phosphate, orthophosphoric
acid, ethanol chemical grade (VWR International, Milan, Italy).
Acetonitrile was HPLC-gradient grade. Purified water was obtained from the purification system
Milli-Q, according to Ph. Eur. 10.0 ed.
2.2. Preparation of Oral Formulations
The exact amount of glycerin (23.6 mL) was weighed on an analytical balance and poured into a
beaker. Sodium saccharin, EDTA and sodium benzoate were crushed to a fine powder with mortar and
pestle, then, the exact amount of each was weighted and the powders were transferred into the same
beaker. Then, XG or the mixture of gums (XG:GG) 1/1 w/w was added. All substances were mixed
to form a homogeneous mixture, then, the exact weighted amount of BU (1 mg/4 mL) was added
and carefully mixed. Purified water was weighed and added, then stirred until a uniform system
was obtained. Different percentages of gums were used: F1P was prepared using XG 2% w/w, F2P
with XG:GG 2% w/w, F3P with XG 1.5% w/w and F4P with XG:GG 1.5% w/w. Placebo formulations
were prepared for rheological and technological evaluation. BU was added only to obtain final loaded
formulations F1, F2 and F4. The composition of the formulations is reported in Table 1.
Table 1. Composition (expressed in grams) of the formulations for 240 mL (four doses each of 60 mL).
Excipients F1P F1 F2P F2 F3P F4P F4
Budesonide (BU) - 0.06 - 0.06 - - 0.06
Xanthan gum (XG) 4.80 4.80 2.40 2.40 3.60 1.80 1.80
Guar gum (GG) - - 2.40 2.40 - 1.80 1.80
Sodium saccharin 0.24 0.24 0.24 0.24 0.24 0.24 0.24
Glycerin 29.74 29.74 29.74 29.74 29.74 29.74 29.74
EDTA 0.24 0.24 0.24 0.24 0.24 0.24 0.24
Sodium benzoate 0.45 0.45 0.45 0.45 0.45 0.45 0.45
Water up to (mL) 240 240 240 240 240 240 240
2.3. Measurements of pH Values of the Formulations
The pH was measured at time T= 0, using a pHmeter CyberScan 1100 (Eutech Instruments/Thermo
Fisher Scientific, Waltham, MA, USA).
2.4. Drug Content
About two grams of each formulation were exactly weighed and transferred into a 10 mL amber
glass volumetric flask, bringing up to volume with ethanol. Then, the flask was placed in an ultrasound
bath for 20 min. The sample was then centrifuged for 5 min at 3500 rpm. A portion of the supernatant
was diluted to 2:5 with the mobile phase composed of phosphate buffer pH 3.2:acetonitrile:ethanol
(68:30:2 v/v/v) and analyzed [23]. The remaining supernatant was completely and accurately removed
and 10 mL of fresh ethanol were added to repeat the same extraction procedure. For each preparation,
extraction was performed twice.
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2.5. Stability Study
Samples of F1 were stored in an incubator (INCU-Line, VWR International, Milan, Italy) at 40 ◦C.
The drug content was measured at time T = 0, T = 10, 20, 60 days. Evaluation of BU content was also
performed after T = 30 days at room temperature exposed to light.
2.6. Determination of Rheological Properties
The steady and dynamic shear rheological properties of the formulations were carried out using a
controlled stress/strain rheometer Anton Paar MCR 302 (Anton Paar GmbH, Graz, Austria) equipped
with a plate-plate geometry (25 mm diameter and 500 μm gap). The temperature was controlled by a
Peltier system on the bottom plate. Each sample was transferred to the rheometer plate and was then
equilibrated at 25 ◦C for 5 min before steady and dynamic shear rheological measurements were taken.
2.6.1. Steady Shear Measurements
Flow behavior was evaluated at controlled strain mode to obtain flow rheological data (shear
stress and shear rate) over a shear rate range of 0.1–100 s−1 at 25 ◦C. The shear stress-shear rate data
were fitted to the well-known power law and Casson models [27] to describe the flow properties of
the samples.
2.6.2. Dynamic Shear Measurements
Dynamic rheological data were obtained from frequency sweeps over the range of 0.628–62.8 rad
s−1 at 2% strain using a small-amplitude oscillatory rheological measurement. The applied 2% strain
was confirmed within the linear viscoelastic region by strain sweep measurement. Frequency sweep
tests were also performed at 25 ◦C. The RheoCompass software (Anton Paar GmbH, Graz, Austria)
was used to obtain the experimental data and to calculate the storage (or elastic) modulus (G′), loss (or
viscous) modulus (G”) and loss factor (tan δ = G”/G′).
2.7. Quantitative Determination of Syringeability
The measurement of the injection force was performed in compression mode by using a
software-controlled texture analyzer (Instron 5965, ITW Test and Measurement Italia S.r.l., Trezzano
sul Naviglio, Italy). A 10 mL syringe (SOFT-JECT®, VWR International, Milan, Italy) filled with 9 mL
formulation was positioned in the dynamometer holder, downward needle. The plunger end of the
syringe was placed in contact with a 50 N loading cell. Testing was carried out at the crosshead speed
of 0.5 mm/s. The loading force required to displace the plunger was measured as a function of plunger
displacement. The following parameters were also determined from the force-displacement plot:
• Plunger-stopper break loose force (or “initial glide force,” PBF): the force required to initiate the
movement of the plunger;
• Maximum force (MF): the highest force measured before the plunger finishes its course at the
front end of the syringe;
• Dynamic glide force (DGF): the force required to sustain the movement of the plunger to expel the
content of the syringe.
A schematic representation of the syringeability test setting and a general force-displacement
plot are illustrated in Figure 1. The registered force values were normalized by dividing them for the
cross-sectional area of the cylindrical plunger. The experiments were performed in triplicate.
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Figure 1. Syringeability test setting and a general force versus displacement curve (PBF: plunger-stopper
break loose force; MF: Maximum force; DGF: Dynamic glide force).
2.8. Mucoadhesive Properties and In Vitro Esophagus Penetration
The in vitro mucosal penetration study was performed adapting the flow-through test described
by Cilurzo et al. [28] by using fresh porcine esophageal tissue obtained by a local slaughterhouse. The
mucosa epithelium was separated by mucosal specimens using a scalpel.
In-house equipment of three components was built up (Figure 2): (a) in series mucosa supports
set at an angle of 45◦, (b) peristaltic pump and (c) collector of fractions. The apparatus was designed
to investigate at the same time the elution of the preparation from the mucosal surface and the drug
penetration into the tissue.
Figure 2. Apparatus used to evaluate mucoadhesive properties and mucosal penetration in vitro.
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A dose of the selected formulation was deposited onto a 3 × 2 cm mucosal surface corresponding
to a total amount of about 500 mg. Then, the porcine esophageal membrane was placed on the sample
support and pH 6.8 phosphate buffer solution (PBS) was dropped at a rate of 1 mL/min to simulate the
physiological environment and the saliva swallowing. The test was performed at room temperature.
The residence time was qualitatively estimated by checking the time required for each formulation
to be thoroughly washed away from the surface of the mucosa exposed to the washing medium. In
all cases, after 30 min from the beginning of the experiment, the apparatus was dismantled, and the
applied test sample was peeled away using an adhesive tape strip [28]. The mucosa samples were then
washed from both sides with 5 mL of purified water and homogenized. The amount of the penetrated
drug was extracted with 2 mL methanol and assayed by HPLC.
2.9. Drug Content Analysis
The analysis was carried out by HPLC-DAD (Agilent 1100, Agilent, Santa Clara, CA, USA) using
an RP-C18 column (LC 150 × 4.6 mm, 5 μm) with pre-column (Phenomenex, Torrance, CA, USA). The
mobile phase was composed of phosphate buffer pH 3.2:acetonitrile:ethanol [29]. The elution was
carried out in gradient (Table 2). The flow rate was 1.7 mL/min, the wavelength was set at 240 nm and
the injection volume at 10 μl. The retention times of the 22R and 22S epimers were 8.8 min and 9.1 min,
respectively. A calibration curve was prepared twice solubilizing in ethanol 10 mg of BU in a 100 mL
volumetric flask. Dilution to obtain 0.1, 0.2, 0.5, 1 and 2 μg/mL concentration were performed (22R: R2
= 0.99930; 22S: R2 = 0.99999).
Table 2. The gradient of the mobile phase.
Time (min)






0–10 68→50 30→48 2
10–11 50 48 2
11–16 50→68 48→30 2
2.10. Statistical Analysis
Tests for significant differences between means were performed by the one-way ANOVA followed
by Turkey-Kramer post-analyses. Differences were considered significant at the p < 0.05 level.
3. Results and Discussion
As the number of patients suffering from EE is increasing, among both adults and young
population, the need to have a standardized topical dosage form has grown. Moreover, the widespread
habit of mixing the industrial inhalation product with sweeteners (among them is largely used an
artificial sweetener based on sucralose in maltodextrin/glucose) should not be the first choice. Instead,
the use of a viscous preparation as a vehicle is well established in improving the efficacy of topical
corticosteroid administration. The proprietary blend Mucolox™ gave good results [26], but it is
composed of a very complex blend. For these reasons, other simpler compositions, already in use
in hospital pharmacies, deserve to be investigated. Quite diffused is the use of viscous formulation
containing XG as a thickening and rheological agent (F1P and F1, Table 1).
XG is a polysaccharide, largely applied in the food industry. It is highly stable in a wide range of
pH and ionic strength, and, dispersed in water at moderate temperatures, it increases its viscosity even
at low concentration [30,31]. Temperature preparation can modify the ordered or disordered state of
xanthan chains, as this state is controlled by temperature.
According to the already in use hospital preparation (F1, Table 1), six pharmacists were enrolled
and each of them compounded a batch. At the end of the preparation process, performed at room
temperature, BU was completely dispersed, and the gel-like liquid appeared homogeneous. Dispersion
26
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is due to the low BU solubility in water [32]; good improvement of solubilization could be obtained
using mixtures with ethanol, but this approach must be discarded in the pediatric population for
limitations in the use of this excipient [33]. The use of glycerin, usually foreseen in mixture with
rheological agents, can contribute in improving BU solubility, but this is not enough to obtain its
complete solubilization. The measured pH and drug content are reported in Table 3. pH values were
close to 5 and no significant changes in pH were observed during the storage period. To exactly
measure the drug content, the extraction procedure reported in the literature [23] was performed twice,
as a too high amount of BU remained not extracted after a single exposure to solvent. Variability among
operators was low (CV% = 2.7) and immediately after preparation, the mean content was within
the range of acceptability, fixed in ±10% w/w, according to the Italian Pharmacopoeia (Table 3). The
chemical stability study showed that the preparation has good stability, as evidenced by the accelerated
stability study (storage for over 60 days in an incubator at 40 ◦C; Table 3) and confirmed the need to
avoid the exposure to light for long period when the preparation is handled by caregivers or patients.
Indeed, preparations left at room temperature for over 30 days at the light showed a reduction of
more than 50% in strength (Table 3). The addition of sodium benzoate allows to avoid microbiological
contamination [23].
Table 3. Chemical characterization of the in-use preparation in the hospital pharmacy (F1: XG 2%).
pH values and drug content at preparation time (T = 0) and at the end of the storage period in an
incubator in dark condition (T = 60 days). Drug content determined after 30 days at room temperature




(mg/mL, n = 6)
T = 0 60 days T = 0 60 days, 40 ◦C, dark 30 days, r.t., light
F1 4.629 ± 0.020 4.814 ± 0.115 0.262 ± 0.007 0.246 ± 0.018 0.103 ± 0.022
To test the technological properties of these systems, their adhesion on the site of action (i.e.,
esophageal tissue) or the handling during the application, F1P was modified and a mixture of XG and
GG was used (F2P, Table 1). The addition of galactomannans such as locust bean gum or GG to a solution
of XG at room temperature causes a synergistic increase in viscosity, both at dilute and concentrated
solution [27]. GG is a galactomannan that forms colloidal solutions with elevated viscosity even at
very low concentrations. It is anionic in nature and it remains stable and gives consistent viscosity
over a wide pH range [34]. The viscosity of XG:GG mixtures depends on operational properties such
as the dissolution temperature of gums, polymer concentration and relationship between XG and
galactomannan. Indeed, with the polymer concentration and the ratio between the gums being fixed,
in case of extemporaneous preparation, attention must be paid to the temperature at which each
polysaccharide has been solved [35].
Rheological characterization was performed on the placebo samples based on XG (F1P and F3P)
and XG:GG (F2P and F4P), mixed at room temperature. They have different behaviors: formulations
containing the mixture of the gums have higher shear stress in comparison to those containing only
XG, as already reported in the literature [35], but the shear sensitivity is different. As shown in Figure 3,
XG samples have a linear stress-strain dependence, whereas XG:GG samples have a pseudoplastic
behavior, with the stress vs. strain lowering at higher shear rates. When reaching the highest shear
rates, XG:GG 1.5% (F4P) starts having lower stress than XG 2% (F1P). Given the slope of the curves (i.e.,
pseudoplastic vs. linear dependence), the behavior is expected to be confirmed at shear rates higher
than 100 s−1, which is the highest that can be reached with the experimental setup used. In addition,
samples loaded with the active principle were investigated and it was concluded that the behavior
was not influenced by the presence of BU (F1 and F4, Table 4). The pseudo-plastic behavior of XG:GG
samples indicates that physicochemical properties of such formulations are similar to the ones of linear
polymers, i.e., the effect of ionic interactions or other weak bonds (such as hydrogen or van der Waals
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bonds) creating branching and reversible crosslinking between the macromolecular chains of the gums
and other ingredients of the formulations is negligible. This behavior is in agreement with the one
previously observed by Jo et al. on gum mixtures [27]. The same authors evidenced a pseudoplastic
behavior also for the single gums in water solution. In our work, the presence of glycerin, adding a lot
of –OH groups in the formulation, seems to increase the formation of entanglements and weak bonds
in the formulation of XG alone, within the shear range tested. Table 4 also shows the difference in
viscosity of the samples at the highest shear rates, confirming that the XG:GG sample viscosity has
a far less marked increase than that of XG samples in the 50–100 s−1 range. This trend is due to the
pseudoplastic behavior of XG:GG samples.
Figure 3. Plots of shear stresses versus shear rates of XG and XG:GG mixtures.
Table 4. Viscosity values and injection force measurements of each formulation.
Form.
Viscosity (Pa*s) Δη 100 vs.
50 s−1 (%) Loss factor
◦ Injection force
50.1 (s−1) 70.8 (s−1) 100 (s−1) DGF (kPa) MF (kPa) PBF (kPa)
F1P 128.15 136.12 144.25 12.6 0.157 ± 0.015 90.01 ± 31.16 77.87 ± 14.50 66.25 ± 5.24
F1 127.22 135.75 144.83 13.8 0.160 ± 0.016 -* -* -*
F2P 190.48 197.68 204.46 7.3 0.190 ± 0.040 83.28 ± 8.68 87.08 ± 7.30 58.57 ± 14.13
F3P 81.57 87.09 92.42 13.3 0.171 ± 0.018 78.08 ± 24.23 85.00 ± 29.67 63.11 ± 19.28
F4P 130.67 134.89 135.60 3.8 0.231 ± 0.045 121.69 ±14.75
126.39 ±
14.78 89.49 ± 27.24
F4 126.77 128.5 130.02 2.6 0.242 ± 0.047 -* -* -*
Note: ◦ average ratio and standard deviation of G”/G’ over the whole curve; * value not determined.
A different behavior among the formulations was also evidenced from the performed dynamic
shear measurements. In particular, as shown in Figure 4, a markedly different trend in loss modulus
is visible. In XG:GG samples, the G” has only slight variations over the angular frequency range
used, whereas in XG samples, it markedly increases as the frequency gets higher, especially at the
highest frequencies.
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Figure 4. Plots of log ω versus log G” of XG and XG:GG mixtures.
To identify elastic or viscous behavior, loss factor values can be calculated. When this value is
smaller than the unit, a sample is more elastic than viscous, and this has been suggested as a rheological
criterion for safe-swallow foods meant for dysphagia [36]. All proposed formulations had low loss
factor values (Table 4). Moreover, while loss factor values for F1P, F2P and F3P were similar, F4P had a
loss factor significantly higher than all the other samples (p < 0.0001).
The administration of this preparation in very young patients was performed by caregivers,
normally the parents, by means of a big syringe containing 60 mL of the formulation. During this
treatment, some difficulties due to the hard extrusion of the formulation from the syringe were
described by the users. The values measured for the injection force measured for placebo formulations
are reported in Table 4.
In the force vs. displacement plot of low-viscosity formulations (Figure 1), two different portions
can be identified: the former is related to the force required to displace the plunger, (i.e., PBF). This
event is followed by a plateau (second portion), indicating that the streamline of the formulation
through the needle occurs with a constant force. In this portion, the average load required to sustain
the movement of the plunger to expel the content of the syringe is calculated and reported as DGF.
PBF values were not statistically different among the tested products (p = 0.3890), suggesting that
the force required to initiate the movement of the plunger was independent from the formulation.
The measured extrusion forces showed that F4P required a slightly higher extrusion force (in
terms of DGF) with respect to the other formulations, even if the differences were not statistically
significant (p = 0.1565). Moreover, in the shear stress plots, F4P showed also a pseudoplastic behavior
that could not be detected with the syringeability test, probably because the applied force felt below
the useful range of stress. In the case of this pseudoplastic formulation, taking into consideration the
loss factor value, another rheological parameter, we can observe that it was higher if compared to the
other formulations, suggesting that F4P has a more pronounced viscous component, even if its overall
behavior was mainly elastic. However, overall results show that in any case low forces are needed to
extrude the formulations from a syringe, despite the differences highlighted in the rheological studies.
The chemical and technological effects of the combination of the two gums in the revised
formulations are reported in Table 5. Formulation F3 was considered of minor interest because of the
lower shear stress and therefore it was not further investigated. Placebo formulations showed pH
values from 4.975 (F2P) to 5.155 (F4P). As in the case of F1, the addition of BU did not change these
values (Table 5). The formulations can be expected to be non-irritating to the buccal mucosa since the
pH of the esophageal mucosa is reported to be 6.8 in healthy subjects [37].
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Table 5. Chemical and technological characterization of the modified preparation.
Batch pH T = 0 Permanence Time (min)
BU Penetrated the Mucosa
(mg/g mucosa) (%)
F1 4.976 28 ± 4 0.790 ± 0.192 0.610 ± 0.132
F2 5.156 29 ± 2 0.783 ± 0.231 0.562 ± 0.152
F4 5.068 25 ± 5 0.901 ± 0.367 0.682 ± 0.270
As far as the mucoadhesive properties are concerned, comparing the formulations, a similar
sliding time from the mucosa samples was observed for all of them. Thanks to the establishment
of interactions between the mucosal layer and the bioadhesive polymer, it was possible to obtain
formulations able to persist onto the mucosal surface for about 30 min.
The good mucoadhesive properties can be due to the presence of free –COO¯ groups of XG. As a
matter of fact, it is well known that polymers that exhibit a high density of available hydrogen bonding
groups (–COO− groups of XG) can interact more strongly with mucin glycoprotein [38]. Moreover,
hydrogen bonds are involved in the formation of a strengthened network, thus contributing to the good
bioadhesive strength of the tested formulations. The permanence time onto the mucosa samples was
not influenced by the presence of the drugs into the formulations. Because of the similar residence time,
the percentages of BU that penetrated the mucosa by the different formulations were not significantly
different (Table 3). A very small percentage of BU loaded remained in the mucosae; therefore, to
optimize the use of the corticosteroid, further evaluations could be done with formulations containing
a reduced amount of the active principle with respect to that used in the present work.
As it is known, penetration of BU into the mucosa is the final combination of many events; the
physicochemical characteristics of the molecule, and the mucoadhesive properties and viscosity of
the formulation. The advantage of increased viscosity of the formulation is a reduced outflow from
the mucosal surface, with a consequent increase in the contact time of the drug with the mucous
membrane, and therefore, in its penetration into the tissue. On the other hand, an excessive viscosity
could obviously create problems in the extrusion from a syringe. The results showed that the use
of the two gums in combination can help to modulate the viscosity of the formulation, however,
remaining within an optimal range such as to be retained onto the mucosal surface for enough time.
Moreover, thanks to its pseudoplastic behavior, the extrusion of such formulations through a syringe
can take place in a feasible way. Unfortunately, this aspect could not be fully investigated through the
experiments carried out in this work, since the viscosity data should be collected in a higher shear
range to highlight a correlation between syringeability test and viscosity measurements.
4. Conclusions
The prepared formulations showed suitable technological and rheological characteristics for the
treatment of EE. As the addition of GG to XG caused an increase in viscosity, the choice of a mixture of
gums allows the use of thickening agents in a reduced amount. In this case, the obtained results were
not significantly different from those measured with the formulation already in use. Considering the
limited percentage of BU absorbed in the in vitro penetration experiments, further evaluations should
be carried out to rationalize the drug content and reduce the risk of systemic side effects.
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Abstract: Triterpenes from the outer bark of birch have many beneficial biological and pharmacological
activities. In particular, its wound healing efficacy is of paramount importance. Apart from that,
particles of a birch bark dry extract aggregate into a three dimensional network when they are
dispersed in lipids yielding a semi-solid oleogel. However, gel formation requires high amounts of
the extract, which then acts at once as the active ingredient and the gelling agent. Infrared spectra
of the respective mixtures proved that hydrogen bonds play a crucial role in the formation of the
gel network. Dicarboxylic acids had almost no effect on gel strength. Monoalcohols increased
the firmness of the oleogel with a decreasing effect from methanol > ethanol > butanol > octanol.
All tested terminal diols increased the gel strength whereas vicinal diols affected the gel strength
negatively. The effect was highly dependent on their concentration. The different effects of the diols
are linked to their structure and polarity. The most pronounced enhancement of gelation was found
for 1,6-hexanediol, which reduced the amount of triterpene extract (TE), which is necessary for the
formation of an oleogel by a factor of 10.
Keywords: birch bark extract; oleogels; hydrogen bonding; triterpene; rheology; gel strength
1. Introduction
It is well known, that triterpenoids, widespread secondary plant metabolites, have many beneficial
biological and pharmacological activities [1,2]. Triterpenes from birch bark are of exceptional interest.
The following triterpenes are the most common in the outer bark of the white birch: betulin, lupeol,
betulinic acid, oleanolic acid, and erythrodiol (Figure 1) [3,4].
Figure 1. Chemical structure of triterpenoids with Lupan and Oleanan type skeleton.
There are different ways described in the literature to extract and isolate these triterpenes, such as
extraction of triterpenoids with organic solvents like n-heptane [4,5] or ethanol [6]. Other methods
used include supercritical fluid technology [3], ultrasonic-assisted extraction [7], and sublimation [8].
Triterpenes have antiviral, antibacterial, and antitumoral activities [9,10]. Moreover, a triterpene
extract from the outer bark of birch was shown to enhance wound healing ex vivo as well as in vivo in
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humans [11–13]. In January 2016 an oleogel consisting of solely sunflower oil and birch bark extract
got European marketing authorization for the treatment of partial-thickness wounds [11]. In this
formulation, the triterpene extract functions as the active substance as well as an excipient. In such
binary mixtures, the extract forms a three-dimensional gel network and immobilizes the liquid oil [12].
A similar aggregation of triterpenes through hydrogen bonds was also shown in organic solvents [13,14].
The aggregation of a substance and the resulting gelling effect is also described for so called organogels,
where different classes of gelling agents such as glycerol ester, fatty acid, fatty alcohols, or sterols are
used [15]. These are so called low-molecular-weight-gelators, and 12-hydroxystearic acid was one of
the first substances investigated intensively; it was shown that both its hydroxyl and carboxyl group
play a crucial role during gelation [16]. These gelators are also of exceptional interest in the food
industry as an alternative to saturated triglycerides for structuring oils, in which secondary valence
bonds (e.g., hydrogen bonds) play a vital role [17]. It was also shown that specific substances are able to
induce the interaction of the gelling agents and thus increase the gel strength of such organogels [18,19].
In the same direction, results with triterpene extract (TE) oleogels indicated that the gel strength is
affected by a complex interplay of liquid–solid interaction as well as the interaction of suspended TE
particles. Up to date it is not fully understood how this kind of gelation is exactly brought about and
how additives affect it. However, there are clear hints that hydrogen bonds play an essential role in
this process [12]. From a formulator’s point of view, the formation of a particulate gel network using
the active ingredient might be problematic because it has to be added in comparably large amounts.
Moreover, it is an inherent disadvantage that the concentration of the active ingredient and the gelator
cannot be changed independently. Finally, the formation of a three-dimensional particulate network
takes a lot of time because the rearrangement of the particles is a rather slow process.
Therefore, the aim of this study was to (1) find additives which are able to increase the gel strength
and accelerate the gel formation and (2) further increase knowledge on the mechanism behind the
formation of the particulate gel network. To this end, the strength of oleogels consisting of birch
bark extract, sunflower oil, and several additives that might form H-bonds was studied by means
of oscillation rheology. The interaction between TE particles and additives was characterized by IR
spectroscopy. Furthermore, the effect of the additives on the solubility of the TE was analyzed.
2. Materials and Methods
2.1. Materials
The dry birch bark extract was a gift from Amryt AG (Niefern-Oeschelbronn, Germany). It was
produced by enhanced organic solvent extraction using n-heptane [5]. The chemical and physical
characterization of the extract is shown in Table 1.
Table 1. Chemical and physical characteristics of the birch bark dry extract.








1,2-Propanediol was obtained from Caesar & Loretz GmbH (Hilden, Germany). Methanol, ethanol,
butanol, octanol, ethylene glycol, 1,3-butanediol, 1,4-butanediol, 1,5-pentanediol, 1,2-hexanediol,
1,6-hexanediol, 2,5-hexanediol, 1,9-nonanediol, adipic acid, and azealic acid were purchased from
Sigma Aldrich (Taufkirchen, Germany) with a purity >95%. Succinic acid was from Merck KGaA
(Darmstadt, Germany) and 1,2-pentanediol was from BASF (Zurich, Switzerland).
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2.2. Gel Preparation
The dry triterpene extract was sieved through a number 500 sieve before further use. Thereafter,
an 8% stock oleogel was produced by homogenizing the extract for 2 min at 8500 rpm in sunflower oil
by means of an Ultra Turrax (Ika Labortechnik, Staufen, Germany). The additives were added to the
stock oleogel in a predetermined amount and the final formulation was again homogenized for 1 min
at 8500 rpm. Oleogels were analyzed 24 h after preparation.
2.3. Rheology
Rheology of the oleogels was measured in oscillation mode using a Gemini 150 (Bohlin Instruments,
Pforzheim, Germany) equipped with a 25 mm plate/plate geometry using a gap of 1 mm. After a
pre-shear phase of 40 s and 5 min recovery time, an amplitude sweep was performed with a logarithmic
ramp, deformation rate of 0.01–1000%, and a frequency of 1 s−1. The gel strength of the oleogels
was expressed as the mean of the storage modulus G’ in the linear viscoelastic range. In general, gel
strength of all oleogels was measured 24 h after preparation in order to allow formation of the gel
network after intense shearing during the manufacturing process.
2.4. ATR–Infrared Spectroscopy
The samples were analyzed with a Spectrum One FTIR-Spectrometer (Perkin Elmer, Rodgau,
Germany). They were placed on the surface of an optical fiber and spectra were taken with a wave
number ranging from 4000 cm−1 to 670 cm−1. In total, 31 spectra were cumulated and evaluated using
the software Spectrum v. 3.01 (Perkin Elmer, Rodgau, Germany).
2.5. Particle Size Measuring
The particle size distribution of the oleogels was measured through laser diffraction using a
Sympatec Helos (Sympatec GmbH, Clausthal-Zellerfeld, Germany), with a lens focal length of 100
mm and measuring range of 0.9–175 μm. For these measurements oleogels were produced with light
liquid paraffin and an extract concentration of 8%. After diluting the sample in a ratio of 1:10 with the
oil phase, the sample was added in a cuvette where it was stirred in paraffin to get a homogeneous
dispersion. Measurements were taken at an optical concentration of 25–30%.
Laser diffraction results are expressed as ×10, ×50, and ×90 values based on a cumulative volume
distribution. To ensure comparability between rheology and particle size measurements, respective
oleogels for particle sizing were also stored at 25 ◦C.
3. Results and Discussion
3.1. Effect of Additives on Gel Strength
Previous studies dealing with oleogel formation with TE particles hypothesized that the formation
of the gel network is markedly assisted by dissolved bi-functional triterpene molecules, (e.g., betulin).
In order to check this, the effect of several mono- and bi-functional additives was studied systematically.
Figure 2 shows the effect of the different additives on the gel strength of an oleogel consisting of
sunflower oil and 8% triterpene extract.
Most tested excipients with hydroxyl functional groups were able to increase gel strength. In the
series of the mono-functional alcohols, the gel strength decreased with their chain length. The addition
of methanol gave the highest increase in gel strength. None of the used dicarboxylic acids (adipic acid,
succinic acid, azelaic acid) affected the gel strength, which is explained by the creation of cyclic dimers
of the dicarboxylic acids [20,21]. The additives prefer interacting with each other instead of the extract
particles. All diols with terminal hydroxyl groups increased the gel strength. The effect was dependent
on the alkyl chain length of the diols and showed maximum values with 1,6-hexanediol, leading to a
9-fold increase in viscosity when 2% of this substance were added. The gel strength decreased again
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when the chain length further increased. Diols with vicinal hydroxyl groups (e.g., 1,2-hexanediol),
affected the gel strength negatively. Again, the effect was dependent on the chain length. Accordingly,
the most prominent reduction in gel strength was seen with 1,2-hexanediol.
Figure 2. Gel strength of oleogels with sunflower oil, 8% triterpene extract (TE), and 2% additive; an
oleogel without any additive serves as a reference; mean ± SD, n = 3.
3.2. IR-Measurements
It is well known that gel is formed through hydrogen bonds between extract particles, which is
shown by IR spectroscopy [12]. Figure 3 shows IR spectra of plain TE oleogels prepared with increasing
TE concentrations.
Figure 3. IR spectra of oleogels in sunflower oil with increasing TE concentration.
Free hydroxyl groups usually show an absorption band at 3700 cm−1. If the hydroxyl groups
are involved in hydrogen bonds the absorption band is shifted to the 3500–3200 cm−1 wavenumber
range. In Figure 3 it is clearly seen that the absorption band at 3300 cm−1 increases with increasing
TE concentration. This indicates an increasing number of hydrogen bonds, which is in line with an
increasing gel strength [12]. Diols have been shown to markedly affect gel strength in a positive or
negative manner. IR spectra were taken to further elucidate the behavior of the diols. Figure 4 shows
the IR spectra of a plain 8% TE oleogel in comparison to those measured after the addition of several
diols with terminal hydroxyl groups, which enhanced the gel strength.
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Figure 4. IR spectra of oleogels (8% TE) in sunflower oil with terminal diols (2%).
As expected, the IR spectra of the oleogels with the gel enhancing additives showed a fortified
broad absorption band at 3400 cm−1, indicating that these diols are able to interact intensely with the
extract particles via hydrogen bonds. The characteristic absorption band increased in the series from
ethylene glycol to 1,6-hexanediol, which corresponds to an increasing firmness of the oleogel. The
intense interaction of 1,6-hexanediol was accompanied by a splitting of the absorption band at 3400
cm−1 probably due to interactions between adjacent molecules. As demonstrated by 1,9-nonanediol, a
further increase in the chain length of the terminal diol resulted in a reduction of both the absorption
band at 3400 cm−1 as well as the gel strength. Figure 5 shows IR spectra of a plain 8% TE oleogel and
after the addition of pentanediols and hexanediols with either terminal or vicinal hydroxyl groups.
Figure 5. IR spectra of oleogels (8% TE) in sunflower oil with vicinal diols and their corresponding
terminal diols (2%).
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Independent from the chain length of the diols, the absorption band at 3400 cm−1 is significantly
smaller when adding vicinal diols instead of terminal diols. However, although a marked hydrogen
bonding of the vicinal diols is still detectable, they do not increase the gel strength but rather reduce
the firmness of the respective oleogels. As the absorption band of oleogels with vicinal diols is still
larger compared to the plain oleogel, it could be concluded that the vicinal diols interact substantially
with the superficial hydroxyl groups of the TE particles, but they are not able to link the TE particles
together. To the contrary, they shield the superficial hydroxyl groups of the TE particles and hence
prevent them from building a three dimensional particulate gel network as exemplary visualized in
Figure 6.
Figure 6. Schematic drawing of interaction between (a) 1,6-hexanediol and extract particle;
(b) 1,2-hexanediol and extract particle (dimensions are not to scale).
Like the gel enhancing effect of the terminal diols, the gel weakening effect of the vicinal diols and
the absorption band at 3400 cm−1 were more pronounced with increasing chain length of the diols.
3.3. Influence of the Enhancer Concentration on the Gel Strength
As the number of interacting superficial hydroxyl groups on the TE particles is limited it was of
great interest if the effect of the additives on the gel strength depends on their concentration. To this end,
oleogels were produced with terminal diols in the concentration range from 0.25–2% (corresponding to
approx. 2–30 μmol m−2). As shown in Figure 7, the gelation enhancing effect of terminal diols was
highly dependent on their concentration, with a maximum effect mostly in the range of 0.5–1%.
Figure 7. Gel strength of oleogels (8%) with terminal diols in a concentration range of 0.25–2%; an
oleogel without any additive serves as a reference; mean ± SD, n = 3.
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The firmness of the oleogels decreased again when the diol concentration exceeded the optimal
range. However, this did not come with a decreasing absorption band at 3400 cm−1 (data not shown).
Therefore, it is hypothesized that the surplus of diol forms hydrogen bonds with other diol molecules
instead of the TE particles, leading to a less rigid three-dimensional network.
3.4. Particles Size of Oleogels
Fumed silica particles are comparable to gel oils by forming a three dimensional network [22]. The
gelling mechanism is very similar compared to the triterpene oleogels. In oleogels using silica particles,
the particles grow during storage because of further aggregation of the particles. This leads to a higher
gel strength. We expected a similar particle growth with the TE oleogels. Moreover, 1,2-hexanediol
was expected to have a negative effect, and 1,6-hexanediol to have a positive effect, on the growth of
particle aggregates in line with the observed effect on gel strength. Figure 8 shows the particle size
distribution and the gel strength of a plain oleogel during its one month storage at 25 ◦C.
Figure 8. (a) Particle size distribution (×10, ×50, and ×90 values) and (b) gel strength of an oleogel (8%
TE in paraffin) during one month of storage; mean ± SD, n = 3.
As can be seen, laser diffraction revealed minimal particle size directly after homogenization. Due
to aggregation, the measured particle size (×10 and ×50 value) subsequently increased steadily during
storage. This aggregation of the particle is in line with measurements of the gel strength of the oleogel
which also rises during storage. During storage, the ×90 values remained almost unaffected within the
first week of storage and showed a significant increase after 1 month. This indicates that the interaction
forces increased during storage to such an extent that the small shear forces during sample preparation
were not sufficient to further disaggregate the larger aggregates completely.
This behavior changed substantially in the presence of 1,2-hexanediol and 1,6-hexanediol (Figure 9).
While 1,2-hexanediol inhibited particle aggregation during one month of storage, the measured
particle size in the presence of 1,6-hexanediol was significantly larger directly after homogenization.
Four hours after preparation, the particle size distribution was already comparable to the plain oleogel
after one month of storage. The firmness of the oleogel with 1,6-hexanediol was too high to allow a
particle size measurement after 4 h. Obviously, 1,6-hexandiol extensively promotes the interaction of
TE particles.
Again, the gel strength of the oleogels were in line with the results of the particle size measurements
(Figure 10).
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Figure 9. Particle size distribution of oleogels (8% TE in paraffin) during one month of storage with
(a) 2% 1,2-hexanediol and (b) 2% 1,6-hexanediol; mean ± SD, n = 3.
Figure 10. Gel strength of oleogels (8% TE in paraffin) during one month of storage with 2%
1,2-hexanediol and 1,6-hexanediol; mean ± SD, n = 3.
During one month of storage, the gel strength in the presence of 1,2-hexanediol remained almost
constant at a low level due to insufficient interaction of the TE particles. In contrast, oleogels with
1,6-hexanediol showed a marked increase in the gel strength during one month of storage. At first
sight, this behavior is comparable to plain oleogels, however, the absolute values of the gel strength
are much higher in the presence of 1,6-hexanediol.
The mechanism behind these huge differences between 1,2-hexanediol and 1,6-hexanediol is
already illustrated schematically in Figure 7. 1,6-Hexanediol with its terminal OH groups has the ability
to act very effectively as a linker between the TE particles. Due to its much smaller size compared to the
TE particles, 1,6-hexanediol is able to link the particles faster and more flexibly and thus more efficiently
lead to a pronounced activation of the gel network. 1,2-Hexanediol with its vicinal OH groups has
an amphiphile and adsorbs to the superficial functional groups of the TE particles. Consequently,
the hydrocarbon chain is oriented to the continuous phase and prevents the formation of hydrogen
bonds. This is comparable to the negative impact on the aggregation of silica particles dispersed in
DMSO when the number of sites for hydrogen bonding of silanol groups was reduced by surface
modification [22].
3.5. Extract Saving Effect of Additives
In the oleogels, TE represents the active component as well as the gel forming excipient. This brings
about that higher amounts of TE are required than probably necessary for the intended therapeutic
effect. In this context, supplementing the oleogel with 1,6-hexanediol as the most effective gelation
enhancer should drastically reduce the required concentration of TE necessary for gel formation.
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To this end, oleogels with different TE concentrations were produced without and with the
addition of a rather low concentration (0.5%) of 1,6-hexanediol (Figure 11).
Figure 11. Dissipation factor d with different concentrations of TE with and without 1,6-hexanediol
(0.5%); mean ± SD, n = 3.
Without additives, the critical gelation concentration of TE in sunflower oil was 3% as indicated
by a dissipation factor in the linear viscoelastic region ≤1. In the presence of 0.5% 1,6-hexanediol, the
critical gelation concentration dropped to <1% TE. Even at such low TE concentrations, the resulting
oleogels with 1,6-hexanediol are highly elastic as indicated by a dissipation factor <0.1.
4. Conclusions
Hydrogen bonds are mainly responsible for the formation of the gel network in oleogels with
birch bark dry extract. Additives, which can act as linkers between the extract particles, enhance the
formation of a particulate network. The most pronounced effect was observed in diols with terminal
hydroxyl groups. 1,6-Hexanediol gave the best results and allowed the formation of an oleogel with
a drastically reduced concentration of TE. This effect depends on the concentration of the gelation
enhancer. A concentration in the range of 0.5% to 1% was found to be optimal. In contrast, 1,2-diols
impaired gel formation by blocking superficial OH groups on the extract particles and preventing
them from building a three dimensional particulate network.
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Abstract: Amphotericin B (AmB) is a potent antifungal successfully used intravenously to treat visceral
leishmaniasis but depending on the Leishmania infecting species, it is not always recommended
against cutaneous leishmaniasis (CL). To address the need for alternative topical treatments of
CL, the aim of this study was to elaborate and characterize an AmB gel. The physicochemical
properties, stability, rheology and in vivo tolerance were assayed. Release and permeation studies
were performed on nylon membranes and human skin, respectively. Toxicity was evaluated in
macrophage and keratinocyte cell lines, and the activity against promastigotes and intracellular
amastigotes of Leishmania infantum was studied. The AmB gel remained stable for a period of
two months, with optimal properties for topical use and no apparent toxic effect on the cell lines.
High amounts of AmB were found in damaged and non-damaged skin (1230.10 ± 331.52 and 2484.57
± 439.12 μg/g/cm2, respectively) and they were above the IC50 of AmB for amastigotes. Although
there were no differences in the in vitro anti-leishmanial activity between the AmB solution and gel,
the formulation resulted in a higher amount of AmB being retained in the skin, and is therefore
a candidate for further studies of in vivo efficacy.
Keywords: Amphotericin B; Sepigel 305®; Leishmania infantum; cutaneous leishmaniasis; topical
treatment
1. Introduction
Leishmaniasis are a group of diseases caused by species of Leishmania protozoan parasites and
transmitted by the bite of Phlebotomine sand flies. Nearly 12 million people are infected in 98 countries
worldwide [1]. There are three main forms of the disease and the manifestations depend on the
infecting species, the immunological system of the patient and the area of inoculation [2,3]. Cutaneous
leishmaniasis (CL), the most common form, can appear as single or multiple skin lesions, starting as
a papule and potentially evolving into an ulcer; mucocutaneous leishmaniasis involves the destruction
of mucous membranes; and visceral leishmaniasis (VL) is a fatal form affecting internal organs [4]. In the
Mediterranean area, Leishmania infantum is the main causal agent of VL and CL [5], and particularly in
Spain, L. infantum is the responsible for the endemic CL cases [6,7].
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Although there is no universal consensus on the treatment of CL [8], pentavalent antimonials
still remain the first-line therapy, frequently used in combination with pentoxifylline or paromomycin
to maximize treatment efficacy despite the toxic side effects and the development of resistances [9].
Pentavalent antimonials (meglumine antimoniate and sodium stibogluconate) are administered
intravenously or by painful intralesional injections which are frequently discontinued by patients,
which promotes resistances [10].
Amphotericin B (AmB) is a polyene macrolide antibiotic that opens ion channels and aqueous
pores in the Leishmania membrane by binding to ergosterol, making the bilayer thinner and increasing
the permeability and loss of intracellular compounds, thereby triggering lysis and parasite death [11].
AmB intravenous injections are used as a second-line treatment for CL, but they cause severe toxicity,
particularly nephrotoxocity in the case of conventional AmB. Liposomal AmB (Ambisome®) has been
demonstrated to be more effective and less toxic, but its high cost makes its use difficult in developing
countries [12,13].
In the last five years, research directed to improve delivery systems for the treatment of
leishmaniasis has focused considerable attention on AmB as an active component [14], mainly
using a parenteral administration approach. PLGA polymeric nanoparticles have been studied
for intralesional and intravenous administration of AmB [4,15], as well as diverse emulsions and
micelle formulations for intravenous use [16,17]. Considerable research is also being directed into
the development of oral or topical formulations, as they imply greater patient compliance and fewer
side effects. Chitosan has been investigated as a nanocarrier for oral administration [18], as well
as an ingredient in an emulsion of nanoparticles [19]. Dermal delivery has been achieved with
microneedles that generate micropores in the epidermis for the administration of an AmB solution [20].
For the topical treatment of CL, a combination of cyclodextrin plus AmB has been studied in a gel
formulation [21], and ultradeformable liposomes have also been postulated [22].
Pharmaceutical gels are semisolid dosage forms consisting of a solvent thickened by the addition
of colloidal substances. Colloids are polymers with gelling capacity and constitute a dispersed phase,
and the liquid solvent is the continuous phase. The most common solvents used in gel formulation are
water or hydroalcoholic solutions that form hydrogels.
Hydrogels form cross-linked polymer chain networks able to capture large quantities of water in
the spaces between chains and are widely used as vehicles in topical drug delivery [23]. They provide
a refreshing sensation on the skin, are not sticky and have an optimal appearance. Sepigel 305®,
which is composed of the fatty oil isoparaffin, the gelation-promoting polymer polyacrylamide and
the non-ionic emulsifier laureth-7, forms hydrogels that permit the addition of hydrophilic and
lipophilic substances.
The objective of this work was to develop a topical formulation incorporating AmB for CL
therapy. AmB is a very hydrophobic molecule and is poorly soluble in water and most organic
solvents. Using the capacity of Sepigel 305® to include hydrophobic substances, we developed an AmB
hydrogel-based formulation with optimal organoleptic characteristics. The stability was assessed by
examining the physicochemical properties of the gel for two months. Permeation and retention studies
were performed ex vivo in human skin, tolerance was checked in healthy volunteers, and toxicity
and leishmanicidal activity were examined in vitro in promastigotes and intracellular amastigotes of
Leishmania infantum.
2. Materials and Methods
2.1. Reagents
Amphotericin B and Sepigel 305® were purchased from Acofarma (Barcelona, Spain). Dimethyl
sulfoxide (DMSO) and NaOH were obtained from Sigma-Aldrich (Darmstadt, Germany). TranscutolP®
was provided by Gattefossé (Barcelona, Spain). The distilled water used to perform the assays was
acquired from a Mili-Q® Plus System (Millipore Co., Burlington, MA, USA).
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2.2. Parasite Strains and Cultures
For the parasitology experiments, the Leishmania infantum strain (MHOM/ES/2016/CATB101) was
isolated from a patient with CL in Spain, and promastigotes were maintained at 26 ◦C in supplemented
Schneider complete medium at pH 7.0 with 20% heat-inactivated fetal calf serum, 25 μg/mL gentamicin
solution (Sigma, St. Louis, MO, USA), and 1% penicillin (100 U/mL)–streptomycin (100 mg/mL)
solution (Sigma, St. Louis, MO, USA).
2.3. Gel Preparation
Briefly, the gel-based 1% Sepigel 305® formulation was prepared with constant mechanical stirring
(solution A). Subsequently, 150 mg of AmB was dissolved in 5 mL of DMSO, of which 1 mL was slowly
added under agitation to 30 mL of solution A. The resulting solution was adjusted to pH 6 with NaOH
2N solution, thus obtaining AmB gel at a final concentration of 1000 μg/mL.
2.4. Physicochemical Characterization of the AmB gel
2.4.1. Morphological Analysis
The internal morphological structure was observed under scanning electron microscopy (SEM)
using a FEI Quanta 200 (Hillsboro, OR, USA) in high-vacuum conditions. AmB gel was dried off for 14
days under a vacuum desiccator and a sample of 0.1 g was covered with carbon.
2.4.2. Swelling and Degradation Tests
Dried and fresh AmB gel were utilized to perform the swelling and degradation tests. In both
studies, the AmB gel was kept in PBS (pH = 5.5) for 21 min at 32 ◦C. Samples (n = 5) were weighed
after wiping the superficial water at determined timeslots every 3 min. The swelling ratio (SR) was




where Ws is the weight of the swollen AmB gel at 3 min intervals and Wd is the weight of dried gel.






where Wi is the weight of the AmB gel at the initial point of the experiment and Wd is the gel weight
every 3 min at preselected time points.
2.4.3. Porosity Study
The porosity percentage is based on the sinking of the AmB gel previously dried in absolute
ethanol for 20 min and weighing it every 2 min when the excess of ethanol is blotted.




where W1 stands for the weight of the dried AmB gel, W2 is the weight of the AmB gel after each
immersion every 2 min, ρ is the density of ethanol and V is the volume of the AmB gel.
2.5. Stability Studies
Samples of the AmB gel were stored at different temperatures (room temperature (RT), 4 ◦C and
37 ◦C) to determine the stability of the formulation.
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The pH values were registered with universal test paper (Ahlstrom-Munksjö, Helsinki, Finland)
by directly spreading the samples (n = 3) and checking the visual appearance and drug loading after 1,
30 and 60 days.
The AmB content was analyzed using a previously validated High-Performance Liquid
Chromatography (HPLC) methodaccording to international guidelines, with linearity, sensitivity,
accuracy, precision and selectivity as described by Sosa et al. (2017) [24]. The calibration curves were
prepared with freshly prepared stock solutions of AmB ranging from 0.39 to 200 μg/mL. The analytical
method was precise, with coefficient of variation between 0.02% and 8.79%, a relative percent error
between−1.16% and 3.46%, and linear within the range of concentrations used (0.39–200μg/mL), with a p
value corresponding to the ANOVA applied to the mean values of 0.05. AmB was determined using
a Waters® 515 HPLC Pump, a 717 Plus Autosampler and a 2487 Dual λ Absorbance Detector (Waters®,
Milford, MA, USA). The assay was carried out using a Kromasil® Eternity C18 (250 mm × 4.6 mm ×
5 μm, Teknokroma, Barcelona, Spain). The mobile phase was a mixture of acetonitrile:acetic acid:water
(52:4.3:43.7 v/v/v) and was pumped through the C18 column at a flow rate of 0.5 mL/min. A volume of
10 μL was injected per sample and finally the elute was analyzed at 406 nm. All measurements were
performed at RT and at isocratic conditions of elution.
Destabilization phenomena were inspected by multiple light scattering and analysis of
backscattering and transmission profiles using a TurbiScanLab® (Formulaction Co., L’Union, France)
with a pulsed near-infrared light source (γ = 880 nm) at 25 ◦C, 1, 30 and 60 days after the preparation
of the AmB gel.
2.6. Rheological Studies
A rotational rheometer (Thermo Scientific HaakeRheostress 1, Thermo Fischer Scientific, Karlsruhe,
Germany) with a cone plate set-up, a fixed lower plate and a mobile upper cone Haake C60/2◦ Ti was
used to carry out the rheological assay. Measurements were taken in duplicate at 25 ◦C and 4 ◦C
24 h after gel preparation, as the rheometer is equipped with a ThermoHaake Phoenix II + Haake
C25P (Thermo Fischer Scientific, Waltham, MA, USA) to control the temperature. The shear rate ramp
program encompassed a ramp-up period from 0 to 50 s−1 for 3 min, a constant shear rate period of
50 s−1 for 1 min and a ramp-down period from 50 to 0 s−1 for 3 min. The data acquired from flow
curves (τ = f(
.
γ) were fitted to different mathematical models (Newton, Bingham, Ostwald-de-Waele,
Herschel-Bulkley, Casson and Cross) and the best fit was selected according to the correlation coefficient
value (r). Mean viscosity curve (η = f(
.
γ)) values were determined from the constant share section at
50 s−1 [25].
2.7. Spreadability Test
The spreadability (n = 3) of AmB gel was determined by placing 0.5 g of the formulation between
a plate and a millimeter glass plate cover. Different weights (2, 5, 10, 20, 50, 100, 200 and 300 g)
were successively placed on top for 2 min each at RT. Spread diameters were measured and fitted
into mathematical models using GraphPad Prism® version 6.0 (GraphPad Software Inc., San Diego,
CA, USA).
2.8. In Vitro Release Studies
AmB release was assessed in an 0.64 cm2 area of Franz diffusion cells (FDC 400; Crown Glass,
Somerville, NJ, USA) on nylon membranes (0.45 μm) (Sterlitech Corporation, Kent, WA, USA).
Pure DMSO solution continuously stirred at 600 rpm and 32 ± 0.5 ◦C was used as the receptor medium
to accomplish sink conditions. Then, 0.75 g of AmB gel and 0.75 mL of AmB solution were deposited
in the donor compartment. The study was performed in three replicates for a period of 48 h and the
AmB was determined by HPLC-UV at preselected time points.
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2.9. Ex Vivo Permeation Studies
Human skin from a donor undergoing plastic surgery at Barcelona-SCIAS Hospital (experimental
protocol reference number: BEC/001/16, Barcelona, Spain) was used to perform the permeation assays in
Franz diffusion cells, as described in the previous section. Skin was sliced into 400 μm thick specimens
and the integrity was checked by measuring the transepidermal water loss (TEWL) parameters [26].
To damage the tissue, the stratum corneum of healthy skin was partially removed 7 times with the tape
stripping technique. Then, both healthy and damaged skin were used in the experiments. After this,
0.75 g AmB gel was deposited on the upper side of the skin, facing the stratum corneum. Transcutol P®
was used as the receptor medium and was kept at 32 ± 0.5 ◦C in the receptor compartment. After 24 h,
the amount of AmB in the receptor compartment as well as inside the skin was quantified by HPLC in
three replicates. The drug retained in the skin was extracted after washing and cutting the permeation
area with an ultrasound bath and cooling for 15 min.
2.10. In Vivo Tolerance Studies
Ten volunteers with healthy skin took part in the study, which was approved by the Ethics
Committee of the University of Barcelona (reference number: IRB00003099; date: 20 March 2018),
following the Declaration of Helsinki guidelines [27]. Participants were asked not to use any kind of
cosmetics on the flexor side of the left forearm in the days before the test. Measurements were carried
out at baseline, 30 min after the volunteers arrived in the test room, and then at 15 min, 1 h and 2 h
after the application of 0.5 g of AmB gel. TEWL and the stratum corneum hydration (SCH) values were
measured by a Tewameter® TM 300 (Courage-Khazaka electronic GmbH) and a Corneometer® CM 825
(Courage-Khazaka electronic GmbH), respectively, in accordance with international guidelines [28].
2.11. In Vitro Cytotoxicity Assay
Three different cell lines were used to establish the cytotoxic effect of the AmB gel—two macrophage
cell lines (RAW 264.7 and J774A.1) and a keratinocyte cell line (HaCat). A suspension of 5 × 104
cells/mL of each cell line was seeded in 96-well plates (Costar 3596, Corning Incorporated, NY, USA)
and cultured at 37 ◦C and 5% CO2 atmosphere in RPMI-1640 complete medium [10% heat-inactivated
fetal calf serum and 1% penicillin (100 U/mL)–streptomycin (100 mg/mL)] for 24 h. After that, serial
dilutions of the AmB gel and AmB solution were added and the conditions were maintained for
another 24 h. Finally, the reagent WST-1 (Roche Diagnostics GmbH) was added at a concentration of
10% to all wells and the plate was incubated for 4 h in the same conditions regarding temperature and
CO2 atmosphere. Absorbances were read at 450 nm (Multiskan EX, Thermo Electron Corporation,
Shanghai, China). To determine the concentration that inhibits 50% of cell viability (CC50), a linear
regression analysis was performed, and the experiments were performed in triplicate [29].
2.12. In Vitro Leishmanicidal Activity against Promastigotes
Promastigotes were cultured in cell culture flasks. To assess their activity, serial dilutions of AmB
gel and AmB solution were prepared in Schneider medium and placed in a 96-well plate (Costar 3596,
Corning Incorporated, NY, USA). A suspension of 106 promastigotes/mL in a logarithmic phase were
added to the previous dilutions and incubated at 26 ◦C for 48 h. Parasitic growth was evaluated using
the phosphatase acid method described by Carrió et al. (2000). Briefly, the samples were lysed, and the
enzymatic reaction was revealed with p-nitrophenyl phosphate by alkalization. The optical density
was read at 405 nm (Multiskan EX, Thermo Electron Corporation, Shanghai, China). The IC50 (the
concentration that inhibits 50% of parasite growth) was calculated by variable transformation and
linear regression analysis, and the experiments were performed in triplicate [30].
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2.13. In Vitro Leishmanicidal Activity against Amastigotes
The cell line J774A.1 was used to study the activity of the AmB gel against amastigotes.
A concentration of 5 × 104 cells/mL was seeded in an 8 LabTek chamber slide system (Nunc®,
Rochester, NY, USA) and incubated for 24 h at 37 ◦C in a 5% CO2 atmosphere. Late stationary phase
promastigotes from a 5-day growth culture were added in a ratio of 1:10 (macrophage:parasites) and
incubated for 24 h in the same conditions. After the elimination of free promastigotes by washing,
fresh RPMI-1640 complete medium with serial dilutions of gel or solution was added, and incubation
was carried out for 48 h in the same conditions. Untreated cultures were included as a positive control.
Slides were fixed and stained with Giemsa to evaluate the number of amastigotes in 300 macrophages
and the percentage of infected cells was determined in triplicate. The IC50 was expressed as the
percentage of growth inhibition with respect to the untreated controls [31].
2.14. Statistical Analysis
The data collected in the studies were analyzed by one-way parametric analysis of variance
(ANOVA), followed by a multiple comparison Tukey test (p < 0.05 = statistically significant differences)
using Prism® V. 5 (GraphPad Software Inc., CA).
3. Results
3.1. Physicochemical Characterization of the AmB gel
Figure 1 shows the homogeneous laminar disposition of undulating layers of AmB gel, with holes
or cavities between the layers.
  
(A) (B) 
Figure 1. Images of amphotericin B (AmB) gel under SEM, (A) undulating layers (887×) and (B) detail
of cavities between layers (5092×).
The AmB gel described a hyperbolic model in the swelling experiment, with a kinetic constant
of k = 3.66 min (r2 = 0.9986). Gel degradation was completed in 10 min and was represented by
a one-phase exponential model, where the kinetic constant was k = 0.31 min−1 (r2 = 0.9992) and the
porosity percentage was ~85.47% ± 0.73%. The swelling and degradation graphs generated by the
AmB gel are shown in Figure 2.
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Figure 2. Swelling ratio (left) and degradation (right) of AmB gel during 21 min in PBS medium.
3.2. Stability Studies
The AmB gel presented a pH value of 5–6 throughout the experiment. The yellow colour of the
AmB formulation remained unchanged at all temperatures tested in the study period. No lumps or
precipitation were observed.
Figure 3 shows the backscattering profile of Amb gel at 25 ◦C over a period from 1 to 60 days.
No sedimentation, flocculation or coalescence phenomena were detected.
Figure 3. Laser backscattering (BS) profile of AmB gel over 60 days at 25 ◦C. The left side corresponds
to the bottom of the vial containing the sample, whereas the right side corresponds to the sample
behavior at the top.
The initial AmB content revealed the gel formulation had 95.99% entrapment efficiency.
The concentration of AmB in the gel over time is summarized in Table 1. The AmB content of
the gel samples did not present statistical differences (p > 0.05) at the tested temperatures after 60 days
of storage at 4 ◦C, whereas a significant decrease in the AmB content of the gel was observed when it
was maintained at RT and 37 ◦C.
Table 1. Concentration of AmB and SD at the beginning of the experiment (t0 = initial time) and 60
days later (t60) at different storage temperatures.
AmB (μg/mL ± SD)
t0 t60 RT t60 37
◦C t60 4 ◦C
AmB gel 959.90 ± 84.27 199.65 ± 27.99 70.95 ± 13.59 916.70 ± 99.78
3.3. Rheological Studies
The AmB gel presented rheo-thinning (pseudoplastic) behavior at 25 ◦C and 4 ◦C (Cross model;
r2 = 0.9996 and r2 = 0.9998, for the two temperatures, respectively). The viscosity at 50 s−1 was 1542.5
± 3.49 mPa·s, and there was ahysteresis loop with an area of 194.4 Pa/s at 25 ◦C. The viscosity at 50 s−1
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was 1457 ± 4.04 mPa·s, and there was also a hysteresis loop with an area of 160.1 Pa/s at 4 ◦C. Figure 4
shows the rheological graphs.
 
(A) (B) 
Figure 4. Rheological behavior of AmB gel showing a hysteresis loop. (A) Behavior at 25 ◦C and (B)
4 ◦C.
3.4. Spreadability Test
The spreadability of AmB gel followed a hyperbola kinetic model:
[S = Smax ×W/(Kd +W)]
where S represents the extended surface in cm2, Smax is the maximum extension surface in cm2,
W stands for the weight attached in g and Kd is the kinetic constant in g. Figure 5 shows the resulting
graph and equation.
Figure 5. Graphicalhyperbolic behavior of AmB gel spreadability.
3.5. In Vitro Release Studies
The amount of AmB released from the solution and gel at 48 h of the experiment was 753.01 ±
83.43 μg/cm2 and 501.02 ± 58.17 μg/cm2, respectively (Figure 6), which represents an AmB release of
100.40 ± 11.13%from the solution and 66.80 ± 8.9% from the gel. The mathematical model with the best
fit was one-phase exponential association.
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Figure 6. Released amounts (Q) of AmB from the solution and gel through nylon membranes for 48 h.
3.6. Ex Vivo Permeation Studies
Table 2 summarizes the amount of AmB obtained in the permeation studies with damaged and
non-damaged skin. No AmB flux was observed across the skin barrier.
Table 2. Amounts of AmB found in the permeation studies after 24 h in damaged and non-damaged skin.
Assay
AmB gel
Non-Damaged Skin Damaged Skin
Permeation (μg/cm2) ± SD Not detected Not detected
Retention in skin (μg/g/cm2) ± SD 2484.57 ± 439.12 1230.10 ± 331.52
3.7. In Vivo Tolerance Studies
At 15 min of AmB gel application, decreased values of TEWL were observed, as well as an increased
hydration of the stratum corneum, with statistically significant differences compared with all the time
points in the experiment. The graph in Figure 7 shows the variations of biomechanical properties.
Figure 7. Biomechanical parameters: TEWL (transepidermal water loss) and SCH (stratum corneum
hydration) values for 2 h after AmB gel application (* p < 0.05; ** p < 0.01; *** p < 0.001).
3.8. In Vitro Cytotoxicity Assay
As seen in Figure 8, the CC50 of Sepigel 305® in the cell lines assayed was higher than 75.0 μg/mL.
The CC50 of the AmB gel and solution was higher than 25.0 μg/mL (Figure 9).
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Figure 8. Cytotoxicity of the gelling excipients in cell lines HaCaT, RAW 264.7 and J774A.1.
Figure 9. Cytotoxicity of AmB solution and AmB gel in cell lines HaCaT, RAW 264.7 and J774A.1.
3.9. In Vitro Leishmanicidal Activity against Promastigotes and Amastigotes
Table 3 summarizes the activity on promastigotes and amastigotes. The IC50 of the AmB solution
and AmB gel was 0.35± 0.02 μg/mL and 0.56± 0.12 μg/mL against promastigotes, and 0.91± 0.07 μg/mL
and 0.87 ± 0.10 μg/mLagainst amastigotes, respectively. The selectivity index (SI) values of AmB
solution and AmB gel were higher than 25 for both macrophage cell lines.
Table 3. Activity in vitro against promastigotes and amastigotes, cytotoxicity of AmB solution and
AmB gel and selectivity index (SI).
Formulations (μg/mL)
IC50 (μg/mL ± SD) SI CC50 (μg/mL)
Promastigotes Amastigotes SIRAW SIJ774A.1 RAW 264.7 J774A.1
AmB solution 0.35 ± 0.02 0.91 ± 0.07 27.52 27.52 >25 >25
AmB gel 0.56 ± 0.12 0.87 ± 0.10 28.74 28.74 >25 >25
4. Discussion
Although AmBisome®, an AmB liposomal formulation for intravenous administration, isvery
effective for the treatment of visceral leishmaniasis, its high price limits its use in the routine treatment
of CL, despite an agreement with the World Health Organization and Gilead Sciences resulting in
a price reduction in developing countries [32]. A topical formulation that achieves dermal drug
delivery is a goal in CL treatment, as it will allow patients to administer their own treatment, avoid the
discomfort of painful injections and reduce costs.
Gels are colloidal systems used in drug delivery to the skin that may improve the distribution and
stability of compounds, as well as reduce undesirable systemic effects [33]. The self-emulsifying agent
Sepigel 305® allows a simple and cost-effective formulation of gels for topical use, as the emulsification
process does not require any heat energy [34]. In the current study, we formulated an AmB gel
made with multifunctional polymer formulation Sepigel 305® as a possible topical alternative in the
CL therapy.
Drug release is affected by the degradation of the gel in a physiological environment and
also the swelling ratio—the faster the swelling of the gel is accomplished, the greater its porosity.
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The degradation rate of the AmB gel was constant and completed in 10 min, indicating it was not
dependent on the remaining amount of polymer. The high porosity percentage of the AmB gel
was corroborated by SEM images, which revealed undulating layers uniformly arranged and spaces
between the layers, resembling holes or cavities. We reported similar levels of swelling, degradation
and porosity in a previously characterized meglumine antimoniate Sepigel 305® [35].
Near the isoelectric point, the pH of AmB gel was 5–6, which means it is biocompatible and suitable
for skin application [36]. The visual appearance of the formulation remained unchanged throughout
the experiment, which was in line with the backscattering profiles used to evaluate the physical stability
of the formulation over a long period of time. The superimposed graphs (Figure 3) showed variations
below 10%, which is indicative of stability [37,38]. The variability in the AmB concentration at t0 in
the analysis content could be explained because different batches of AmB gel were prepared in order
to dispose of fresh formulation to perform the experiments. Moreover, the AmB content in the gel
remained constant over a span of 60 days at 4 ◦C, indicating that the drug is chemically stable when
refrigerated. By contrast, at RT the stability analysis indicated that less than 20% of the main active
ingredient was detectable, and it was even lower when stored at 37 ◦C. This could represent a limitation
for the storage and clinical manipulation, as refrigeration is not always available. These stability
results differ from the marketed AmB liposome formulations (AmBisome®, Abelcet®), where the
stability is guaranteed for around 24–48 h at 2–8 ◦C once the reconstitution has been performed. Also,
Rizzo et al. (2018) found rapid AmB degradation within 2 days when analyzing its stability in different
combinations of AmB solutions [39]. Other studies support the use of excipients for semisolid dosage
forms to increase the stability of AmB [24,38,40].
Rheological analysis provides information about aspects of the product application. The AmB
gel exhibited rheo-thinning behavior (a term used by the Rheology Society to replace pseudoplastic
behavior) and high viscosity, and showed a hysteresis loop in the rheograms, indicating a probable
thixotropic comportment of the gel. Thixotropic behavior is an advantage in topical formulations,
favoring application, as the viscosity of the formulation varies with friction and retention on skin is
enhanced [41]. Friction reduces the viscosity of thixotropic fluids, which permits a good spreadability,
and the initial status of the gel is recovered once the friction stops. The high spreadability of the AmB
gel, as shown in Figure 5, can be explained by the dependence of the viscosity on the shear rate and
shear time. When the gel was submitted to deformation (added weights), the viscosity decreased and
spreadability was enhanced.
The AmB release profile was assessed to check that the gel was well formulated and permitted
the AmB liberation to monitor the kinetic behavior [42]. The data obtained demonstrated a constant
release for 48 h in a Fickian diffusion process. At 48 h, the amount of AmB released through the nylon
membranes was 100% for the AmB solution because there were no impediments, and it confirms the
suitability of the membrane, while AmB from the gel was 66.80% liberated. It is an expectable value
for a modified release formulation where the excipients play an important role in the liberation of the
drug. In a comparative study, Potúcková et al. (2008) reported that drug release was increased when
the excipient in the marketed formulation was replaced by Sepigel 305® [43].
Permeation was studied on both damaged and non-damaged skin, as CL lesions can manifest as
a nodule or a papule entirely covered with epidermis, or as an ulcer without this layer. No permeation
of AmB from the gel was detected in the receptor compartment in either skin type after 24 h. In contrast,
high amounts of AmB were retained in both types, with higher values in the non-damaged skin,
suggesting that the stratum corneum acts as a reservoir of the drug. The reservoir effect of skin is
helpful in the topical treatment of CL nodules or papules because the local depot effect potentiates the
treatment duration as this kind of lesion is covered by the epidermis layer [44]. In contrast, this depot
effect will not occur in ulcerated lesions. The high deposition of AmB in both kinds of skin observed
in this study could indicate a long availability, as commonly required. The achieved levels of AmB
retained in both kinds of skin resulted in a higher value than the IC50 of AmB for amastigotes, which is
considered a goal for successful treatment [45].
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Studies on other topical AmB formulations applied on human skin and porcine vaginal mucosa
have also reported the absence of AmB in the receptor compartment and high amounts retained inside
tissues [24,38]. This behavior can be explained by the high lipophilicity of AmB, which limits its ability
to pass through the aqueous dermal structure. Our studies in both kinds of skin reflect that AmB
is able to cross the stratum corneum to the epidermis and dermis. Our results with stripped skin
(“damaged skin”) are comparable to those obtained with porcine vaginal mucosa, which does not
present stratum corneum layer, and AmB can reach the dermis but is not distributed in the systemic
circulation. This suggests that after topical application, part of the drug would remain in the epidermis
and dermis, thus avoiding systemic side effects. As well as providing a high drug concentration in the
skin, an effective topical treatment of CL should target the amastigotes of Leishmania parasites in the
phagolysosome of infected macrophages in the papillary dermis, which is found immediately below
the epidermis [46].
In contrast with these results, Jaafari et al. (2019) reported an AmB flux through mouse
full-thickness skin to the receptor compartment after the application of AmB liposomes and corroborated
the permeation in vivo when the same liposomes were administered in a mouse model [47]. Different
studies carried out with AmB nanoemulsions formulated with surfactants for topical delivery reported
a high retention of the drug in rat skin and flux to the receptor compartment [40,48,49]. The surfactants
in the nanoemulsions enhance AmB permeation by destabilizing the cellular bilayer lipids in the
stratum corneum, increasing deformation and enhancing the permeation [50]. It is also relevant that
rat skin may lead to a greater permeation of drugs [51], as observed in studies reporting the higher
permeability of rat skin compared with human skin [52,53].
The biomechanical parameters of transepidermal water loss and stratum corneum hydration
were monitored for 2 h after application to evaluate skin integrity. The values obtained revealed
a decrease in the TEWL immediately after AmB gel application, as well as an increased hydration
of the stratum corneum due to an occlusive effect of the formulation. This was probably caused by
the high lipophilicity of the drug. The TEWL and hydration of the stratum corneum basal values
were recovered over 1 h after application, indicating changes in the skin are reversible. Furthermore,
no discomfort after the gel application was reported by the volunteers, who did not experience any
burning sensation, irritation or itching.
Sepigel 305® and the AmB gel and solution did not show toxicity in the range of dilutions
assayed on the three cell lines tested in the experiments. The results corroborate previous reports of
safety of using Sepigel 305® in topical formulations, with the exception of one case of allergic contact
dermatitis [54].
No differences in the in vitro activity against Leishmania infantum promastigotes and amastigotes
were observed between the AmB solution and the formulation, indicating an absence of a synergistic
effect between the gel excipients and the AmB.
Due to the safe usage of other AmB formulations that has been previously reported in healthy
volunteers [55], and prompted by the study of López et al. (2018), who concluded that their 3%
AmB cream tested in patients with uncomplicated CL needed reformulation of either the vehicle or
concentration [56], we propose Sepigel 305® as a suitable vehicle for 0.1% AmB for topical treatment.
Allowing a good release of the AmB with high amounts of the drug retained in excised human
skin, the formulation could be a potential tool for CL treatment, as only a few doses of AmB are
required to kill the parasite. Further assays in an animal model should be performed to establish the
antileishmanial efficacy of the AmB gel.
5. Conclusions
The development of a topical treatment for CL is desirable, as painful intralesional treatments
are widely rejected by patients. In this context, we elaborated an AmB gel with optimal sensorial and
functional properties that was shown to be stable for 60 days at 4 ◦C. The organoleptic characteristics
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of the gel are compatible with usage on skin, as it has a suitable pH, good spreadability and drug
release, and did not produce irritation.
Damaged and non-damaged skin were exposed to amounts of AmB considered sufficiently high
to exert local action against CL. No AmB was detected in the receptor compartment due to its high
molecular weight and lipophilicity. This represents an advantage as the treatment would avoid
systemic toxicity.
No cytotoxic effects were observed in the macrophage or in the keratinocyte cell lines. Although
the antileishmanial activity of AmB was not affected by the gel formulation in vitro, the AmB gel
should undergo in vivo testing to further evaluate its activity and efficacy in the treatment of CL.
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Abstract: An IVRT method was developed and validated to confirm its reproducibility, precision,
sensitivity, selectivity, accuracy, robustness, and reliability. A novel approach was used to demonstrate
the appropriateness of the IVRT method to accurately assess “sameness” between topical products
and to confirm that the methodology applied also possesses the requisite discriminatory power to
detect differences should such differences exist between products. In the first instance, the reference
product (Metrocreme®) containing 0.75% metronidazole (MTZ) was tested against itself as a positive
control, to accurately demonstrate “sameness”, where the results met the relevant acceptance criteria
falling within the limits of 75–133.33% in accordance with the FDA’s SUPAC-SS guidance. In addition,
two specially prepared creams containing 25% less and 26% more MTZ, i.e., 0.563% and 0.945%,
served as negative controls and were compared against the reference product. Neither of these creams
fell within the “sameness” acceptance criteria, thereby confirming the discriminatory ability of the
IVRT method to detect differences between MTZ products. Furthermore, another cream containing
0.75% MTZ tested against the reference product was shown to be pharmaceutically equivalent to
the reference product. These results confirm the appropriateness of the IVRT method as a valuable
tool for use in the development of topical MTZ products intended for local action and indicate the
potential for general use with other topical products.
Keywords: IVRT; metronidazole; topical cream; semisolid dosage forms; sameness; FDA’s SUPAC-SS
guidance; acceptance criteria; positive and negative controls; discriminatory ability
1. Introduction
In vitro release testing (IVRT) entails measurement of the drug released from the vehicle into
a receptor medium, separated by an inert membrane [1] and used to quantify the amount of active
pharmaceutical ingredient (API) released from semisolid dosage forms and to determine its release
rate [2]. The application of IVRT to assess “sameness” of semisolid dosage forms following minor
changes related to an approved topical dosage form was described in the United States Food and Drug
Administration’s (FDA’s) SUPAC-SS guidance [3]. Furthermore, IVRT is a USP compendial method
used for performance testing of semisolid dosage forms [4] and is also an extremely useful tool in
product development [5]. It has been proven to be useful to detect differences in qualitative (Q1) and
quantitative (Q2) properties between similar products and also in the microstructure and arrangement
of matter between formulations (Q3) [6]. In 2003, the experts from FIP/AAPS pointed out that there was
an absence of a standard in vitro test that could be applied to semisolid dosage forms [7]. Until recently,
however, amongst the numerous publications involving the application of IVRT, comprehensive
validation of IVRT systems and methods have been conspicuously absent from the literature. Although
various efforts [8–10] have been made by several researchers to develop a standardized method to
measure in vitro drug release from a product using diffusion cells, a comprehensive validation that
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would be generally applicable to all topical dermatological dosage forms has only recently been
published [11]. This is essential to ensure that the developed IVRT method and the associated system
has the necessary discriminatory capabilities to determine “sameness” between products and also,
more importantly, differences, which may affect clinical performance.
Since clinical endpoint studies have been made mandatory by most of the regulatory authorities
to establish the safety and efficacy of generic topical products except in the case of topical corticosteroid
products wherein a vasoconstrictor assay (VCA) or human skin blanching assay (HSBA) is accepted in
accordance with the US FDA’s guidance, an appropriate IVRT method could provide valuable and
compelling information to justify waivers of bioequivalence studies (biowaivers) for topical semisolid
products intended for local action. In this respect, it is interesting to note that the US FDA [12–15] and
the European Medicines Agency (EMA) [16] have published guidances that recommend the use of IVRT
for such purposes. It is interesting to note that the abovementioned FDA guidances are product-specific
and the acceptance criteria are based on those recommended in the USP [4], in accordance with the
FDA’s SUPAC-SS guidance [3], whereas the acceptance criteria in the recent EMA draft guideline [16]
are more stringent. Furthermore, the EMA draft guideline [16] describes the validation conditions
and requisite discriminatory power of the method to support claims of therapeutic equivalence with a
reference product instead of undertaking clinical trials.
In view of the fact that market approval of a generic topical metronidazole (MTZ) product
requires a clinical endpoint study in patients to show safety and efficacy of such products, an IVRT
method was developed to investigate “sameness” and differences between a test formulation and the
market-approved reference product, Metrocreme®. The primary objective, therefore, was to investigate
the feasibility of using a nonclinical approach, such as IVRT, for consideration as a biowaiver to obtain
market approval. Consequently, an attempt was made to develop and comprehensively validate an
IVRT method which has the necessary discriminatory power to detect “sameness” and differences
in topical cream products containing 0.75% MTZ. A novel approach of incorporating a positive
control wherein the reference product was compared to itself and two negative controls, i.e., products
containing <25% or >25% potency compared to the reference product, was implemented.
2. Materials and Methods
2.1. Materials
2.1.1. Chemicals
MTZ was obtained from Sigma-Aldrich and stored in a cool, dry area that was free from light
exposure. HPLC-grade methanol (200 UV ROMIL—SpSTM Super Purity Solvent) was obtained from
Romil Ltd. (Waterbeach, Cambridge, UK). The water used for chromatography was prepared by
reverse osmosis, followed by filtration through a Milli-Q system (Millipore, Bedford, MA, USA).
2.1.2. Formulations
Metrocreme® (Galderma Laboratorium GmbH, Dusseldorf, Germany) containing 0.75% MTZ
was used as the reference MTZ cream. Creams containing 0.375%, 0.75% (T1), and 1.125% MTZ were
specially manufactured to validate the IVRT method. In addition, creams T2 and T3, which contained
25% less (0.563%) and 26% more (0.945%) MTZ than the reference product were used as negative
controls at the lower and upper acceptance limits, respectively, in accordance with the SUPAC-SS
limits [3], to establish the utility of the developed and validated IVRT method to assess inequivalence.
Test cream (T1) was also used to assess “sameness” for the purpose of marketing a generic MTZ cream.
2.1.3. Equipment
Mettler® Model AE 135 analytical balance (Mettler® Inc, Zurich, Switzerland) and MX5 Mettler®
Toledo Microbalance (Mettler® Inc, Zurich, Switzerland) were used for weighing samples and standards,
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respectively. Micropipettes P100 and P1000 (Pipetman™, Gilson®, Villiers-le-Bel, France) were used to
transfer standard and sample solutions for dilutions.
The concentration of hydrocortisone in PVT samples was analyzed on a Waters Alliance HPLC
system that was equipped with a separation module (Model 2695) and a PDA detector (Model 2996)
and Empower® 3 data acquisition system (Waters, CT, USA). The chromatographic separation was
achieved by using a Phenomenex Luna® C18 (2) 5 μm (150 × 4.6 mm) column (Torrance, CA, USA)
maintained at 25 ◦C. The mobile phase consisted of acetonitrile: water (30:70 v/v). A flow rate of
1 mL/min was maintained, and a detection wavelength of 254 nm was used. Samples were injected at
ambient temperature during analysis.
The concentrations of MTZ were determined by using a Waters Acquity UPLC system equipped
with a photo diode array detector (PDA), Empower® 3 data acquisition system (Waters, Milford, MA,
USA). The chromatographic separation was achieved by using an Acquity UPLC BEH C18 1.7 μm
(2.1 × 100 mm). A mobile phase of methanol/water (40/60 v/v) was pumped at a flow rate of 0.2 mL/min,
and the eluate was monitored at a wavelength of 318 nm. Samples (2 μL) were injected at ambient
temperature during analysis.
In vitro release studies were performed by using a Hanson VDC system (Hanson Research
Corporation, Chatsworth, CA, USA) consisting of six vertical diffusion cells (Volume: 7.9 mL, orifice:
15 mm) with closed cell tops, mounted on a six-station LGA platform and a magnetic stirrer (Variomag®,
Berkley, CA, USA), and a Control Unit (Telemodul 40S H+P Labortechnik GmbH, Munich, Germany),
connected to a PolyScience circulating water bath (Niles, IL, USA). The diffusion cells and apparatus
were assembled with donor and receptor chambers that were separated by a chosen membrane.
The receptor chamber was filled with 7.9 mL of SABAX Pour Saline (0.9% NaCl solution, Adcock
Ingram Critical Care (Pty) Ltd., Midrand, South Africa), which served as the receptor fluid and
maintained at 32 ◦C (to mimic the physiological temperature). The receptor medium was continuously
stirred, using individual magnetic stirrer bars, coupled with helical mixer springs, in each of the VDCs.
One-milliliter syringes (Terumo® (Philippines) Corporation, Laguna, Philippines) with sampling
needles (21G x 3.5” Terumo® Spinal Needle, Terumo® Corporation, Tokyo, Japan) were purchased
from local pharmacies.
2.2. Methods
2.2.1. UPLC Method Validation
The UPLC method was validated according to ICH guidelines and relevant criteria, as described
by Tiffner et al. [11].
2.2.2. Apparatus Qualification
Factors that can influence the drug release were assessed to comply with the requirements of an
apparatus qualification test in accordance with the USP procedures for apparatus qualification for
the VDC system [4,17]. Environmental factors such as suitable working area, workbench levelness,
no direct exposure to sunlight and/or direct cooling vents, and failure-resistant power supply to all
the electronic components were ensured. The system was placed on a dedicated sturdy wooden
workbench with a free distance of more than 76 cm above the system. Additionally, the orifice diameters
and capacities of each of the VDCs, the temperature of the receptor medium, stirrer speed, and the
dispensed sample volume were validated.
2.2.3. Performance Verification Test (PVT)
The PVT was performed by using 1% hydrocortisone cream (Emo-Cort®, GlaxoSmithKline Inc.,
Mississauga, ON, Canada) applied on Tuffryn membranes [17,18]. Two IVRT runs were performed,
each with six VDCs in parallel, by stirring the receptor medium at 600 rpm and maintaining the
receptor medium temperature at 32 ± 1 ◦C. Prior to the commencement of the experiment, the receptor
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chambers were filled with degassed receptor medium consisting of ethanol: water (30:70 v/v) and VDC
system were allowed to equilibrate at 32 ± 1 ◦C for approximately 30 min. The cream was accurately
weighed (~300 mg) and applied evenly onto the relevant membranes, which had been presoaked in
the receptor medium for 30 min. Aliquots of 200 μL were withdrawn from the receptor chambers of
each of the 6 VDCs at 1, 2, 3, 4, 5, and 6 h, and the VDCs were subsequently replenished with 200 μL of
receptor medium after each withdrawal.
2.2.4. MTZ Solubility and Receptor-Fluid Selection
Various receptor fluids such as SABAX Pour Saline (0.9% NaCl solution, Adcock Ingram Critical
Care (Pty) Ltd., Midrand, South Africa), lactate buffer pH 4.5, phosphate buffer pH 4.5, phosphate
buffer pH 6.8, water/ethanol (50:50 v/v), phosphate buffer pH 4.5: ethanol (50:50 v/v), and 0.9% NaCl
solution/ethanol (50:50 v/v) were investigated. The solubility of MTZ in these receptor fluids was
evaluated in triplicate by placing 200 mg MTZ in 10 mL of receptor fluid to yield a saturated solution.
The solution was stirred for 6 h at 600 rpm and 32± 1 ◦C and allowed to stand at 32± 1 ◦C overnight [11].
Aliquots of the supernatant were withdrawn, filtered, diluted, and then analyzed on a UPLC, to
determine the concentration of dissolved MTZ. The receptor medium should be able to dissolve
>10-fold maximum expected concentration of the drug.
2.2.5. Membrane Screening
Membrane screening was carried out by using various synthetic membranes: Magna Nylon
(0.45 μm, 25 mm, GVS Life Sciences, Sanford, ME, USA); Tuffryn (0.45 μm, 25 mm, Pall Corporation,
Ann Arbor, MN, USA); HVLP (0.45 μm, 47 mm, Merck Millipore Ltd., Ireland); Cellulose acetate
(0.45 μm, 25 mm, Sartorius, Göttingen, Germany); Mixed Cellulose Ester (0.45 μm, 47 mm, Advantec
MFS, Inc., Pleasanton, CA, USA), and Strat-M® (25 mm, Millipore, MA, USA). Binding of MTZ to the
membranes was investigated by immersing individual membranes (n = 3) in 10 mL of 0.9% sodium
chloride solution containing MTZ at 32 ± 1 ◦C, for 6 h. The test solution without any immersed
membrane, prepared in triplicate, was allowed to equilibrate for 6 h at 32 ± 1 ◦C and was used as a
control. The MTZ concentrations in all the solutions were determined by using the UPLC method
described above. Recoveries were calculated for each of the test solutions containing the membranes
by comparing them with the control solution. The mean percent recovery for each membrane should
be within ±5% [11].
2.2.6. Sampling Duration
IVRT runs were performed by varying the duration of the runs and the sampling intervals. Three
runs were performed—6 h IVRT run with sampling at every 30 min; a 3 h run with sampling at every
15 min; and a 1.5 h run with sampling at every 15 min. The sampling duration with desired linearity
(R2 > 0.95) and recovery (≤30%) was considered based on Higuchi’s assumptions [19,20]. At least 6
sampling intervals were used.
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2.2.7. IVRT Method
Each of the IVRT runs was conducted by using six VDCs in parallel, and the receptor medium
was stirred at 600 rpm, while maintaining the temperature at 32 ± 1 ◦C. Prior to the commencement of
the experiment, the receptor chambers were filled with degassed 0.9% NaCl solution, and the VDC
system was allowed to equilibrate at 32 ± 1 ◦C, for approximately 30 min. The cream was accurately
weighed (~300 mg) and applied evenly onto the Nylon membranes, which had been presoaked in the
receptor medium for 30 min. Aliquots of 200 μL were withdrawn from the receptor chambers of each
of the 6 VDCs every 15 min for 90 min, and the VDCs were subsequently replenished with 200 μL of
receptor medium after each withdrawal. The stirring was stopped during sample withdrawal and
immediately resumed once the aliquots were withdrawn and receptor media replenished in all the
VDCs. Care was taken that the duration between the stopping and resumption of the stirring was less
than 1.5 min. The aliquots were analyzed by using the UPLC method described above.
2.2.8. Calculation of Release Rates
The periodical concentrations of MTZ measured using a UPLC method were used to determine the
amount of API released. The Higuchi model, which assumes the existence of perfect sink conditions,
was used to determine the release rates, using Equation (1). Dilution of the receptor medium due to
replacement of the sampled amount was taken into account, and the concentrations of MTZ in the











Qn = amount released at time (n) per unit area in μg/cm2;
Cn = concentration of drug in receptor medium at different sampling times (n) in μg/cm3;
Vs = volume of the sample in cm3;
Vc = volume of the cell in cm3;
Ac = area of the orifice of the cell in cm2.
In accordance with Higuchi’s square root approximations [20] given by Equation (2), a plot of Q
vs.
√







Q = the amount absorbed at time t per unit area of exposure μg/cm2;
A = the concentration of drug expressed in μg/cm3;
Cs = the solubility of the drug in μg/cm3;
D = the diffusion constant of the drug molecule.
Hence, the release rate corresponds to the slope of the regression line of the plot of Qn vs.
√
t.
Qn is affected by sample volume, VDC volume, and by the diameter of the orifice of the VDC. Hence,
these parameters were carefully evaluated during apparatus qualification [11,17].
2.2.9. Validation of the IVRT Method
The IVRT system was validated in accordance with the method described by Tiffner et al. [11].
Metrocreme® (Galderma Laboratorium GmbH, Düsseldorf, Germany) containing 0.75% MTZ, being
an RLD, was used as the reference MTZ cream. Cream products containing 0.375%, 0.75%, and 1.125%
MTZ were used to establish the sensitivity, selectivity, and specificity of the IVRT method.
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Differences in release rates between the creams containing different concentrations of MTZ were
evaluated to determine the sensitivity of the method.
Specificity of the method was assessed by investigating proportionality of the MTZ release rate
to the MTZ concentration in the test creams. A box and whisker plot was prepared to estimate the
coefficient of determination (R2). The specificity of the method can be confirmed if a specifically
proportional linear relationship can be established between the formulations of different strengths, i.e.,
R2 > 0.9.
The statistical approach for product “sameness” testing described in the USP general chapter
<1724> [4] was applied to analyze all results. The selectivity of the IVRT method was investigated
by determining the release rates of the lower and higher strengths of MTZ test creams (i.e., 0.375%
and 1.125%, respectively) and compared with the release rates of the 0.75% MTZ test cream. Pairwise
comparisons of MTZ release rates in three IVRT runs performed as a part of linearity, precision, and
reproducibility investigations were evaluated in order to establish whether the reference, Metrocreme®,
0.75% MTZ was equivalent to itself.
The effect of two temperature variations (−2 and +2 ◦C) relative to the nominal temperature of
32 ◦C (at 32 ± 1 ◦C) and also two stirring-rate variations (−60 rpm and +60 rpm) relative to the nominal
stirring rate of 600 rpm were investigated in order to determine the robustness of the method to minor
perturbations, using the reference product, Metrocreme®, 0.75% MTZ.
Dose depletion was assessed by determining the amounts of MTZ released from the cream during
the IVRT runs and recovered in the receptor solution. The recovery was calculated by dividing the
average cumulative amount released at the last time point (t = 90 min) by the amount of MTZ present
in the applied dose (~2.25 mg) by using data from each of the 18 VDCs within the 3 IVRT runs.
2.2.10. Comparative IVRT of MTZ Cream Products
In order to confirm the utility of the developed and validated IVRT method for assessment of
“sameness” and differences between MTZ creams, comparative IVRT runs were conducted with the
test (T1, T2, and T3) and the reference cream. The testing was carried out in accordance with the FDA’s
SUPAC-SS guidance [3]. Initially, two IVRT runs were carried out to compare T1 and the reference,
such that the arrangement enabled the measurement of drug release from each of the creams in all six
cells at the end of the experiment. Following this, three IVRT runs were carried out to compare creams
T2 and T3 with the reference, to serve as negative controls in such a way that the drug release from each
of the creams was measured in all six cells at the end of the experiment. Additionally, the two IVRT
runs conducted as a part of IVRT validation served to determine whether the method can accurately
detect “sameness”, wherein the reference product was compared to itself to serve as a positive control.
The cumulative amount of MTZ released per unit area was plotted against the square root of time
and the release rates were determined. A total of six release rates per cream were obtained. Pairwise
comparison was carried out by computing the ratios of release rates (T/R ratios) and establishing the
90% confidence interval (CI), using the Mann–Whitney U Test, where the 90% CI should lie within
the limits of 75–133.33% to confirm “sameness” between products, in accordance with the FDA’s
SUPAC-SS guidance [3].
3. Results
3.1. Validation of the UPLC Method and Qualification of the IVRT System
The developed UPLC method was validated for the analysis of MTZ in IVRT samples, and the
results are summarized in Table 1, according to the acceptance criteria defined in the ICH guidelines.
The results for qualification of the IVRT system are described in Table 2.
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Table 1. Predefined acceptance criteria and the results obtained from the UPLC validation for IVRT
method [11].
Parameter Acceptance Criteria Results Pass
Selectivity and specificity RTp − RTpm < 10%
ICn = 0 μg/mL, ICnm = 0 μg/mL
0.063%
ICn = 0 μg/mL, ICnm = 0 μg/mL
Yes
Linearity
75% of the standards meet the following
criteria:
For 5–100 μg/mL: ICmeas,lin ∈ [ICnom ± 15%]
For 0.5 μg/mL: ICmeas,lin ∈ [ICnom ± 20%]
R2 ≥ 0.950





For IS100 and IS50: ISmeas,ac ∈ [ISnom ± 15%]
For IS5: ISmeas,ac ∈ [ISnom ± 20%]




Intra-day CV < 15% for IS100 to IS50
Intra-day CV < 20% for IS5
1.30%, 0.63%, and 0.66% for IS100
1.03%, 0.93%, and 0.11% for IS50
1.07%, 6.29%, and 7.35% forIS5
Yes
Inter-day CV < 15% for IS100 to IS50











For IS100 and IS50: ISmeas,ac ∈ [ISnom ± 15%]
For IS5: ISmeas,ac ∈ [ISnom ± 20%]













LLOQ, LOD - LLOQ: 0.5 μg/mLLOD: 0.167 μg/mL
RTp = retention time of MTZ in positive control (min). RTpm = retention time of MTZ in matrix positive control (min).
ICn = concentration in negative control (μg/mL). ICnm = concentration in matrix negative control (μg/mL). ICmeas,lin
= measured concentration during the linearity run (μg/mL). ICnom = nominal concentration (μg/mL). ISmeas,ac =
measured average concentration of the spiked solutions in the accuracy run (μg/mL). ISnom = nominal concentration
of the spiked solutions (μg/mL). ISx = concentration of the spiked samples where x is concentration in μg/mL.





Mean ± Tolerance Range of Variation Mean Range of Variation
Capacity of the
cells 7.00 ± 0.35 mL ≤0.21 mL 7.92 mL 0.02 mL No
Diameter of the
orifice 15.00 ± 0.75 mm ≤0.45 mm 14.98 mm 0.10 mm Yes
Temperature of the
receptor medium 32 ± 1
◦C - 32.07 ◦C 0.05 ◦C Yes
Speed of the
magnetic stirrer 600 ± 60 rpm ≤12 rpm 601.67 rpm 2.53 rpm Yes
Dispensed
sampling volume 200 ± 10 μL - 203.67 μL 4.58 μL Yes
Bench top levelness Not more than 1◦ <1◦ Yes
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3.2. Performance Verification Test
The results obtained from the PVT runs are summarized in Table 3.
Table 3. Predefined acceptance criteria and results of the performance verification test (PVT).
Parameter Acceptance Criteria Results
Intra-run variability
Intra-run CV for the first run (n = 6 VDCs) < 15% 8.13%
Intra-run CV for the second run (n = 6 VDCs) < 15% 12.85%
Inter-run variability Inter-run CV for both runs (n = 12 VDCs) < 15% 10.30%




The observed solubilities of MTZ were >2848.10 μg/mL in all the receptor fluids, which is >10
times the maximum expected concentration.
3.4. Membrane Screening
Average percentage recoveries of 98.47 ± 0.81, 98.07 ± 2.09, 97.84 ± 1.27, 97.70 ± 1.63, 96.80 ± 1.97,
and 91.04 ± 3.28 for Nylon, Tuffryn, Cellulose acetate, Strat-M, HVLP, and Mixed Cellulose Ester,
respectively, were obtained.
3.5. Sampling Duration
The release rates and coefficients of determination (R2) for different times are shown in Table 4.
Significant differences between release rates by using different sampling durations were observed by
using the F-test, which generated p-values > 0.05.
Table 4. Differences in parameters observed by using various sampling duration (mean ± SD).
Time (min) Release Rate (μg/cm2/min1/2) R2 Value Recovery (%)
90 39.47 ± 2.30 0.998 ± 0.003 29.90 ± 1.20
180 34.19 ± 1.97 0.988 ± 0.006 38.32 ± 1.19
360 27.58 ± 2.09 0.994 ± 0.002 42.75 ± 3.57
3.6. Validation of the IVRT Method
The results obtained from the three IVRT runs of 0.75% MTZ cream confirmed a linear relationship
(R2 ≥ 0.99) between the amount of drug released and the square root of time.
The mean release rates for 0.375%, 0.75%, and 1.125% MTZ creams were 19.17 μg/cm2/min1/2,
40.04 μg/cm2/min1/2, and 66.28 μg/cm2/min1/2, respectively, and a linear relationship (R2 = 0.9994) was
observed between the release rates of the different strengths of MTZ cream (Figure 1).
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Figure 1. Box and whisker plot of the measured release rates for the three test MTZ creams, with
concentrations of 0.5% (blue), 1% (green), and 1.5% (red).
The data to assess selectivity are depicted in Table 5, where the 90% CI for the reference product,
Metrocreme®, 0.75% MTZ, against itself, fell within the acceptance criteria of 75–133.33% [3], whereas
that for the 0.75% MTZ cream against the 0.375% and 1.125% MTZ creams fell completely outside the
75–133.33% limits.
Table 5. Computed 90% CI to assess the selectivity of the IVRT method.
Pairwise Comparison *
Computed 90% CI
Lower Limit Upper Limit
0.375% MTZ cream vs. 0.75% MTZ cream 45.10 52.47
1.125% MTZ cream vs. 0.75% MTZ cream 152.04 167.79
Metrocreme®, 0.75% MTZ (run 1) vs. Metrocreme®, 0.75% MTZ (run 2) 93.61 100.22
Metrocreme®, 0.75% MTZ (run 1) vs. Metrocreme®, 0.75% MTZ (run 3) 87.40 97.66
Metrocreme®, 0.75% MTZ (run 2) vs. Metrocreme®, 0.75% MTZ (run 3) 93.06 99.76
* The release rates used for pairwise comparison are provided under supplementary materials in Tables S1–S5.
The mean release rates obtained for the robustness runs were 45.67 μg/cm2/min1/2 for 30 ◦C,
600 rpm; 47.83 μg/cm2/min1/2 for 34 ◦C, 600 rpm; 47.02 μg/cm2/min1/2 for 32 ◦C, 540 rpm; and
48.19 μg/cm2/min1/2 for 32 ◦C, 660 rpm.
The mean recoveries for IVRT runs conducted as a part of linearity, precision, and reproducibility
were found to be 30.27 ± 0.52%, 29.00 ± 0.60%, and 29.98 ± 0.81% respectively, confirming that the dose
depletion was within the specified range of ≤30%.
3.7. Comparative IVRT of MTZ Topical Cream Products
A comparison between the reference and test product T1 is depicted in Figure 2. The mean
release rates were 37.80 ± 2.01 μg/cm2/min1/2 and 32.89 ± 1.60 μg/cm2/min1/2 for the reference and T1,
respectively. The calculated upper and lower limits for the pairwise comparison were 81.72% and
91.24%, which fell within the CI limits of 75–133.33% (supplementary materials, Table S6).
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Figure 2. Release-rate curves from 0.75% MTZ cream (T1) vs. Metrocreme®, 0.75% MTZ (R).
The comparison between the reference and the test products T2 and T3 is depicted in Figure 3.
The mean release rates were 38.47 ± 1.35 μg/cm2/min1/2 for the reference and 27.42 ± 0.99 μg/cm2/min1/2
and 51.20 ± 0.60 μg/cm2/min1/2 for the test creams T2 and T3, respectively.
Figure 3. Release-rate curves from 0.563% and 0.945% MTZ cream (T2 and T3) vs. Metrocreme®, 0.75%
MTZ (R) (n = 6).
The calculated upper and lower limits for the pairwise comparisons were outside the CI limits of
75–133.33% for both test creams (Table 6). The CI limits for the positive control were well within the
acceptance criteria (75–133.33%), as shown in Table 6.
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Lower Limit Upper Limit
Positive control
Metrocreme®, 0.75% MTZ vs. Metrocreme®, 0.75% MTZ 93.61 100.22 Pass
Negative controls
0.563% MTZ cream vs. Metrocreme®, 0.75% MTZ 68.25 74.21 Fail
0.945% MTZ cream vs. Metrocreme®, 0.75% MTZ 128.36 137.11 Fail
* The release rates used for pairwise comparison are provided under supplementary materials in Tables S7–S9.
4. Discussion
The developed UPLC method, validated for the analysis of MTZ in IVRT samples in accordance
with the ICH guidelines, met the acceptance criteria for all the validation parameters described by
Tiffner et al. [11]. It was found to be selective, linear over a range of 0.5–100 μg/mL, accurate, precise,
robust, sensitive with an LLOQ of 0.5 μg/mL, and offering sample stability for seven days. All the
parameters essential for qualification of the IVRT system met the predefined acceptance criteria as
described by Tiffner et al. [11], with an exception of the VDC volume. The mean capacity of the VDCs
did not conform to the specifications provided by the manufacturer. However, it was precise and
suitable for conducting IVRT experiments. Hence, the subsequent IVRT experiments were conducted
by using these cells, and the calculations were tailored accordingly.
The results obtained from the PVT runs duly complied with the predefined acceptance criteria,
and the low variabilities observed during the runs confirm the suitability and reproducibility of the
IVRT system for its relevant application.
Although the observed solubilities of MTZ were >10 times the maximum expected concentration,
as recommended [9], 0.9% NaCl solution was chosen as the receptor medium for subsequent studies,
as it more appropriately reflects physiological conditions and is inexpensive and readily available. All
the membranes except the Mixed Cellulose Ester membrane showed an acceptable recovery, indicating
low MTZ binding. The membranes were therefore confirmed to be inert and would not act as a
rate-limiting barrier for MTZ. Because of its higher-percentage recovery and availability, Nylon was
chosen as the membrane of choice for this study.
The release profiles obtained from the IVRT runs with different sampling durations and intervals
showed significant differences in MTZ release rates. It was observed that the release rates decreased
considerably with time, whereas the recovery increased, resulting in curvature in the release profile.
The profiles showed a deviation from linearity after 90 min. This is in agreement and closely correlated
with the Higuchi’s square root approximations [19,20]. Deviation from linearity of release of API from
different semisolid dosage forms may be due to differences in physicochemical properties of such
formulations. This can be explained by considering the square root approximations developed by
Higuchi, which presumes that the percent of API released from the applied dose is ≤30%. The Higuchi
equation describes the initial 30% release from topical formulations under perfect sink conditions as
linear. Since the ultimate objective of this study was not to evaluate complete release from the cream
but to assess the “sameness” between two creams containing 0.75% MTZ, an IVRT method spanning
over a duration of 90 min, with a sampling interval of 15 min, was chosen in accordance with the
Higuchi’s approximation (recovery ≤30%).
The inter-run and intra-run variabilities were <15%, confirming that the IVRT method was precise
and reproducible. The mean release rate for 0.75% MTZ cream was higher than that of 0.375% MTZ
cream and lower than that of 1.125% MTZ cream, indicating that the method was sensitive to the
changes in MTZ concentrations. The linear relationship (Figure 1) indicated that the release rate
proportionately increased with the increase in MTZ concentration, demonstrating the specificity of the
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developed IVRT method. The IVRT method has the necessary ability to determine “sameness” as the
90% CI for the reference product, Metrocreme®, 0.75% MTZ, against itself, fell within the acceptance
criteria of 75–133.33% [3]. Furthermore, the ability of the method to assess differences was confirmed
as the 90% CI for the 0.75% MTZ cream against the 0.375% and 1.125% MTZ creams fell completely
outside the 75–133.33% limits. From the results obtained, it is evident that the method also has the
discriminatory ability to detect differences in MTZ concentrations between the respective products.
This outcome was expected, as the creams (0.375%, 0.75%, and 1.125%) differed only in terms of Q2
properties (i.e., the amount of MTZ) and contained the same ingredients and also were manufactured
using the same process. Q1 and Q3 properties were therefore constant for all the creams. The developed
IVRT method is thus sensitive to the changes in the formulations specifically related to differences in
Q2. Minor differences in stirring rates (±60 rpm) or temperature (±2 ◦C) did not significantly affect
MTZ release rates, i.e., they did not deviate from the nominal values by more than 15%. These results
suggest that the developed IVRT method possesses the necessary properties to confirm robustness.
Since it is important to confirm the discriminatory ability of the IVRT method, both positive
and negative controls were included to indicate “sameness” and differences, if any, in terms of the
FDA’s SUPAC-SS acceptance criteria [3]. Interestingly, acceptance criteria of 90–111% with a 90% CI
was recommended in the recent EMA draft guideline [16]. This increased stringency is somewhat
questionable. The reference product was used as a positive control when compared to itself during
validation studies, whereas, for different strengths of the MTZ creams at concentrations below (T2) and
above (T3) the acceptance limits were used as negative controls. Accordingly, a comparison between
the reference and test product T1 indicated “sameness” between the two creams, thereby confirming
that the IVRT method has the requisite properties.
Based on the results from the positive control studies, the ability of the IVRT method to indicate
“sameness” was confirmed. Furthermore, data using negative controls indicated the capability of the
IVRT method to detect inequivalence between MTZ creams.
5. Conclusions
The apparatus qualification and PVT of the IVRT system duly complied with the necessary
requirements to assess the release of API from topical cream products. The low variabilities observed
during the PVT runs confirm the suitability and reproducibility of the IVRT system for its relevant
application. An IVRT method was carefully developed and comprehensively validated to assess the
release of MTZ from cream products, taking into account the various parameters that may affect the
API release rate. The validation procedures were carried out in accordance with the recommendations
in both the FDA guidance [3,4] and EMA draft guideline [16]. It was then successfully applied
to assess “sameness” for the purpose of marketing a generic MTZ cream, wherein a 0.75% MTZ
cream was compared with the reference, Metrocreme®, 0.75% MTZ. Furthermore, the inclusion of
a positive and negative controls was a novel approach to demonstrate the discriminatory power of
the IVRT method. The positive and negative controls complied with the necessary acceptance criteria
for equivalence and inequivalence, respectively, confirming the discriminatory power of the IVRT
method. This is in accordance with the SUPAC-SS acceptance criteria [3] for a biowaiver, where
generic products containing <25% or >25% potency compared to the reference product are deemed
inequivalent. The resulting data indicate that the developed IVRT method can be applied to accurately
and precisely assess “sameness” and differences (Q2) between MTZ cream products as a valuable
procedure in formulation development. Furthermore, this method has potential for use as a tool to
obtain a biowaiver for MTZ creams.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/2/119/s1,
Table S1: 0.375% MTZ cream vs 0.75% MTZ cream, Table S2: 1.125% MTZ cream vs 0.75% MTZ cream, Table S3:
Metrocreme®, 0.75% MTZ (run 1) vs Metrocreme®, 0.75% MTZ (run 2), Table S4: Metrocreme®, 0.75% MTZ
(run 1) vs Metrocreme®, 0.75% MTZ (run 3), Table S5: Metrocreme®, 0.75% MTZ (run 2) vs Metrocreme®, 0.75%
MTZ (run 3), Table S6: 0.75% MTZ cream vs Metrocreme®, 0.75% MTZ, Table S7: Metrocreme®, 0.75% MTZ vs
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Metrocreme®, 0.75% MTZ, Table S8: 0.563% MTZ cream vs Metrocreme®, 0.75% MTZ, Table S9: 0.945% MTZ
cream vs Metrocreme®, 0.75% MTZ.
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Abstract: A liposomes-in-hydrogel system as an advanced wound dressing for dermal delivery
of curcumin was proposed for improved chronic wound therapy. Curcumin, a multitargeting
poorly soluble active substance with known beneficial properties for improved wound healing, was
incorporated in deformable liposomes to overcome its poor solubility. Chitosan hydrogel served as a
vehicle providing superior wound healing properties. The novel system should assure sustained skin
delivery of curcumin, and increase its retention at the skin site, utilizing both curcumin and chitosan to
improve the therapy outcome. To optimize the properties of the formulation and determine the effect
of the liposomal charge on the hydrogel properties, curcumin-containing deformable liposomes (DLs)
with neutral (NDLs), cationic (CDLs), and anionic (ADLs) surface properties were incorporated in
chitosan hydrogel. The charged DLs affected the hydrogel’s hardness, cohesiveness, and adhesiveness.
Importantly, the incorporation of DLs, regardless of their surface charge, in chitosan hydrogel did not
decrease the system’s bioadhesion to human skin. Stability testing revealed that the incorporation of
CDLs in hydrogel preserved hydrogel´s bioadhesiveness to a higher degree than both NDLs and
ADLs. In addition, CDLs-in-hydrogel enabled the most sustained skin penetration of curcumin.
The proposed formulation should be further evaluated in a chronic wound model.
Keywords: curcumin; deformable liposomes; liposome surface charge; hydrogel; chitosan;
wound therapy
1. Introduction
The treatment of chronic wounds is one of the most important global health care issues in the
aging society. Chronic wounds are challenging to treat due to the diversity of factors contributing to
slow/impaired healing. The hostile environment of the wound comprising degradative enzymes and
elevated pH, as well as the complexity of physiological processes, requires an effective advanced drug
delivery system as a wound dressing [1,2]. An ideal wound dressing should reduce infection, moisturize
the wound, stimulate the healing mechanism, accelerate the wound closure, and reduce/control scar
formation [3].
Recently, the incessant release of free radicals has been proposed as one of the key factors
responsible for activation of the inflammatory system, leading to impaired repair of the wound [4].
Therefore, the effective control of free radical levels in the wound and subsequent inflammation could
assist in enhanced wound healing and scar control. Various antioxidants could be utilized to control
free radicals during wound healing.
Curcumin has been proposed as one of the most promising [5]. Moreover, curcumin is a molecule
able to active multiple pathways, contributing to improved wound healing [6]. The antioxidant,
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anti-inflammatory, and anti-bacterial properties of this pleiotropic molecule need to be more
utilized [7,8]. Although curcumin is a very promising molecule to be included in wound dressings,
its hydrophobicity, extensive metabolism, and limited skin penetration often hamper its wider
use [9]. We have recently proven that curcumin, a multitargeting active substance, exhibits superior
anti-inflammatory properties when incorporated in tailored deformable liposomes [10]. In this work,
we went a step further in the development of curcumin-based wound dressings and combined the
beneficial properties of curcumin as an active moiety and chitosan hydrogel as a superior vehicle to
form a bioactive wound dressing targeting the treatment of chronic wounds.
An ideal dressing should assure an enhanced therapeutic outcome and reduction of pain accompanied
with wound dressing changes [11]. Among the possible material to be used in the manufacturing of
bioactive dressings, natural polymer-based wound dressings, such as hydrogels, represent promising
advanced delivery systems with a low risk of toxicity and side effects due to their biodegradability and
biocompatibility [12,13]. Hydrogels mimic the biochemical, biomechanical, and structural features of
the extracellular matrix (ECM), serving as superior matrices for wound treatment [13,14]. Hydrogels
additionally possess good bioadhesiveness that can contribute to a prolonged retention time of the
incorporated drug/active substance at the wounded skin site. This, together with the sustained drug
release via hydrogel, can result in higher drug/active substances’ concentrations at the skin site while
reducing possible systemic absorption and consequent adverse effects [15].
Chitosan represents one of the most studied natural polymers for the development of effective
hydrogel-based wound dressings due to its numerous intrinsic biological properties. Its biocompatibility
and bioadhesiveness, together with intrinsic bacteriostatic effect, make this biopolymer effective in
promoting wound healing while also preventing biofilm formation [16,17]. In spite of the numerous
advantages of chitosan hydrogels, the hydrophilic environment provided by chitosan hydrogel limits
the incorporation of lipophilic drugs/active compounds and remains a pharmaceutical challenge.
Liposomes as carriers for poorly soluble drugs/active molecules assist in overcoming this hydrogel
limitation; the combination of these two delivery systems is a promising approach to achieve controlled
dermal drug delivery and effective localized skin therapy [18–20]. The liposomal phospholipid bilayers
allow the incorporation of lipophilic substances, improving their solubilization and enabling their
inclusion into the hydrophilic chitosan hydrogel. Moreover, the ability of liposomes to assure sustained
drug/substance release might improve targeted drug delivery to the specific skin layer(s) [19,21].
Liposomes also benefit from their incorporation in the hydrogel vehicle. The hydrogel can prevent
rapid liposome clearance from the skin site and additionally protect from rapid degradation by
preserving their membrane integrity [22]. Moreover, incorporation of liposomes in hydrogel will confer
adequate viscosity to the liposomal dispersions to be topically administered [23].
The drug/substance release from a liposomes-in-hydrogel system is determined by the hydrogel
properties, such as the polymer composition, mesh size, and porosity, combined with the liposomal
physicochemical characteristics, namely the liposomal composition, size, and surface charge.
In addition, the lipophilicity of the incorporated drug needs to be considered [24]. To the best
of our knowledge, relatively little has been published on the incorporation of deformable liposomes
(DLs) in chitosan hydrogel. DLs have shown superior ability in promoting drug penetration into the
deeper skin layers in comparison to conventional liposomes [10,25]. In this study, we designed the
DLs-in-chitosan hydrogel as a combined advanced delivery system, targeting the treatment of chronic
wounds. Considering that chitosan has lateral amino groups conferring positive charge to its chains,
the incorporation of charged liposomes could trigger interactions between the two delivery systems,
affecting the hydrogel’s texture properties, liposomes’ integrity, and drug release [24]. We therefore
focused on the effect of the liposomal surface charge on the hydrogel’s properties, such as the texture
properties and bioadhesiveness; neutral (NDLs), cationic (CDLs), and anionic (ADLs) DLs were
individually incorporated in chitosan hydrogel.
The effect of the liposomal surface charge on curcumin penetration from DLs-in-hydrogel systems
through the ex vivo full thickness human skin was also evaluated.
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2. Materials and Methods
2.1. Materials
Curcumin (≥94% curcuminoid content; ≥80% curcumin) was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Lipoid S 100 (>94% soybean phosphatidylcholine, PC) was a generous gift
from Lipoid GmbH (Ludwigshafen, Germany). High molecular weight (MW) chitosan (Brookfield
viscosity 800.000 cps and degree of deacetylation of 77%), polysorbate 20, stearylamine (SA), sodium
deoxycholate (SDCh), methanol, disodium hydrogen phosphate dihydrate, monobasic potassium
phosphate, sodium chloride, propylene glycol (PG), glycerol, and acetic acid were all purchased from
Sigma-Aldrich (St. Louis, MO, USA). Albunorm® (human serum albumin, 200 mg/mL) was produced
by Octapharma AG (Lachen, Switzerland).
2.2. Preparation and Characterization of Deformable Liposomes
Curcumin-containing DLs bearing different surface charges were prepared by the film hydration
method as previously described [26]. NDLs comprised PC and polysorbate 20 (total 200 mg), in a
weight ratio of 85:15. CDLs comprised the same lipid and surfactant composition as NDLs, in addition
to SA (weight ratio to PC 1:9). ADLs were composed of PC and SDCh (total 200 mg) in a ratio of 85:15
(w/w) (Table 1). All DLs were prepared by dissolving curcumin (20 mg), PC, and, when applicable,
the different surfactants, in methanol. The organic solvent was evaporated under vacuum (55 mbar)
at 55 ◦C (Büchi Rotavapor R-124 with Büchi Vacuum Pump V-700, Büchi Labortechnik AG, Flawil,
Switzerland) and the obtained film was hydrated with 10 mL of phosphate buffer saline (PBS). PBS
(pH 7.4) contained the following salts composition: 2.98 g/L Na2HPO4·2H2O, 0.19 g/L KH2PO4, 8 g/L
NaCl. The liposomal dispersions were kept at 4 ◦C for 24 h prior to size reduction.












NDLs 2.0 17.0 - - 3.0
CDLs 2.0 15.3 - 1.7 3.0
ADLs 2.0 17.0 3.0 - -
All DLs were reduced to a vesicle size of 200× 300 nm by hand extrusion through the polycarbonate
membrane (Nuclepore® Track-Etched Membranes, Whatman House, Maidstone, UK). In brief, all
DLs were extruded five times through 800-nm pore size membrane. NDLs were further extruded
four times through 400-nm pore size membrane, whereas CDLs and ADLs were extruded through
the same pore size membrane two and seven times, respectively. All liposomal dispersions were
characterized in terms of vesicle size by photon correlation spectroscopy using a NICOMP Submicron
Particle Sizer Model 370 (NICOMP Particle Sizing system, Santa Barbara, CA, USA) and zeta potential
using Malvern Zetasizer Nano—ZS (Malvern, Oxford, UK) [26].
The entrapment efficiency of curcumin in DLs was determined after the centrifugation of the
liposomal dispersion at 3000 g for 10 min using a Biofuge stratos centrifuge (Heraeus instruments
GmbH, Hanau, Germany) to remove unentrapped curcumin. Liposomes were subsequently dissolved
in methanol and the entrapped curcumin determined spectophotometrically at 425 nm (SpectraMax 190
Microplate Reader, Molecular Devices, San Jose, CA, USA). The entrapment efficiency was expressed
as curcumin/lipid ratio (μg/mg), after quantification of the PC content in all DLs formulations (data
not shown).
2.3. Preparation of Chitosan Hydrogels
Chitosan hydrogels were prepared according to a method described earlier [27]. In short, glycerol
(10%, w/w) was mixed with an aqueous solution of acetic acid (2.5%, w/w). High MW chitosan
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(2.5%, w/w) was introduced into the mixture by hand stirring. To remove entrapped air, the mixture
was bath-sonicated for 30 min. The prepared hydrogels were stored in a sealed container at room
temperature for 48 h to allow complete swelling.
2.4. Preparation of DLs-In-Hydrogels
To prepare 10 g of liposomes-in-hydrogel formulation, 1.5 g of the different DLs (15%, w/w) were
individually incorporated in the freshly prepared chitosan hydrogel after it was allowed to swell for
48 h at room temperature (Section 2.3) by hand-stirring [28]. The final concentration of curcumin in the
liposomal hydrogel was 135 μg/g. As a control, free curcumin was incorporated in the hydrogel in the
same concentration after dissolving in PG and subsequent incorporation in chitosan hydrogel by hand
stirring. The DLs-in-hydrogel formulations were kept at room temperature for 2 h prior to further
handling. The homogeneity test was performed to assure that liposomes were well dispersed within
the liposomes-in-hydrogel formulation by sampling (5 aliquots were sampled from various places
within hydrogel) and the curcumin concentration was determined in each aliquot.
2.5. Texture Analysis
All liposomes-in-hydrogel formulations were characterized in terms of the hardness, cohesiveness,
and adhesiveness using a Texture Analyzer TA.XT Plus (Stable Micro Systems Ltd., Surrey, UK) [27].
The hydrogel (25 g) was placed in a beaker and a disc (35 mm in diameter) pushed down into the gel
(distance of 10 mm) and withdrawn at a speed of 4 mm/s. The starting position of the disc was below
the hydrogel surface. The hardness was calculated as the maximal force achieved when the disc was
pushed down into the gel. The cohesiveness was expressed as the work necessary to push down the
disc into the hydrogel while the adhesiveness as the work required during the upwards movement of
the disc. Each formulation was tested five times and the measurements performed in triplicates.
2.6. Bioadhesion Test
The bioadhesion of hydrogels to the skin was tested as described earlier [28]. The full thickness
human skin originated from the abdomen of female patients after plastic surgery. A written consent
was obtained from the patients prior the surgery. No ethical approval was required from the Norwegian
Ethical Committee, since we used skin to be disposed of after the surgery; the experiments were
conducted according to the Declaration of Helsinki principles. The skin was cleared from the
subcutaneous fatty tissue and rinsed with PBS prior the storage at −20 ◦C. The skin was thawed in
PBS ca. 30 min prior to the experiment and subsequently fixed on a rig for Texture Analyzer TA.XT
Plus (Stable micro systems, Surrey, UK). The bioadhesion test was performed by filling a die with
the hydrogel formulation (150 μL), which was consequently pinched onto the skin for 10 s applying
a force of 25 g. The bioadhesion was determined by measuring the force required to detach the die
from the skin (detachment speed of 0.1 mm/s). Moreover, the die was weighed before and after each
bioadhesion test to determine the amount of formulation retained onto the skin surface at the end of
the test. Each formulation was tested five times and the human skin rinsed with ethanol between each
measurement. Tests were conducted in triplicates.
2.7. Hydrogel Stability Testing
To evaluate the chitosan hydrogel stability and the influences of the liposomal surface charge on the
stability of DLs-in-hydrogel, the stability testing was performed after the storage of the DLs-in-chitosan
hydrogels for one month at room temperature (23–24 ◦C). The texture properties (Section 2.5) and
bioadhesiveness (Section 2.6) of the chitosan hydrogel were determined before (one day after the
formulation was prepared) and after the storage (day 30).
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2.8. Ex Vivo Skin Penetration Studies
Ex vivo curcumin penetration from the different DLs-in-chitosan hydrogels was evaluated using
the full thickness human skin in Franz diffusion cells (diffusion area of 1.77 cm2, PermeGear, Bethlehem,
PA, USA) [26]. The human skin originated from the excised skin panni obtained from female patients
who underwent abdominoplasty, after they gave written consent (see Section 2.6). The experiments
were conducted in agreement with the Declaration of Helsinki principles. The human skin for the ex
vivo penetration studies was prepared as described in Section 2.6. The slices of human skin used in the
skin penetration studies had a thickness of 1.10 to 1.30 mm. All DLs-in-chitosan hydrogel formulations
(1.2 mL) were added in the donor chamber, whereas the receptor chamber was filled with 12.0 mL
of Albunorm (5%, v/v) solution in PBS. As a control, curcumin in PG-in-hydrogel served as a control.
The experiments were conducted for 8 h and sampling of the receptor medium (500 μL) was performed
every hour. To maintain the sink conditions, the withdrawn receptor medium was replaced by an equal
volume of fresh Albunorm® (5%, v/v) solution in PBS. The penetrated curcumin was quantified as
described in Section 2.2 using a standard curve of curcumin in Albunorm®/PBS (1:1, v/v). Experiments
were performed in three replicates.
2.9. Statistical Analyses
To determine the level of significance (p < 0.05), statistical analyses were performed using one-way
ANOVA test followed by Bonferroni’s multiple comparisons test performed on GraphPad Prism
version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA).
3. Results and Discussion
Chronic wounds exhibit severe molecular and cellular deficiencies and are heterogenous across
the patient population; therefore, they are difficult to treat. At present, no wound dressing can be
considered as “one size fits all”; however, there is a consensus in the field that chronic wound treatment
should shift from conventional dressings towards precision medicine approaches [14]. It is known that
the remodeling phase of wound healing comprises the deposition of extracellular matrix (ECM) in a
well-defined network prior to wound contraction [3]. Chitosan promotes wound healing via stimulation
of ECM formation as well as facilitating the mobilization, adhesion, and accumulation of red blood cells
and platelets forming blood clots at the wound site [14]. Chitosan hydrogel could therefore be a perfect
vehicle to incorporate bioactive molecules within nanoformulations. The combination of liposomal
curcumin, assuring anti-inflammatory activity, and chitosan, providing wound healing and antimicrobial
activities, could assure a synergistic effect and superior performance. The therapeutic potential of the
novel dressing will be dependent on the characteristics of each component as well as their interplay.
3.1. Liposomal Characteristics
Considering the liposomes-in-hydrogel formulation, the liposomal size is known to influence
both the hydrogel properties and the release of lipophilic compounds from liposomes-in-hydrogel
systems [24]. Therefore, focusing on exploring the effect of the liposomal surface charge on both hydrogel
properties and curcumin penetration through human skin, we aimed to prepare DLs of a similar vesicle
size. The chosen vesicle size range was 200 to 300 nm, which has been suggested as appropriate for
assuring dermal delivery via liposomes by offering the reservoir of the liposome-associated drug in
the skin [29]. The extrusion method, utilized to reduce the vesicle size, allows the manufacturing of
rather homogeneously distributed vesicles in the desired size range, as reported earlier [26]. For each
liposomal dispersion, we adjusted both the number of extrusion cycles and membrane pore size,
obtaining curcumin-containing DLs within the size range of 200 to 300 nm (Table 2), as targeted.
Moreover, the vesicle size distribution was rather homogeneous for all DLs, as indicated by the rather
low polydispersity.
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NDLs 288.73 ± 2.46 0.17 ± 0.02 –3.03 ± 0.24 51.54 a ± 0.99 43.97 ± 0.85
CDLs 252.24 ± 51.63 0.17 ± 0.01 34.01 ± 0.56 71.94 ± 2.32 55.04 ± 1.78
ADLs 291.54 ± 26.48 0.17 ± 0.01 –34.83 ± 0.64 89.67 ± 14.03 76.40 ± 11.96
Results are presented as mean (n = 3) ± SD. a Significantly lower vs. ADLs (p < 0.05).
DLs bearing different surface charges (Table 2) were obtained by including the selected surfactant
in the liposomal phospholipid bilayers. NDLs comprised polysorbate 20 as a non-ionic surfactant,
which conferred a neutral surface to DLs, as well as the neutral lipid, namely PC. Ionic surfactants
were employed to obtain CDLs and ADLs, respectively. SA was responsible for the positive charge
of CDLs, whereas SDCh conferred the negative charge to ADLs surface, both in agreement with the
literature [30,31].
The entrapment efficiency of curcumin in the different DLs varied according to the liposomal
composition (Table 2). The presence of surfactant might contribute to a lower entrapment of lipophilic
compounds, such as curcumin; both substances are competing for accommodation within the liposomal
phospholipid bilayer. Moreover, it is known that the drug/active substance incorporation capacity
is additionally dependent on the type of employed surfactant [32]. In our case, ADLs exhibited the
highest entrapment efficiency for curcumin. A possible explanation might be the higher lipophilicity
of SDCh compared to polysorbate 20, thus improving the curcumin solubility and therefore enhancing
the curcumin loading capacity for ADLs [32]. The presence of SA in CDLs has been shown to alter the
lipid packing of liposomes by causing a charge repulsion [33]. This can therefore affect curcumin’s
accommodation within the CDLs bilayer, as previously reported for the drugs of a similar lipophilicity
as curcumin, such as celecoxib [34].
3.2. Effect of the Liposomal Surface Charge on the Texture Properties of Liposomes-In-Hydrogel
The development of effective hydrogel-based wound dressings requires their optimization in
terms of hydrogel’s texture properties. For hydrogels as wound dressings, the hydrogel’s hardness can
determine the ease of its application onto the skin, whereas the adhesiveness influences the hydrogel’s
contact time with the skin. These factors consequently contribute to the efficacy of the treatment and
assure patient compliance by reducing the frequencies of administration and the related pain caused
by wound dressing changes [11]. While optimizing liposomes-in-hydrogel formulations, an evaluation
of the texture properties of the hydrogel is required considering that the incorporation of DLs bearing
different surface charges can affect the hydrogel texture properties [24]. Possible interactions between
charged DLs and positive chitosan chains might change/affect the chitosan network, thus modifying its
texture characteristics. The effect of the liposomal surface charge of curcumin-containing DLs on the
hydrogel properties is presented in Table 3.
Table 3. The effect of the liposomal surface charge on the texture properties of liposomes-in-hydrogel.
Chitosan Hydrogel Composition Hardness (g) Cohesiveness (g*s) Adhesiveness (g*s)
Plain hydrogel 164.8 ± 11.1 359.6 ± 10.6 346.8 ± 8.0
CUR-in-hydrogel 148.7 ± 20.1 262.2 ± 17.0 248.5 ± 20.1
CUR-NDL-in-hydrogel 107.0 a ± 4.2 226.5 a,b ± 1.7 216.5 a ± 2.8
CUR-CDL-in-hydrogel 116.8 a ± 6.7 212.3 a,b ± 5.5 200.9 a,b ± 9.4
CUR-ADL-in-hydrogel 124.6 ± 21.0 204.0 a,b ± 13.5 190.7 a,b ± 8.6
Results are presented as mean (n = 3) ± SD. CUR: curcumin. a Significantly lower vs. plain hydrogel (p < 0.05);
b significantly lower vs. CUR-in-hydrogel (p < 0.05).
The incorporation of DLs negatively affected the original hydrogel texture properties (plain
hydrogel). The incorporation of deformable liposomes weakened the hydrogel properties to a higher
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extent than the incorporation of free curcumin (CUR-in-hydrogel, Table 3). Due to the hydrophobic
nature of curcumin, its incorporation in chitosan hydrogel in the form of free curcumin (not incorporated
in DLs) was achieved by prior dispersion of curcumin in PG. The presence of PG has been shown
to exert a positive effect on the viscoelastic properties of hydrogels by triggering hydrogen bonding
between chitosan, water, and the solvent [35]. This might explain the positive effect of free curcumin
in PG on the hydrogel properties compared to DLs. Vanić and co-workers [36] observed changes in
the hydrogel texture properties when deformable propylene glycol liposomes were incorporated in
Carbopol hydrogel; as in our case, the hydrogel texture properties were reduced. The incorporation
of DLs in Carbopol hydrogel also affected the hydrogel texture when compared to a marketed gel
product, although the authors did not focus on the effect of the liposomal surface charge [37]. Similar
to our findings, Hurler and collaborators [24] also observed weakened chitosan hydrogel properties
due to the incorporation of conventional liposomes bearing different surface charges. The charged
DLs enhanced the hydrogel hardness while weakening both the cohesiveness and adhesiveness, as
compared to NDLs (Table 3).
3.3. Effect of Liposomal Surface Charge on Hydrogel Bioadhesion to Human Skin
Bioadhesiveness represents an important feature responsible for the effectiveness of hydrogel-based
wound dressings. Good hydrogel bioadhesion to human skin can prolong the retention time of the
incorporated drug/active substance at the skin site, thus resulting in an enhanced therapeutic effect.
Considering the presence of the exudate in chronic wounds/burns, the contact time of the hydrogel to
the skin might be reduced by a loss of the original hydrogel texture characteristics due to the high
water content in the wounded area of exudating wounds [11]. Improved hydrogel bioadhesion to
human skin might overcome this limitation. We therefore evaluated a possible effect of the liposomal
surface charge on the chitosan hydrogel bioadhesiveness. Based on the method developed earlier in
our laboratory [28], we evaluated the hydrogel bioadhesion to human skin by determining the force
required to remove the hydrogel formulation from the skin (Figure 1a) and the amount of hydrogel
formulations retained onto the skin surface at the end of the bioadhesion test (Figure 1b).
Figure 1. Effect of the liposomal surface charge on liposomes-in-hydrogel bioadhesiveness, expressed
as the (a) detachment force and (b) amount of formulation retained onto the human skin surface.
Results are expressed as mean (n = 3) ± SD.
The bioadhesiveness expressed as the detachment force was not affected by the incorporation
of curcumin-containing DLs, regardless of the liposomal surface charge. Both CDLs- and
ADLs-in-hydrogel exhibited a similar bioadhesiveness as plain hydrogel, whereas NDLs-in-hydrogel
showed the strongest bioadhesion to human skin. As observed for the texture properties, NDLs with a
neutral surface seemed to stabilize the chitosan network to a higher extent compared to the charged
DLs. Their neutral liposomal surface assures minimal interactions with the polymer, thus leaving
unaltered the intrinsic bioadhesive properties of chitosan hydrogel.
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The amount of the hydrogel retained on the skin was similar for all tested DLs-in-hydrogel
systems. Moreover, the high amount of hydrogel retained onto the skin (approximately 70%) observed
for all DLs-in-hydrogel is encouraging considering the need to potentially overcome the challenge
of hydrogel exposure to wound exudate and reduced retention time when hydrogel is applied on
exudate-rich wounded area. The high water content associated to those wound types is responsible for
the limited adhesion of the wound dressing at the skin site. Therefore, the good bioadhesive properties
of DLs-in-hydrogel systems confirmed herewith are promising in prolonging the retention time of
novel dressing, including curcumin, at the wounded area rich in exudate, potentially enhancing its
therapeutic outcome. Further studies involving the exposure to wound exudate are required to confirm
these preliminary findings.
3.4. Stability of Hydrogel
The incorporation of charged DLs in chitosan hydrogel has shown to influence, to a higher extent,
the hydrogel’s texture properties (Table 2) and, to a lesser extent, the bioadhesiveness (Figure 1),
possibly attributable to triggered interactions between charged DLs and chitosan. We therefore further
explored the effect of the liposomal surface charge on the stability of liposomes-in-hydrogel. Wound
dressings that can maintain their original properties when stored at room temperature would enable
easier administration both by the patient itself or a caretaker. The liposomes-in-hydrogel formulations
were stored at room temperature (23–24 ◦C) for one month and both the texture properties and
bioadhesiveness of formulations were determined and compared with the properties of the original
formulations. As expected, the original texture properties were preserved to a higher extent when
NDLs were incorporated in the hydrogel compared to both CDLs and ADLs (Figure 2). The minimal
interaction between neutral DLs and chitosan network seems to maintain the original hydrogel texture
properties whereas the charged DLs weakened the texture properties due to electrostatic interactions.
However, the findings were still considered acceptable, considering that the testing was performed at
room temperature.
Interestingly, the evaluation of the hydrogel’s stability in terms of its bioadhesiveness showed
that the original bioadhesion to human skin was better preserved when CDLs were incorporated in the
hydrogel (Figure 3). Both the detachment force (Figure 3a) and the amount of formulation retained
onto the skin surface (Figure 3b) for CDLs-in-hydrogel moderately increased compared to both NDLs-
and ADLs-in-chitosan hydrogel. However, the differences were not significant, and more experiments
would be required to confirm the observed trend.
Although the original bioadhesiveness of liposomes-in-hydrogel was enhanced by the presence
of NDLs, suggesting that the neutral surface of NDLs might exert a positive effect on hydrogel
bioadhesiveness (Figure 1), the results from the hydrogel stability testing indicate that the positively
charged DLs can better preserve hydrogel bioadhesiveness for a longer time as compared to NDLs.
Considering the variability of human skin in respect to the source, the differences were not significant.
The repulsion between positive CDLs and chitosan chains might stabilize the liposomes in the hydrogel
matrix, thus preserving chitosan bioadhesion to human skin.
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Figure 2. The effect of the liposomal surface charge on liposomes-in-hydrogel texture properties:
stability testing. (a) hardness, (b) cohesiveness, and (c) adhesiveness, determined on day 0 and after
storage at 23 to 24 ◦C for 30 days. Results are expressed as mean (n = 3) ± SD.
The bioadhesiveness of the dressing is one of the main factors determining the time curcumin is
retained at the skin site. Despite the rather negative effect of charged liposomes on the texture properties
of DLs-in-hydrogel, the incorporation of CDLs in hydrogel might increase hydrogel bioadhesiveness,
thus assuring a longer time for curcumin to exert its biological activities. The significance of the
superiority of CDLs in hydrogels needs to be confirmed. For comparison, visual evaluation of the
hydrogels stored for one month indicated that the control, namely curcumin-in-hydrogel (non-liposomal
curcumin in hydrogel), exhibited clear curcumin precipitation (data not shown). This was additional
conformation that to deliver curcumin at the wounded site, combined formulations comprising
liposomes and hydrogel are highly advantageous.
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Figure 3. The effect of the liposomal surface charge on liposomes-in-hydrogel bioadhesiveness: stability
testing. (a) Detachment force and (b) amount of formulation retained onto the skin surface, determined
on day 0 and after the storage at 23 to 24 ◦C for 30 days. Results are expressed as mean (n = 3) ± SD.
3.5. Ex Vivo Curcumin Penetration from DLs-In-Hydrogel into Human Skin
As dermal delivery systems, both DLs and chitosan hydrogel have shown ability to assure
controlled and sustained skin penetration of the associated drug. When used in combination, this
action can be enhanced and, together with the prolonged retention time at the targeted skin site,
might lead to improved localized wound therapy [18,19]. Moreover, this can result in a reduction in
frequency of wound dressings’ changes, improving patient compliance and the easiness of dressing
administration. The incorporation of curcumin-DLs in the hydrogel introduces additional barriers that
curcumin has to face and cross before reaching the targeted site. Therefore, curcumin release from the
DLs-in-hydrogel followed by its skin penetration is a complex process and depends on several factors.
The lipophilicity of curcumin will influence this process, especially its partitioning into the hydrogel,
whereas its aqueous solubility will determine the diffusion rate through the hydrophilic hydrogel
matrix, as reported for other lipophilic compounds [38]. The liposomal surface charge represents an
additional factor that can affect curcumin penetration through/into the skin [39]. Moreover, due to the
positively charged chitosan chains, the liposomal surface charge can determine possible interaction
between DLs and chitosan [24]. This can affect the integrity of the liposomal bilayer when embedded
into the hydrogel, thus influencing the release of curcumin. By exploring the abovementioned factors,
the development of liposomes-in-hydrogel formulations for controlled dermal delivery of curcumin
can be tailored and effective therapy assured.
Figure 4 presents the skin penetration profiles of curcumin from the different curcumin-DLs-in-
hydrogel systems. A minimal amount of penetrated curcumin was detected, regardless of the liposomal
surface charge. This can be contributed to the slow diffusion of curcumin when released into the
hydrophilic hydrogel due to its poor water solubility. In agreement with our findings, Jain and
collaborators [25] also reported a rather slow in vitro release of curcumin from lipospheres embedded
in hydroxyl propyl methyl cellulose-based gel.
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Figure 4. Ex vivo curcumin penetration from different DLs-in-hydrogel through full thickness human
skin (n = 3 ± SD).
As a control, curcumin-in-hydrogel was used; curcumin was incorporated in the hydrogel in a
form of solution in PG in the same concentration as in DLs.
The NDLs-in-hydrogel release profile exhibited the highest amount of penetrated curcumin, even
in comparison to curcumin-in-hydrogel (Figure 4). However, the differences were not statistically
different and can only be considered as a trend. It is important to point out that the experiments
were performed using human skin of different donors, adding to larger SD. NDLs with their neutral
surface are not expected to interact with the chitosan chains. The minimal interaction between NDLs
and chitosan chains might also marginally interfere with NDLs’ mobility within the polymer matrix,
allowing faster curcumin delivery into/through the skin via NDLs. Thomas and collaborators [40]
reported the enhancement of curcumin skin penetration from nanosystems-in-chitosan hydrogel
compared to free curcumin-in-hydrogel. They incorporated curcumin in nanoemulsions further
incorporated in chitosan hydrogel and observed a higher rat skin penetration of curcumin as compared
to free curcumin-in-hydrogel. Sun and co-workers [41] reported higher penetration of curcumin from
PLGA nanoparticles-loaded in Carbopol gel compared to free curcumin-in-gel, although they tested
the formulations on mouse skin.
The charged DLs-in-hydrogel exhibited more sustained, although not significant, skin penetration
of curcumin compared to NDLs-in-hydrogel and control (curcumin-in-hydrogel). Considering the
possible electrostatic interactions that can be triggered when charged DLs are embedded into the chitosan
network, the liposomal membrane might be more preserved, thus limiting curcumin partitioning into
the hydrogel. The electrostatic interactions between negative DLs and positive chitosan chains can
cause immobilization of ADLs within the hydrogel matrix, thus limiting initial curcumin diffusion into
the hydrogel prior to reaching the skin. El Kechai and collaborators [42] proposed low mobility of
liposomes bearing opposite charge to the hydrogel chains; the authors observed that positive liposomes
were highly immobilized in the negative hyaluronic acid hydrogel. On the other hand, the higher
repulsion occurring between CDLs and chitosan, both positively charged, might stabilize the CDLs
membrane and limit curcumin partitioning into the chitosan hydrogel. Hurler and collaborators [24]
also observed a similar release pattern when testing the in vitro release of a lipophilic compound from
positively charged liposomes embedded in chitosan hydrogel, in agreement with our findings.
In our previous work [10], we showed a successful inhibition of S. aureus and S. pyogenes growth
when testing curcumin in deformable liposomes in a curcumin concentration of 100 and 200 μg/mL.
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Furthermore, the curcumin-containing liposomes (even at a curcumin concentration of 2.5 μg/mL)
successfully inhibited nitric oxide production. The concentrations used in the current study are in the
same range as the ones in the aforementioned study, indicating that the delivery rate is compatible
with the working concentration of curcumin in this type of carrier. Compared to Ternullo et al. [10],
the ex vivo release through full thickness human skin exhibited a more sustained release when
the DLs were incorporated into a hydrogel, as expected. Recently, Nguyen and coauthors [43]
reported improved wound healing when utilizing a curcumin–oligochitosan nanoparticle complex
and oligochitosan-coated curcumin-loaded liposomes with a curcumin concentration of 100 μg/mL.
The hydrogel prepared in the current study contains curcumin in a concentration of 135 μg/g and is
therefore similar to the concentration used by Nguen et al. (2019). The curcumin concentration in the
novel dressing is sufficient to achieve the desired biological response.
Considering the prolonged retention time of curcumin assured by chitosan hydrogel and sustained
delivery provided by liposomes-in-hydrogel, we can postulate that curcumin will have a sufficient
time and required concentration at the skin site to exert its therapeutic effect. However, the findings
should be further explored in a suitable wound model.
4. Conclusions
To utilize the wound healing potential of both curcumin and chitosan, we developed a novel
wound dressing comprising curcumin-in-liposomes-in-chitosan hydrogel. Curcumin was incorporated
in deformable liposomes of various surface charges and the effect of the liposomal surface charge on
the performance of chitosan hydrogels was evaluated. Although the original texture properties were
changed to a certain degree upon inclusion of the charged liposomes, the incorporation of DLS in
the chitosan hydrogel did not affect its bioadhesiveness. Neutral deformable liposomes-in-hydrogel
exhibited the strongest bioadhesiveness; however, their neutral surface did not preserve the hydrogels´s
bioadhesion to human skin over longer storage times. The positively charged deformable liposomes
exhibited an ability to stabilize the formulation’s bioadhesiveness and additionally assured sustained
penetration of curcumin through the ex vivo full human skin. The developed advanced dermal delivery
system is therefore promising as a wound dressing.
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Abstract: Niacinamide (NIA) is the amide form of vitamin B3 and has been widely used in
pharmaceutical and personal care formulations. Previously, we reported a comparative study of
NIA permeation from neat solvents using the Skin Parallel Artificial Membrane Permeability Assay
(PAMPA) and mammalian skin. A good correlation between NIA permeation in the different models
was found. In the present work, ten binary and ternary systems were evaluated for their ability to
promote NIA delivery in the Skin PAMPA model, porcine skin and human epidermis. Penetration
enhancement was evident for binary systems composed of propylene glycol and fatty acids in
human skin studies. However, propylene glycol and oleic acid did not promote enhancement of
NIA compared with other systems in the Skin PAMPA model. A good correlation was obtained
for permeation data from Skin PAMPA and porcine skin. However, data from the Skin PAMPA
model and from human skin could only be correlated when the PG-fatty acid systems were excluded.
These findings add to our knowledge of the potential applications of Skin PAMPA for screening
dermal/transdermal preparations.
Keywords: in vitro; permeation; niacinamide; solvent; PAMPA; skin
1. Introduction
Niacinamide (NIA) is the water-soluble form of vitamin B3 (Figure 1). Since its discovery as
a “pellagra-preventing” agent, this molecule has been widely used in personal care and cosmetic
products [1,2]. NIA has been demonstrated to have a number of anti-inflammatory and photo-protective
effects following topical application. The therapeutic benefits of NIA in the management of acne and
atopic dermatitis and promotion of the up-regulation of epidermal lipid synthesis have also been
reported [3,4]. Mohammed, et al. [5] investigated the influence of NIA on the molecular properties of
the human stratum corneum (SC) in vivo. The authors assessed the corneocyte maturity and surface
area from NIA treated and untreated (control) areas, as well as trans-epidermal water loss (TEWL).
The thickness of the SC before and after the application of NIA was determined using confocal Raman
spectroscopy (CRS). The NIA treatment decreased TEWL values, increased the thickness of the SC,
and larger and more mature corneocytes were found in the treated versus control sites. More recently,
evidence from a phase 3 randomized clinical trial points to NIA having a role in the prevention of
non-melanoma skin cancer [6,7].
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Figure 1. The 2D structure of niacinamide.
The discovery and development of robust and accessible human skin surrogates continues to be an
area of considerable interest to industry and regulatory authorities. Recently, we reported the use of the
Skin Parallel Arterial Membrane Permeability Assay (PAMPA) model to assess in vitro permeation of
NIA from a number of solvents, namely, propylene glycol (PG), dimethyl isosorbide (DMI), Transcutol®
P (TC), t-butyl alcohol (T-BA), PEG 400, PEG 600, and a commercial product containing NIA [8]. In vitro
permeation studies were also performed using porcine skin and heat-separated human epidermis.
The permeation studies were conducted under finite dose conditions, namely, 5 μL/cm2 for human/pig
skin and 3 μL/cm2 for the Skin PAMPA model. When the permeation data for the models were
compared, a correlation coefficient (R2) of 0.71 for human skin and PAMPA was obtained and the
corresponding correlation coefficient for porcine skin and PAMPA was 0.88.
A number of studies have reported that combinations of vehicles and/or chemical penetration
enhancers may improve skin uptake and the permeation of actives in a synergistic manner [9,10]. PG is
one of the most commonly used glycols in skin preparations [11]. The synergistic enhancement of drug
delivery to the skin was reported when PG was employed as a co-solvent in delivery systems [12].
In our previous work, a range of neat solvents were evaluated for NIA skin delivery; both PG and TC
were identified as the most promising vehicles for this active [8]. The primary aim of the present work
was to examine the efficacy of combinations of PG or TC with other solvents on the skin uptake of
NIA. The solvents selected were T-BA, DMI, oleic acid (OA), linolenic acid (LA) and caprylic/capric
triglyceride (CCT). These solvents were selected as they encompass varying physicochemical properties
and, where known, different mechanisms of skin penetration enhancement [11,13]. A secondary aim
was to further explore the feasibility of the Skin PAMPA for screening multi-component formulations.
2. Materials and Methods
2.1. Materials
NIA, PG, T-BA, OA, LA, high-performance liquid chromatography (HPLC) grade water and
methanol, were purchased from Sigma-Aldrich, Dorset, UK. DMI and IPM were supplied from
Croda Ltd., Goole, UK. TC and CCT were kind donations from Gattefossé, St. Priest, France.
Phosphate buffered saline (PBS) (pH 7.3 ± 0.2 at 25 ◦C) tablets was supplied by Oxoid, Cheshire, UK.
Pre-coated PAMPA Plates (Pion Inc. PN120657), hydration solution, stirring disks and a Gut-Box™
device were obtained from pION Inc. Billerica, MA, USA.
2.2. Miscibility and Stability Studies
Miscibility studies of all vehicles were conducted to identify appropriate combinations of solvents
for binary and ternary systems. The stability of NIA at a concentration of 5% (w/v) in PG:T-BA (90:10),
PG:OA (10:90), PG:TC (50:50), PG:DMI (50:50), PG:LA (50:50), PG:TC:DMI (50:25:25), TC: T-BA (90:10)
and TC:DMI (50:50), TC:CCT:DMI (50:25:25) and TC:PG:DMI (50:25:25) was examined at 32 ± 1 ◦C
up to 72 h [14]. The concentration of NIA was determined at 0, 24, 48 and 72 h. Samples were
analyzed using the HPLC method validated earlier with a Kinetix® 5 mm Phenyl-Hexyl 250 × 4.6 mm
reversed column (Phenomenex, Macclesfield, UK) with water:methanol (80:20) as the mobile phase.
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The injection volume was set at 10 μL, and the flow rate of the mobile phase was set to 1 mL/min.
The column temperature was set to 30 ◦C and the UV detection wavelength was 263 nm [8].
2.3. The Skin PAMPA Permeation Studies
The influence of binary and ternary solvent systems on the permeation of NIA was initially
screened using the Skin PAMPA model. The Skin PAMPA model was hydrated and prepared following
the procedure described by Luo, et al. [15]. The permeation studies were conducted using a modified
protocol described previously [8]. A dose of 1 μL (corresponding to 3 μL/cm2) was used, as it was
shown to represent a finite dose of NIA formulations in previous Skin PAMPA studies. To maintain the
temperature of the membrane at 32 ± 1 ◦C, the Skin PAMPA apparatus was incubated in a “Gut-Box™”
chamber during the course of permeation studies. Freshly prepared and degassed phosphate buffered
saline (PBS, pH 7.3 ± 0.2) solution served as the receptor medium. Samples were collected at 0.1, 0.2,
0.3, 0.7 1, 1.5, 2 and 2.5 h. The concentration of NIA in the receptor medium at each interval was
quantified using the HPLC method validated previously [8].
2.4. Permeation Studies in Porcine and Human Skin
Vertical glass Franz diffusion cells were used to conduct in vitro permeation studies of NIA in
full thickness porcine and heat-separated human skin, as reported previously [16,17]. All permeation
studies were conducted under finite dose conditions (5 μL/cm2). Porcine tissue was obtained from a
local abattoir. The human (female, Caucasian) abdominal tissue from three donors following plastic
surgery was obtained from a tissue bank with institutional approval (Research Ethics Committee
reference 07/H1306/98). Porcine and human tissue membranes with a diffusion area of around 1 cm2
were prepared following the procedures described earlier, and the membrane integrity was examined
by a measurement of electrical resistance [8]. The Franz cells were placed into a thermostatically
controlled water bath (JB Nova, Grant, Cambridge, UK) set at 36 ± 1 ◦C during the course of the
permeation studies. The NIA formulations were applied to the skin when the temperature of the skin
surface had equilibrated to 32 ± 1 ◦C (TM-22 Digitron digital thermometer, RS Components, Corby,
UK). A total of 200 μL of receptor medium was withdrawn and replaced with an equal volume of PBS
solution at each sampling interval: 0, 1, 2, 4, 6, 8, 10, 12 and 24 h. At the end of the permeation studies,
the receptor phase was removed, and mass balance evaluation was performed following a procedure
validated previously [18]. The mass balance method is described in the Supplementary Materials.
2.5. Data Analysis
Data were recorded using Microsoft® Excel and analyzed using SPSS® Statistics version 24
(IBM, Feltham, UK) using the procedure described previously [8]. One-way ANOVA with a post
hoc Tukey Test was performed for data that met the assumption of normality and homogeneity of
variance. The Kruskal–Wallis H Test was used for non-parametric data. A p-value of <0.05 was
considered as a statistically significant difference. The correlation between the cumulative amounts of
NIA that permeated in the Skin PAMPA model and mammalian skin was calculated using the Pearson
Product–moment correlation coefficient (R2) in Microsoft® Excel.
3. Results and Discussion
3.1. Stability Determination
The stability of NIA in the seven binary and three ternary systems was confirmed. After 72 h,
the recovery values of NIA in all tested systems were greater than 91.0%. The stability of NIA in the
receptor medium, PBS solution, was confirmed in our earlier work [8]. Stability results are reported in
the Supplementary Materials (Figure S1).
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3.2. Skin PAMPA Permeation Studies
Figure 2A shows the permeation profiles of NIA for PG:T-BA (90:10), PG:OA (10:90), PG:TC
(50:50), PG:DMI (50:50), PG:LA (50:50) and PG:TC:DMI (50:25:25) in the Skin PAMPA model. At 2.5 h,
the cumulative amounts of NIA that permeated through the membrane ranged from 44.2 to 177.4μg/cm2.
PG:T-BA was the most efficient system for NIA delivery compared with all other PG binary or ternary
systems (p < 0.05). The cumulative amount of NIA delivered through the Skin PAMPA model from
neat PG was determined as 163.1 μg/cm2 [8]. No difference was evident when comparing NIA
permeation from PG:T-BA (90:10) and neat PG (p > 0.05). The amount of NIA delivered by PG:OA
(10:90), 140.2 ± 18.9 μg/cm2, was significantly greater than corresponding values for PG:TC (50:50),
PG:DMI (50:50) and PG:LA (50:50) (p < 0.05). The ternary system composed of PG, TC and DMI did
not enhance the permeation of NIA in Skin PAMPA compared with PG:DMI (50:50) and PG:TC (50:50)
(p > 0.05). A significantly lower permeation of NIA was observed for PG:LA (50:50), 44.2 ± 9.4 μg/cm2,
compared with all other binary and ternary systems and neat PG (p< 0.05). Formulations containing TC
and other solvents were subsequently assessed in the Skin PAMPA model under finite dose conditions
(Figure 2B). At 2.5 h, the cumulative amounts of NIA that permeated from TC:T-BA (90:10) and
TC:DMI (50:50) were 160.0 ± 8.5 and 159.9 ± 5.4 μg/cm2, respectively (p > 0.05). The amounts of NIA
that permeated from TC:T-BA (90:10) and TC:DMI (50:50) were significantly higher compared with
corresponding values for TC:CCT:DMI (50:25:25) and TC:PG:DMI (50:25:25) (p < 0.05).
 
Figure 2. Cumulative permeation of niacinamide (NIA) from binary and ternary solvent systems
composed of propylene glycol (PG): t-butyl alcohol (T-BA) (), PG: oleic acid (OA) (), PG: Transcutol®
P (TC) ( ), PG: dimethyl isosorbide (DMI) (), PG: linolenic acid (LA) (( )), PG:TC:DMI (50:25:25, )
(A), TC:T-BA(), TC:DMI(), TC:PG:DMI (50:25:25, ) and TC: caprylic/capric triglyceride (CCT):DMI
(50:25:25, ) (B) in the Skin PAMPA model following the application of 1 μL per well (corresponding to
3 μL/cm2) of formulations. Each data point represents the mean ± SD, n = 4. * p < 0.05.
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Table 1 summarizes the percentages of NIA permeation from the binary and ternary systems.
At 2.5 h, for PG:OA (10:90), PG:T-BA (90:10), PG:TC:DMI (50:25:25), TC:DMI (50:50) and TC:T-BA
(90:10), more than 80% of the applied active was delivered into the receptor phase (p > 0.05). In the
previous study, the cumulative amounts of NIA that permeated for neat TC and PG in the Skin PAMPA
model were 184.7 ± 8.9 and 163.1 ± 1.1 μg/cm2, accounting for 97% and 95% of the applied amounts,
respectively [8]. Compared with neat TC, the TC binary systems did not enhance the permeation of
NIA in the Skin PAMPA model (p > 0.05). Interestingly, compared with neat PG, the permeation of
NIA was enhanced for PG:T-BA (90:10) (p < 0.05). However, the permeation of NIA from PG:LA (50:50)
was significantly lower than NIA permeation from neat PG (p < 0.05).
Table 1. Percentage permeation of NIA from the binary systems in the Skin PAMPA model (n = 4,
mean ± SD).
Formulation Percentage Permeation (%) at 2.5 h
PG:LA (50:50) 26.9 ± 5.7
PG:DMI (50:50) 66.0 ± 6.9
PG:TC (50:50) 68.0 ± 12.3
PG:OA (10:90) 95.2 ± 13.8
PG:T-BA (90:10) 103.7 ± 0.5
TC:T-BA (90:10) 97.3 ± 5.1
TC:DMI (50:50) 97.2 ± 3.3
TC:PG:DMI (50:25:25) 77.5 ± 8.2
TC:CCT:DMI (50:25:25) 75.3 ± 4.9
TC:CCT:DMI (50:25:25) 81.2 ± 3.2
3.3. Porcine Skin Permeation and Mass Balance Studies
The various binary and ternary solvent systems were examined for their influence on NIA
permeation using porcine skin under finite dose conditions (5μL/cm2). Figure 3A,B show the permeation
profiles for the binary formulations composed of PG or TC. For PG:T-BA (90:10), NIA permeation was
detected after 1 h and this system delivered a significantly higher amount of NIA through the tissue
compared with other formulations, namely, 150.3 ± 26.5 μg/cm2 at 24 h (p < 0.05). The cumulative
amounts of NIA that permeated from PG:OA (10:90) and PG:TC:DMI (50:25:25) were 70.2 ± 18.1 and
58.4 ± 7.0 μg/cm2, respectively (p > 0.05). The cumulative permeation of NIA from PG: LA (50:50) was
19.3 ± 13.7 μg/cm2, a value that was significantly lower than PG:T-BA (90:10). The amounts of NIA
that permeated through porcine skin from binary and ternary formulations of TC ranged from 34.1 to
178.0 μg/cm2 (Figure 3B). The cumulative amounts of NIA that permeated from neat TC and PG were
previously reported as 95.1 and 46.0 μg/cm2 in pig skin, respectively [8]. At 24 h, a higher cumulative
permeation of NIA was evident for TC:T-BA (90:10) compared with neat TC or other assessed binary
and ternary systems containing TC (p < 0.05).
The overall recoveries in the mass balance studies for PG:OA (10:90), PG:DMI (50:50), PG:TC
(50:50), TC:DMI (50:50) and PG:TC:DMI were <85% (Table 2). These results are consistent with the
findings of Haque et al. [18]. As the stability of NIA in all formulations was confirmed, it is possible
that the lower recovery might be attributed to the chemical derivatization of this molecule during the
permeation process [19]. The higher total recovery in binary TC-T-BA systems may reflect the potential
of TC:T-BA (90:10) to prevent the chemical derivatization of NIA. However, this hypothesis needs to
be probed further. For PG:T-BA (90:10) and TC:T-BA (90:10), lower percentages of NIA were recovered
from the skin surface compared with all other binary and ternary systems, accounting for 3.5% and
6.1% of applied NIA amounts, respectively (p < 0.05). After 24 h, for all formulations, skin extraction
values ranged from 3.2% to 32.9% of the applied amounts. PG:TC (50:50) significantly increased the
percentage of NIA deposited in porcine skin compared with neat PG (p < 0.05), while no difference was
detected when compared with TC (p > 0.05). The skin retention values observed for the three tested
ternary systems were not significantly different (p > 0.05). Interestingly, comparing the distribution of
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NIA in the tissue for binary and ternary systems, a higher skin retention was evident for TC:CCT:DMI
(50:25:25) than for TC:DMI (50:50) (p < 0.05). CCT is a triglyceride comprising a mixture of caprylic and
capric acid esters and has been widely used in cosmetic products as an emollient [20]. Leopold and
Lippold [21] investigated the mechanism of the penetration enhancing effects of several lipophilic
vehicles including CCT using Differential Scanning Calorimetry (DSC). These authors suggested that
any penetration enhancement effects of CCT are probably caused by the dissolution or extraction of
the stratum corneum lipids. The systems composed of CCT examined here appear promising for the
dermal delivery of NIA, and these formulations were further evaluated using human skin.
 
Figure 3. Cumulative permeation of NIA from binary and ternary solvent systems in porcine skin
following the application of 5 μL/cm2 of formulations. (A) shows the permeation profiles of PG:T-BA(),
PG:OA(), PG:TC( ), PG:DMI(), PG:LA(( )), PG:TC:DMI (50:25:25, ); (B) shows the permeation
profiles of TC:T-BA(), TC:DMI(), TC:PG:DMI (50:25:25, ) and TC:CCT:DMI (50:25:25, ). Each data
point represents the mean ± SD, n = 4. * p < 0.05.
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Table 2. The results of the mass balance studies after the permeation studies using porcine skin under
finite dose conditions (n = 4, mean ± SD).
Formulation Washing % Extraction % Permeation % Total %
PG:DMI (50:50) 47.1 ± 5.4 22.9 ± 13.2 11.5 ± 3.9 81.5 ± 5.6
PG:OA (10:90) 37.1 ± 5.4 9.6 ± 1.0 30.2 ± 7.2 76.8 ± 5.9
PG:TC (50:50) 43.4 ± 3.9 23.4 ± 5.6 13.4 ± 6.9 80.2 ± 6.7
PG:LA (50:50) 55.6 ± 12.3 20.6 ± 4.4 9.2 ± 6.6 85.4 ± 7.9
PG:T-BA (90:10) 3.5 ± 0.8 10.1 ± 7.6 71.3 ± 12.6 84.9 ± 7.1
TC:T-BA (90:10) 6.1 ± 5.2 15.3 ± 11.9 79.5 ± 12.0 100.9 ± 13.8
TC:DMI (50:50) 35.3 ± 13.6 10.7 ± 3.5 35.2 ± 16.0 81.2 ± 1.8
PG:TC:DMI (50:25:25) 36.1 ± 8.5 18.8 ± 8.8 25.1 ± 3.8 80.1 ± 9.7
TC:CCT:DMI (50:25:25) 39.8 ± 15.1 28.0 ± 12.8 18.2 ± 7.6 86.0 ± 8.9
TC:PG:DMI (50:25:25) 43.2 ± 4.0 32.9 ± 13.8 13.2 ± 1.9 89.2 ± 16.8
As shown in Figure 4, 19.3–178.0 μg/cm2 of NIA penetrated through porcine skin at 24 h,
while 44.2–177.4 μg/cm2 was delivered in the Skin PAMPA model at 2.5 h. A correlation coefficient (R2)
of 0.63 was determined for the linear regression of the data (Figure 4). The value was lower compared
with the correlation coefficient determined between the permeation data in Skin PAMPA and porcine
skin for the single solvents under finite dose conditions, R2 = 0.88 [8]. This may reflect the different
interactions of the more complex vehicles studied here in the Skin PAMPA lipids compared with the
single solvents studied previously.
Figure 4. Cumulative amounts of NIA that permeated from assessed binary and ternary solvent
systems in the Skin PAMPA model at 2.5 h plotted against the corresponding values observed in porcine
skin at 24 h. Each data point represents the mean ± SD, n = 4.
3.4. Human Skin Permeation and Mass Balance Studies
NIA permeation was further investigated using heat-separated human epidermis. The permeation
profiles of NIA for these experiments are shown in Figure 5. For the two binary systems, PG:LA (50:50)
and PG:OA (10:90), permeation of NIA was detected 2 h after application. At 24 h, significantly higher
amounts of NIA were delivered from PG:LA (50:50) and PG:OA (10:90) compared with all other binary
and ternary systems (p < 0.05), with cumulative permeation values of 100.4 ± 2.4 and 93.3 ±2.4 μg/cm2,
respectively. The cumulative amounts of NIA that permeated in human skin for neat T-BA, DMI, PG or
TC were reported previously as 50.8, 15.0, 1.8 and 16.4 μg/cm2 [8]. A more efficient skin penetration
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enhancement of NIA is clearly evident for PG:LA and PG:OA compared with these neat solvents
(p < 0.05). No significant increase was observed for NIA permeation from TC binary and ternary
systems compared with neat TC (p > 0.05).
Figure 5. Cumulative permeation of NIA from binary and ternary solvent systems in human skin
following the application of 5 μL/cm2 of formulation. (A) shows the permeation profiles of PG:T-BA(),
PG:OA(), PG:TC( ), PG:DMI(), PG:LA(( )), PG:TC:DMI (50:25:25, ); (B) shows the permeation
profiles of TC:T-BA(), TC:DMI() TC:PG:DMI (50:25:25, ) and TC:CCT:DMI (50:25:25, ). Each data
point represents the mean ± SD, n = 4. * p < 0.05.
Table 3 summarizes the mass balance results of NIA for the human skin studies. The amounts
of NIA remaining on the skin surface range from 27% to 75% of the amounts applied, respectively.
No difference was detected comparing the percentage of NIA recovered from the skin surface for the
different formulations (p > 0.05). The skin retention of NIA for PG:LA (50:50) was determined as 3.4%
of the applied dose. This value was significantly lower (p < 0.05) compared with the skin extraction
values for TC:T-BA (34.7%) and TC:CCT:DMI (29.7%). The percentage of NIA extracted from human
epidermis for neat TC was 32.9% [8]. The corresponding value for TC:T-BA (90:10) was comparable to
the value for neat TC (p > 0.05). As for the percentage permeation, higher values were observed for
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PG:LA (50:50) (46.1%) and PG:OA (10:90) (40.7%) compared to all other binary and ternary systems
(p < 0.05). There was no significant increase in the percentage permeation of NIA from TC binary
systems compared with neat TC (p > 0.05). Statistical analysis confirmed the penetration enhancement
of NIA for the PG/fatty acids (LA and OA) compared with neat PG [8] (p < 0.05). However, in porcine
skin studies, the percentage permeation of NIA for PG:LA (50:50) was significantly lower than for neat
PG and PG:OA (10:90) (p < 0.05).
Table 3. The results of mass balance studies after permeation studies using human skin under finite
dose conditions (n = 4, mean ± SD).
Formulations Washing% Extraction% Permeation% Total%
PG:DMI (50:50) 59.6 ± 7.1 17.4 ± 3.9 5.6 ± 4.0 82.6 ± 7.8
PG:OA (10:90) 37.7 ± 6.7 9.2 ± 0.6 40.7 ± 6.5 87.6 ± 0.8
PG:TC (50:50) 69.8 ± 7.8 29.0 ± 18.5 4.4 ± 2.3 103.1 ± 13.4
PG:LA (50:50) 27.1 ± 5.6 3.4 ± 2.0 46.1 ± 5.1 76.5 ± 5.1
PG:T-BA (90:10) 52.8 ± 9.0 20.1 ± 6.0 12.3 ± 4.2 85.2 ± 10.9
TC:T-BA (90:10) 39.8 ± 16.5 34.7 ± 10.5 15.6 ± 5.6 90.1 ± 5.2
TC:DMI (50:50) 75.1 ± 11.7 13.2 ± 4.7 10.2 ± 4.4 98.5 ± 11.7
PG:TC:DMI (50:25:25) 64.6 ± 4.5 12.2 ± 2.0 6.2 ± 2.3 83.0 ± 4.2
TC:CCT:DMI (50:25:25) 44.9 ± 6.0 29.7 ± 4.9 12.9 ± 3.3 87.5 ± 4.9
TC:PG:DMI (50:25:25) 66.5 ± 9.1 14.6 ± 3.4 6.6 ± 2.5 87.8 ± 6.7
Fatty acids have been reported to be skin permeation enhancers for a range of substances
possessing varying physicochemical properties [11,22,23]. Recently, Pham, et al. [24] applied 13C
polarization transfer solid-state nuclear magnetic resonance (NMR) to investigate the effects of OA
on SC molecular components. The authors mixed 30 mg of dry SC powder with 5% of OA and
then hydrated the mixture with water. The samples were incubated at 32 ◦C for 24 h before NMR
measurement. It was suggested that OA promoted increased mobility of both stratum corneum protein
components and the cholesterol chain segments in the intercellular lipid domains. However, the exact
synergistic mechanism of PG and fatty acids remains unclear. It may also be hypothesized that the fatty
acid first penetrates into the stratum corneum and contributes to increased lipid fluidity, which allows
the diffusion of PG with dissolved NIA.
In the present study, there was no significant difference between the permeation in human skin
and porcine skin for NIA in TC:DMI (50:50) PG:DMI (50:50), TC:CCT:DMI (50:25:25) (p > 0.05). A higher
permeation of NIA in porcine skin compared to human skin was evident for PG:T-BA (90:10), PG:DMI
(50:50), PG:TC (50:50), PG:TC:DMI (50:25:25), TC:T-BA (90:10) and TC:PG:DMI (50:25:25) (p < 0.05).
However, a lower permeation of NIA in porcine skin compared to human tissue was evident for PG:LA
(50:50) and PG:OA (10:90) (p < 0.05). Similar results have been reported by other researchers for other
actives. Shin, et al. [25] noted higher flux values of fentanyl for human skin compared with porcine
skin. Although pig skin has generally been considered to be more permeable than human skin [26–28],
the permeability may be dependent on the molecule of interest. Jung and Maibach [29] reviewed 46
studies which evaluated the permeation of 77 chemicals using both porcine and human skin; for 16
chemicals, permeation was greater in human skin permeation compared with porcine skin.
The cumulative permeation of NIA in human skin ranged from 14.5 to 100.4 μg/cm2;
the corresponding values determined in the Skin PAMPA model ranged from 44.2 to 177.4 μg/cm2.
Higher NIA permeation was observed in the artificial membrane compared with human epidermis for
PG:T-BA (90:10), TC:T-BA (90:10), TC:DMI (50:50), PG:OA (10:90), PG:TC:DMI (50:25:25), TC:CCT:DMI
(50:25:25), PG:DMI (50:50) and PG:TC (50:50) (p < 0.05). Attempts to fit all the permeation data from
the Skin PAMPA model and human epidermis were not successful. However, excluding results for
PG:LA (50:50) and PG:OA (10:90), an R2 value of 0.68 was obtained for the linear regression of the data
(Figure 6). The higher permeability of the Skin PAMPA studies observed in this study is consistent
with findings reported by others. Luo et al. [15] investigated the permeation of ibuprofen from PG,
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PEG 300, commercial gel and spray formulations in the Skin PAMPA model, porcine and human skin.
The authors reported the more permeable nature of the Skin PAMPA model compared to human
skin. Although the authors did not correlate the permeation data obtained from different models,
they reported formulations that delivered a higher amount of ibuprofen in the Skin PAMPA model
were also more efficient in human skin. In our previous work, NIA permeation from neat T-BA, DMI,
TC, PG, PEG 400 and PEG 600 and one commercial product in the Skin PAMPA model were correlated
with porcine/human skin [8]. A correlation coefficient (R2) of 0.71 was established for the Skin PAMPA
with human skin under finite dose conditions. The corresponding correlation between PAMPA model
and porcine skin was determined as 0.88. In this work, a correlation of NIA permeation data in human
skin and PAMPA model could only be obtained when the permeation data for PG-OA and PG-LA
were excluded. Statistical analysis confirmed that the permeation of NIA from PG:LA (50:50) was
significantly lower than neat PG (p < 0.05) in the Skin PAMPA. Additionally, in the Skin PAMPA model,
the permeation of NIA from PG:OA (10:90) was significantly higher compared with PG:LA (50:50)
(p < 0.05), while no difference was observed between these two systems in human epidermis (p > 0.05).
Figure 6. Cumulative permeation data of NIA from assessed binary and ternary solvent systems in the
Skin PAMPA model at 2.5 h, plotted against the corresponding values observed in human skin at 24 h.
Each data point represents the mean ± SD, n = 4.
To our knowledge, this is the first study that has investigated the permeation enhancement of fatty
acids with PG in the Skin PAMPA model. The results obtained in this study suggested that the Skin
PAMPA model is not a suitable model for screening such combinations. The Skin PAMPA model uses a
homogeneous filter-impregnated lipid mixture membrane, containing ~50% of synthesized ceramides
(Certramide), 25% of stearic acid and 25% of cholesterol [30]. The lower permeation of binary solvent
systems composed of PG and fatty acid may reflect the interaction of the lipid components with those
formulations. Both OA and LA are unsaturated C18 fatty acids [31]. These two fatty acids have a
double bond in the conformation [32]. It is possible that OA and LA integrated into the PAMPA
membrane and modified the lateral chain packing in the lipid matrix. This may lead to changes in the
physicochemical properties and permeability of this artificial model. Further studies are needed to
probe this theory.
4. Conclusions
Previous work investigated the dermal delivery of NIA from a series of single solvents. In the
present work, the influence of binary and ternary solvents on the in vitro permeation of NIA was
assessed in the Skin PAMPA model, porcine skin and heat separated human epidermis. The higher
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skin penetration of NIA was evident in human skin for the binary systems composed of PG with fatty
acids (PG-OA, PG-LA) compared with neat solvents investigated previously. A correlation of 0.63
was determined for the permeation data of binary and ternary systems in Skin PAMPA and in porcine
skin. Excluding the PG-OA and PG-LA systems, a correlation of 0.68 (R2) was also evident between
the permeation data obtained in the Skin PAMPA model and human epidermis. Further studies to
investigate the interactions between the Skin PAMPA model and the fatty acids OA and LA are needed
to better understand the potential of this model in the assessment of transdermal/dermal products.
Ultimately, a robust, efficient, accessible artificial skin permeability assay would benefit the regulatory
authorities, the pharmaceutical industry and the patients.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/12/668/s1,
Figure S1: Results of stability studies. Percentage of NIA recovered from tested binary and ternary solvent systems
at 24, 48 and 72 h at 32 ± 1 ◦C (n = 3, mean ± SD).
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Abstract: The use of methadone for the management of pain has received great interest in recent
years. Currently, oral and intravenous formulations are available for clinical use. Dermal delivery
represents an attractive alternative route of administration for this drug as it is associated with
comparatively fewer side effects. The first stage of the work was the preparation of methadone free
base as this form of the drug is expected to permeate the skin to a greater extent than the hydrochloride
salt. Subsequently the molecule was characterized with Nuclear Magnetic Resonance (NMR) and
thermal analysis, the distribution coefficient was determined and solubility studies were conducted
in a range of solvents. In vitro permeation and mass balance studies were conducted under finite
dose conditions (5 μL/cm2) in porcine skin. The results confirmed the more favorable penetration
of methadone free base compared with the salt. The highest cumulative amount of methadone
(41 ± 5 μg/cm2) permeated from d-limonene (LIM). Ethyl oleate (EO), Transcutol® P (TC) and octyl
salicylate (OSAL) also appear to be promising candidate components of dermal formulations for
methadone base. Future work will focus on further formulation optimization with the objective of
progressing to evaluation of prototype dosage forms in clinical trials.
Keywords: dermal delivery; porcine skin; in vitro permeation; methadone; pain
1. Introduction
Neuropathic pain can be caused by injuries, surgery, chemotherapy and a number of disease
conditions such as diabetes mellitus, cancer and human immunodeficiency virus infection [1]. It
can also arise as a direct consequence of a lesion or disease affecting the peripheral nervous system
or the central nervous system [2]. Patients’ overall health-related quality of life is greatly impacted
by neuropathic pain [3] and it is estimated to affect 7–10% of the general population in Europe [4].
The available current knowledge in terms of causes, diagnosis and treatment for peripheral neuropathic
pain is more advanced than that for pain associated with the central nervous system [5]. However, to
date, there are still very few effective treatments available for management of neuropathic pain.
Methadone has traditionally been used in the management of opioid dependence. However, there
is increasing interest in the repurposing of methadone as a cost-efficient treatment for neuropathic
pain [6,7]. Morley, et al. [8] reported the efficacy of oral methadone for the management of neuropathic
pain in a double-blind randomized controlled crossover trial. 19 patients were enrolled in the trial and
a statistically significant (p < 0.05) improvement in pain relief was reported. Methadone is not only a
potent μ-opioid receptor agonist but also a non-competitive N-Methyl-d-aspartate (NMDA) receptor
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antagonist [9]. The combination of NMDA receptor antagonism and opioid receptor agonism induced
by methadone is thought to result in enhanced analgesic efficacy. Animal studies have demonstrated
that the antinociception effect of methadone is mediated by both opioid agonism and NMDA receptor
antagonism in neuropathic pain [10]. The peripheral effect of morphine, a μ-opioid receptor agonist,
was enhanced by combined administration of (+)-HA966, an NMDA receptor antagonist, in a rat
model of neuropathic pain [11]. In addition, Stoetzer, et al. [12] also suggested that methadone is an
unselective blocker of a number of voltage-gated sodium (Nav) channels including Nav1.2, Nav1.3,
Nav1.7, and Nav1.8 with comparable potency to bupivacaine. These studies suggest that methadone is
a promising candidate to be developed for the management of peripheral neuropathic pain.
Dermal delivery of drugs offers a number of advantages compared with other routes of
administration. Constant drug levels in the plasma can be achieved with a decrease in dosing
frequency. Moreover, the avoidance of first pass metabolism results in less intra- and inter-patient
variability. Dermal delivery should also provide higher concentrations of methadone in skin tissues,
thus targeting pain at its source. The peripheral actions of methadone also suggest a lower concentration
of methadone can be delivered via the skin for pain relief compared with oral administration. To our
knowledge, there are only three published papers that have examined the in vitro skin absorption of
methadone. Fullerton, et al. [13] examined the permeation of methadone in human cadaver skin from
simple ethanol solutions. Ghosh and Bagherian [14] also investigated the delivery of methadone free
base from a transdermal patch in human skin. Recently, Muñoz, et al. [15] reported in vitro permeation
studies using porcine skin to evaluate the efficiency of methadone hydrochloride patches. No studies
have examined the in vivo delivery of this compound through the skin.
The aims of the present work were (i) to prepare and characterize methadone free base and (ii) to
identify effective solvents for the dermal delivery of methadone. A concentration of 5% w/v methadone
base solutions was selected based on available formulations for oral use. A range of solvents, spanning
different physicochemical parameters such as polarity and solubilization properties, were selected as
candidate vehicles. These solvents are generally recognized as safe (GRAS) and are already used in
other topical and transdermal dosage forms.
2. Materials and Methods
2.1. Materials
Methadone hydrochloride, tripropylene glycol (TriPG), dipropylene glycol (DiPG), 1-octanol,
1,3-butanediol (1,3-BD), Brij™ O20, isopropyl myristate (IPM), octyl salicylate (OSAL), oleic acid
(OA) and ethyl oleate (EO) were purchased from Sigma-Aldrich, Dorset, UK. Propylene glycol (PG),
ethyl acetate, d-limonene (LIM), high performance liquid chromatography (HPLC) grade water,
acetonitrile, orthophosphoric acid, 85+%, sodium dihydrogen phosphate, sodium hydrogen phosphate
and sodium hydroxide were supplied by Fisher Scientific, Loughborough, UK. Chloroform-d (CDCl3)
was purchased from Cambridge Isotope Laboratories Tewksbury, MA, USA. Labrafac™ lipophile WL
1349 (medium-chain triglycerides of caprylic and capric acids, WL 1349), Transcutol® (TC), propylene
glycol monocaprylate (PGMC) Type II and propylene glycol monolaurate (PGML) Type II were gifts
from Gattefossé, St. Priest, France. Phosphate buffered saline (PBS) (pH 7.3 ± 0.2 at 25 ◦C) was
prepared using Dulbecco A tablets supplied by Oxoid, Cheshire, UK. Full thickness porcine ear skin
was obtained from a local abattoir.
2.2. Preparation of Methadone Base
Methadone hydrochloride (1.730 g, 0.005 mol) was placed in a dry 250 mL round-bottom flask
with a Teflon coated magnetic stirrer. 20 mL of HPLC grade water was added and the mixture was
stirred for 10 min. The pH was then adjusted to 11.0 with 1 M sodium hydroxide solution. The newly
formed precipitate was stirred for 30 min. 100 mL of ethyl acetate was added to the suspension with
stirring for 60 min at 25 ◦C. The organic layer was then collected, and the aqueous layer washed
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with 45 mL (3 × 15 mL) of ethyl acetate. All organic layers were collected together and dried with
magnesium sulfate. Ethyl acetate was removed using a rotary evaporator (Heidolph, Schwabach,
Germany) using a high vacuum line for 5 h. Structural characterization was conducted using proton
nuclear magnetic resonance (1H-NMR) spectroscopy. The spectrum was obtained in chloroform-d
using a Bruker Avance 500 MHz NMR spectrometer (Bruker Corporation, Billerica, MA, USA) and
processed using MestReNova 11.0.4 (Mestrelab Research, Santiago de Compostela, Spain). The Fourier
transform infrared (FTIR) spectra were obtained with a Bruker Alpha Spectrometer with a Platinum
ATR accessory (Bruker Optics, Coventry, UK) in transmittance mode. Spectral analysis and instrument
control were performed with OPUS software v.7.0 (Bruker Optics). The spectrum of each sample was
measured by taking the average of 64 scans at a resolution of 2 cm−1 at room temperature. The reference
background spectrum was recorded before collecting IR spectra.
2.3. Thermal Analysis
The melting points of methadone hydrochloride and methadone free base were measured
using thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). Discovery
TGA (TA instruments, Waters, LLC, USA) was used for the degradation temperature identification.
Approximately 3 mg of sample was placed in a tared aluminium pan. A heating ramp of 10 ◦C/min
to 550 ◦C was used during the analysis. A nitrogen flow of 25 mL/min was supplied to create an
inert atmosphere around the sample. A DSC Q2000 (TA instruments) system was used to measure
the melting point. The sample was weighed in a hermetic aluminium pan which was subsequently
sealed with a hermetic aluminium lid using a Tzero press. An empty hermetic aluminium pan sealed
with a hermetic aluminium lid was used as a reference. Sample and reference pans were heated with a
heating ramp of 10 ◦C/min with nitrogen as the purge gas (50 mL/min).
2.4. HPLC Analysis
The HPLC system used in this study consisted of an Agilent G1322A degasser, G1311A quaternary
pump, G1313A auto sampler, G1316A thermostat column compartment and G1315B diode array
detector (Agilent Technologies, Palo Alto, CA, USA.). The software used to acquire and analyze the
data was ChemStation® for LC 3D, Rev. A. 09.03 (Agilent Technologies). Analysis was performed
with a Luna® Omega 5 μm PS C18 150 × 4.60 mm column (Phenomenex, Macclesfield, UK), equipped
with a universal HPLC guard column packed with a SecurityGuard™ C18 cartridge. The mobile phase
consisted of 20 mM sodium phosphate buffer at pH 3 ± 0.2 and acetonitrile (60:40, v/v) and the flow rate
was 1 mL/min. The column temperature and injection volume were set to 30 ◦C and 10 μL, respectively.
Ultraviolet (UV) detection at 213 nm was employed. The HPLC method was validated in terms of
specificity, linearity, accuracy, precision, limit of detection (LOD) and limit of quantification (LOQ)
according to the International Conference of Harmonization guidelines [16]. Calibration curves in the
concentration range of 0.5–100 μg/mL were constructed (r2 ≥ 0.99) and the LOD and LOQ values were
0.23 and 0.69 μg/mL, respectively.
2.5. Log D
The method used for Log D measurement was the shake flask method, adapted from the
Organization for Economic Co-operation and Development (OECD) guidelines [17]. 0.2 M sodium
phosphate buffer solutions were prepared at pH 6.0, 6.5, 7.0, 7.4 and 11.0 and mutually saturated with
1-octanol by slow-stirring (at 130 rpm) for 48 h at 25 ◦C. The solutions were equilibrated in a separation
funnel for 24 h before separation. Methadone solutions in octanol were prepared at 0.1 and 0.5 mmol/L.
These solutions were then mixed with the aqueous phase (sodium phosphate buffers) at three different
ratios (1:1, 2:1 and 1:2). To reach equilibrium, the mixtures were rotated approximately one hundred
times through 180◦ at room temperature. Before sampling, the mixtures were centrifuged at 25 ◦C and
at 13,000 rpm for 30 min. Samples were taken from each phase with suitable dilution using methanol
and analyzed using the HPLC method described in Section 2.4.
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2.6. Solubility and Stability
Stability studies of methadone free base in the Franz cell receptor medium (6% w/v Brij™ O20 in
pH 7.4 PBS) and a range of neat solvents were conducted for 96 h. A known quantity of methadone free
base was dissolved in the receptor medium or neat solvent. These solutions were placed in Eppendorf®
tubes and sealed with Parafilm® before being placed in a shaker (VWR, Leicestershire, UK) at 32 ± 1 ◦C.
Samples were taken at 0, 24, 48, 72 and 96 h. The samples were diluted when necessary and analyzed
using the HPLC method described in Section 2.4.
The solubility parameter values (δ) of the solvents were calculated by the van Krevelen-Hoftyzer
approach [18] using Molecular Modelling Pro® Version 6.3.3 software (ChemSW, Fairfield, CA, USA).
In total, 13 different single solvents were selected for solubility studies in order to ensure that solvents
with a wide range of solubility parameter values were investigated. Solubility studies were also
conducted with PBS and PBS with 6% Brij™ O20 (w/v) solution to confirm that sink conditions would
be maintained during the in vitro permeation studies.
For solubility determinations, an excess amount of methadone hydrochloride or free base was
added to 0.5 mL of each solvent in Eppendorf® tubes (n = 3). The tubes were sealed with Parafilm®
and placed on a rotator at 32 ± 2 ◦C for at least 48 h. These samples were then centrifuged at 12,000 rpm
for 15 min at 32 ± 1 ◦C. The supernatant was suitably diluted to lie within the range of the calibration
curve of the validated HPLC method, described in Section 2.4.
2.7. In Vitro Permeation and Mass Balance Studies
In vitro permeation studies were carried out as reported previously by Santos, et al. [19] using
vertical glass Franz diffusion cells. Full thickness porcine ear skin was separated from the underlying
tissue at room temperature and then stored at −20 ◦C before use. Skin integrity was assessed by
measuring impedance at a frequency of 50 Hz before applying formulations [20]. The diffusion area was
~1 cm2 and was accurately measured before application of finite doses (5 μL/cm2) of 5% w/v methadone
base solutions. The complete dissolution of methadone in all solvents was confirmed in the preparation
of formulations. 6% w/v Brij™ O20 was added to the receptor phase, PBS pH 7.3 ± 0.2 to ensure the
concentration of methadone never exceeded 10% of its solubility without affecting the integrity of the
skin [21,22]. Sink conditions in this medium were therefore confirmed during experiments. Permeation
studies were performed for 24 h at 32 ± 1 ◦C. 200 μL samples were withdrawn from the receptor
compartment and replaced with 200 μL of fresh receptor medium at 0, 2, 4, 6, 8, 10, 12, 24 h.
Validated mass balance studies were performed after each permeation study. The skin surfaces
were washed three times with 1 mL of methanol. The skin was then placed in Eppendorf® tubes
with 1 mL of methanol. The samples for skin extraction were placed in a shaker overnight to extract
methadone. All Eppendorf ® tubes were centrifuged at 13,000 rpm at 32 ◦C for 15 min before sampling.
The supernatants were sampled and diluted where necessary and analyzed by HPLC.
2.8. Statistical Analysis
Microsoft Excel® 2016 was used for data processing and the calculation of mean and standard
deviation (SD). IBM® SPSS Statistics® 24.0 (IBM SPSS Statistics, Feltham, UK) was used for statistical
analysis. The Shapiro-Wilk test was used to assess the normality of the data. If the p value calculated
from the test was higher than 0.05, the data were assumed to be normally distributed. For normally
distributed data (parametric data), the independent-samples t test and one-way analysis of variance
(ANOVA) with Tukey’s HSD post hoc test were used to analyze two groups and ≥3 groups respectively.
For non-normally distributed data (non-parametric data), the Mann-Whitney U test was used to
test statistical significance between two groups and the Kruskal-Wallis one-way ANOVA test was
performed to investigate statistical differences among different groups (≥3 groups). A probability of p
< 0.05 was considered as a statistically significant difference.
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3. Results and Discussion
3.1. Characterization of Methadone Free Base with NMR and IR Spectroscopy
The 1H-NMR spectrum of methadone hydrochloride is shown in Figure 1. A singlet at 12.00 ppm
suggests the protonation of the tertiary amine while the 1H-NMR spectrum of methadone free base
shows that there is no singlet around 12.00 ppm for the hydrochloride proton (Figure 2). In addition,
all spectral peaks were assigned for both methadone hydrochloride and free base. A water singlet at
1.61 ppm in both spectra may reflect small amounts of water present in the samples [23]. These results
confirm the successful conversion of methadone hydrochloride to the free base. Methadone free base
was obtained as a white powder, with a yield of 92%. The IR spectra of methadone free base and
methadone hydrochloride also support the conclusion that methadone hydrochloride was successfully
converted to methadone free base (Figure S1). Characteristic peaks for methadone were obtained for
both methadone hydrochloride and free base; a broad band at 2399 cm−1 was assigned to the NH+
stretching of methadone hydrochloride.
Figure 1. 1H-NMR spectrum of methadone hydrochloride in chloroform-d. 1H-NMR (500 MHz,
Chloroform-d) δ 12.00 (s, 1H), 7.48–7.35 (m, 8H), 7.25–7.19 (m, 2H), 3.09 (q, 1H), 3.02 (d, 1H), 2.79 (d,
3H), 2.68 (d, 3H), 2.45 (dq, 1H), 2.26–2.14 (m, 2H), 0.86 (t, 3H), 0.73 (d, 3H). A singlet at 12.00 ppm
suggests the protonation of the tertiary amine.
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Figure 2. 1H-NMR spectrum of methadone free base in chloroform-d. 1H-NMR (500 MHz,
Chloroform-d) δ 7.42 (dd, 1.6 Hz, 2H), 7.36–7.30 (m, 6H), 7.28–7.24 (m, 2H), 2.88 (dd, J = 13.9,
5.5 Hz, 1H), 2.46–2.36 (m, 2H), 2.31 (dq, 7.2 Hz, 1H), 2.14 (s, 6H), 2.02 (dd, J = 13.9, 5.6 Hz, 1H), 0.86 (t,
3H), 0.49 (d, 3H). The 1H-NMR spectrum of methadone free base shows that there is no singlet around
12.00 ppm for the hydrochloride proton.
3.2. Thermal Analysis
The thermogravimetric analysis of methadone hydrochloride and methadone free base is shown
in Figure S3. The decomposition of methadone hydrochloride is evident from 167 to 261 ◦C (onset:
230.12 ◦C) while that of methadone free base occurs from 134 to 230 ◦C (onset: 194.35 ◦C).
The DSC thermograms of methadone hydrochloride and the free base are shown in Figure 3.
The melting points of methadone free base and methadone hydrochloride were obtained as the
onset temperatures. The melting point of methadone hydrochloride (235.54 ◦C) is very close to the
degradation temperature of the compound. Only one endothermic event which occurs between 73.5 ◦C
and 79.8 ◦C was observed for methadone free base. The obtained melting point of methadone free base
is 74.00 ◦C which is consistent with the literature (76 ◦C) [24].
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Figure 3. DSC thermograms of methadone hydrochloride and methadone free base.
3.3. Log D Measurement
The predicted values of the Log P for methadone base from ChemAxon and ACD/Labs were
5.0 and 4.2, respectively. These values are higher than the experimental Log P value of 3.93 reported
previously [25]. The measurement of the partition coefficient of an ionizable species should be made in
the non-ionized form according to the OECD guidelines [17]. An appropriate buffer with a pH of at
least one unit above the dissociation constant (pKa) of methadone (pKa = 8.94) [26] should be used to
ensure the compound is present as the free base. Hence, 20 mM pH 11 PBS was used in this study to
measure the partition coefficient of methadone base. The value obtained in this measurement was
4.85 ± 0.03. The Log D values obtained at different pH values are listed in Table 1. The log D value at
pH 7.4 is lower than the experimental value previously reported (Log D7.4 = 2.1) [27], however no
details of the buffer or ionic strength used were given for this earlier measurement.
Table 1. Distribution coefficient of methadone for different pH values at 25 ± 1 ◦C.
pH Log D
6.0 0.31 ± 0.01
6.5 0.80 ± 0.01
7.0 1.35 ± 0.01
7.4 1.82 ± 0.01
11.0 (free base) 4.85 ± 0.03
3.4. Stability and Solubility
After 96 h stability studies at 32 ± 1 ◦C, the recovery values of methadone base in all solvents was
>97%. The chemical stability of methadone free base over 96 h in the receptor medium for permeation
studies and common solvents, including LIM, EO, IPM, WL 1349, OA, PGML, PGMC, TC, OSAL,
TriPG, DiPG, PG, 1,3-BD and ethyl acetate, was confirmed (Figure S4).
The solubility values for methadone hydrochloride in water and ethanol have been reported
previously as 120 and 80 mg/mL, respectively [28]. The solubility of methadone hydrochloride and
free base at 32 ± 1 ◦C was measured in a range of solvents (Table 2). As expected, methadone
hydrochloride is poorly soluble in solvents such as LIM, EO, IPM and OSAL and relatively high
solubility was observed for hydrophilic solvents. The highest solubility of methadone hydrochloride
was observed in PG. The solubility values for methadone free base and its hydrochloride salt in PBS are
0.49 ± 0.01 and 86.66 ± 0.95 mg/mL, respectively. The addition of 6% w/v Brij™O20 in PBS increased the
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solubility of methadone free base and methadone hydrochloride to 2.61± 0.02 and 107.45 ± 1.35 mg/mL,
respectively. Methadone free base has a calculated van Krevelen and Hoftyzer solubility parameter
of 10.07 (cal/cm3)1/2 and its solubility in solvents with solubility parameters, ranging from 8 to 11
(cal/cm3)1/2 was >100 mg/mL (Figure 4). These results are consistent with the theory proposed by
Hancock, et al. [29] i.e., when the solubility parameters of solute and solvent are similar, high solubility
is expected compared with solvents that do not have similar solubility parameters. On the other
hand, solubility parameters only provide an indication of solubility characteristics and cannot account
for all circumstances. Molecules may take up different conformations in the various solvents and
anomalies are possible. It is interesting to note that methadone base has relatively low solubility in
hydrophilic solvents with solubility parameter value above 11 (cal/cm3)1/2 and it showed a lower
solubility in TriPG compared with OSAL. The anomalous solubility behavior of caffeine was also
reported previously [30–32].
Table 2. Summary of the solubility of methadone hydrochloride and free base in neat solvents at
32 ± 1 ◦C. The solubility parameter of methadone free base is 10.07 (cal/cm3)1/2.
Solvent




LIM 342.38 ± 2.99 0.08 ± 0.002
EO 205.46 ± 1.69 0.08 ± 0.01
IPM 179.80 ± 0.89 0.03 ± 0.001
WL 1349 217.66 ± 3.73 0.05 ± 0.001
OA 438.76 ± 2.56 2.53 ± 0.03
PGML 209.43 ± 0.54 19.68 ± 0.79
PGMC 250.74 ± 2.17 28.65 ± 0.46
TC 247.68 ± 0.95 21.96 ± 0.46
OSAL 277.20 ± 6.96 0.05 ± 0.001
TriPG 105.90 ± 0.25 18.03 ± 0.93
DiPG 85.94 ± 0.41 43.97 ± 1.28
PG 24.78± 0.49 201.33 ± 1.30
1,3-BD 26.24 ± 0.05 88.40 ± 0.79
PBS 0.49 ± 0.01 86.66 ± 0.95
PBS + 6% w/v Brij™ O20 2.61 ± 0.02 107.45 ± 1.35
Figure 4. Solubility of methadone free base and methadone hydrochloride in solvents at 32 ± 1 ◦C and
solubility parameters of solvents.
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3.5. In Vitro Permeation and Mass Balance Studies of Methadone Base in Porcine Ear Skin
Eight solvents were selected for in vitro permeation studies of methadone free base in porcine skin
under finite dose conditions (5 μL/cm2). The permeation profiles are shown in Figure 5. The highest
permeation of methadone was observed for LIM (p < 0.01). The cumulative amount of methadone
that permeated after 24 h was 41.3 ± 4.7 μg/cm2 (20.7 ± 2.3% of the applied dose). The results also
suggest EO, TC and OSAL are promising vehicles for methadone. Although methadone hydrochloride
permeation in PG was investigated also, the maximum cumulative amount that permeated through
porcine skin after 24 h was only 2.5 ± 0.6 μg/cm2.
Figure 5. Cumulative permeation profiles of methadone in porcine skin after application of 5% (w/v)
methadone free base in LIM (), EO (), TC (), OSAL (×), PGML (), WL 1349 (), TriPG () and OA
(+) for finite dose (5 μL/cm2) at 32 ± 1 ◦C. Each data point represents the mean ± SD (mean ± SD; 4 ≤ n
≤ 5). ** p < 0.01.
Mass balance studies confirm that high permeation of methadone generally was associated with
high amounts of drug extracted from the skin (Figure 6). Except for LIM, the overall recoveries for other
formulations were within the recovery range (90–110%) recommended in the OECD guidelines [33].
Although the stability of methadone free base in formulations and the receptor fluid was confirmed,
the overall recovery of methadone for LIM was only 86.33 ± 2.15%. However, LIM still delivered
significantly higher (p < 0.05) percentages of methadone into the skin and through the skin compared
with the other solvents. The results confirm that the lowest percentage of methadone recovered from
the skin surface was observed for LIM, followed by EO, OSAL and TC (Figure 6). Except for LIM, the
percentages of applied methadone recovered from the skin surface were significantly higher compared
with the percentages of methadone inside skin and permeated across skin.
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Figure 6. Mass balance results after 24 h finite dose (5 μL/cm2) permeation studies in porcine skin for
5% (w/v) methadone free base in LIM, EO, TC, OSAL, PGML, WL 1349, TriPG and OA at 32 ± 1 ◦C
(mean ± SD; 4 ≤ n ≤ 5). ** p < 0.01.
A proposed mechanism of penetration enhancement for LIM is the disruption of the highly ordered
structure of intercellular lipids which may result in an increase in drug diffusion [34]. The permeation
of LIM through human skin and high affinity of LIM for the epidermis were reported by Cal, et al. [35].
This indicates another potential mechanism that may contribute to high permeation of methadone in
the present study. With the exception of OA, the highest solubility of methadone base was observed
for LIM. The uptake of LIM into skin may create a more favorable environment for methadone and
thus increase the partition of methadone into the stratum corneum (SC). In addition, both skin uptake
and evaporation of LIM can also contribute to an increase in the thermodynamic activity of methadone
and the partition into skin. On the other hand, drug crystallization inside the skin or on the skin
surface may occur as well when LIM permeates through skin. LIM is generally recognized as a safe
ingredient in topical products [36]; the highest concentration used in FDA approved topical products
is 10% w/w [37].
EO is derived from the esterification of OA with ethanol. Both EO and OA have a double bond in
the cis configuration, forming a “kinked” shape [38]. This kink conformation may disrupt SC lipid
packing by introducing a separate phase in the intercellular lipid domain and thus increase the diffusion
of solute through skin [39,40]. The permeation of methadone for OA was significantly lower than that
for EO and other solvents (p < 0.05). This may reflect electrostatic interaction between methadone
free base and the carboxylic acid group of OA. The presence of ionized methadone might also be
expected to reduce the partition of methadone from OA into SC lipids, thus reducing the permeation of
methadone. FTIR was subsequently used to confirm an interaction between methadone free base and
OA (Figure S2). The high solubility of methadone in OA reported above also supports the possibility
of an interaction between OA and methadone free base.
The cumulative amount of methadone that permeated through skin for OSAL was significantly
higher than for PGML and medium-chain triglycerides of caprylic and capric acids (WL 1349) (p < 0.05)
while there is no significant difference between the amounts of methadone extracted from skin for
these solvents (p > 0.05). This indicates that OSAL is more likely to enhance permeation by increasing
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the diffusion of methadone through skin rather than altering the partition of methadone into stratum
corneum. Santos, et al. [41] reported that OSAL is taken up to a high extent by the skin but no effect on
lipid fluidity was observed using DSC and FTIR. The authors proposed that OSAL may enhance drug
diffusion by creating “pools” of solvent within the gel lipid phase.
The cumulative amount of methadone that permeated through porcine skin from TC after 24
h was 21.07 ± 5.12 μg/cm2. Almost double the amount of methadone was recovered following skin
extraction compared with the amount that permeated for this vehicle. TC is miscible with both polar
and non-polar solvents and it has been widely used as a penetration enhancer. Haque, et al. [42]
reported that 53.4% of TC permeated through human skin in Franz cell studies by 19 h. The rapid
skin uptake of TC suggest that TC is likely to enhance permeation by increasing drug solubility in
intracellular lipids. TC may therefore play a key role in driving the partition of methadone into
skin and increasing permeation. Increasing thermodynamic activity of methadone resulting from TC
evaporation and skin uptake may also contribute to the skin permeation of methadone. The highest
concentrations of TC, OSAL and EO used in FDA approved topical products are 49.91% w/w, 8.5% w/w
and 0.14 mg/mL, respectively [37].
Fullerton et al. [13] evaluated the transdermal delivery of methadone free base using human
cadaver skin over 24 h. Solutions of methadone base were prepared in ethanol and propylene
glycol and in ethanol and propylene glycol with either oleic acid or Azone®. The highest amount of
methadone permeated from the ethanol: PG: Azone solution (~400 μg/cm2), however the concentration
of methadone (720 μg/μL) was more than 10-fold greater than that evaluated in the present work.
Ghosh and Bagherian [14] also investigated a transdermal patch containing methadone free base in
human skin. Patches with or without 5% w/w Azone® or 5% w/w n-decylmethyl sulfoxide were tested.
The cumulative amounts of methadone permeation at 24 h in human skin ranged from 1 to 3 mg/cm2.
Again, comparisons with the present work are limited because of the comparatively larger doses of
methadone in the patches compared with the formulations examined here. It is also important to note
that the objectives of these two earlier studies were systemic delivery of methadone for management
of substance abuse rather than local delivery.
4. Conclusions
Methadone free base was prepared from its hydrochloride salt, followed by a series of
characterization studies. A range of solvents was evaluated using in vitro permeation and mass
balance studies in porcine skin and a maximum skin flux of 2.54 ± 0.19 μg/cm2/h was estimated. The
results suggest that TC, LIM, OSAL and EO appear to be promising candidate vehicles for dermal
delivery of methadone base. This is the first study to confirm skin permeation of methadone base
under finite dose conditions. However, for most formulations the majority of the active remained
on the skin surface after 24 h. Future work will focus on development of more complex vehicles
with further optimization and evaluation of skin permeation in human skin. The most promising
formulations will be progressed for investigation in the clinic.
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Abbreviations
1,3-BD 1,3-butanediol
1H-NMR Proton Nuclear Magnetic Resonance
ANOVA One-way Analysis of Variance
CDCl3 Chloroform-d
DiPG Dipropylene Glycol
DSC Differential Scanning Calorimetry
EO Ethyl Oleate
FTIR Fourier Transform Infrared
GRAS Generally Recognized as Safe
HPLC High Performance Liquid Chromatography
IPM Isopropyl Myristate
LIM d-limonene
LOD Limit of Detection
Log D Logarithm to the Base 10 of Distribution Coefficient
Log P Logarithm to the Base 10 of Partition Coefficient
LOQ Limit of Quantification
Nav Voltage-gated Sodium (Nav) Channels
NMDA N-Methyl-d-aspartate
OA Oleic Acid
OECD Organisation for Economic Co-operation and Development
OSAL Octyl Salicylate
PBS Phosphate Buffered Saline
PG Propylene Glycol
PGMC Propylene Glycol Monocaprylate







WL 1349 Labrafac™ lipophile WL 1349
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Abstract: The eradication of bacteria from wound sites and promotion of healing are essential
for treating infected wounds. Nitric oxide (NO) is desirable for these purposes due to its ability
to accelerate wound healing and its broad-spectrum antibacterial effects. We developed an in
situ hydrogel-forming/NO-releasing powder dressing (NO/GP), which is a powder during storage
and forms a hydrogel when applied to wounds, as a novel NO-releasing formulation to treat
infected wounds. An NO/GP fine powder (51.5 μm) was fabricated by blending and micronizing
S-nitrosoglutathione (GSNO), alginate, pectin, and polyethylene glycol (PEG). NO/GP remained stable
for more than four months when stored at 4 or 37 ◦C. When applied to wounds, NO/GP absorbed
wound fluid and immediately converted to a hydrogel. Additionally, wound fluid triggered a NO
release from NO/GP for more than 18 h. The rheological properties of hydrogel-transformed NO/GP
indicated that NO/GP possesses similar adhesive properties to marketed products (Vaseline). NO/GP
resulted in a 6-log reduction in colony forming units (CFUs) of methicillin resistant Staphylococcus
aureus (MRSA) and Pseudomonas aeruginosa, which are representative drug-resistant gram-positive
and -negative bacteria, respectively. The promotion of wound healing by NO/GP was demonstrated
in mice with full-thickness wounds challenged with MRSA and P. aeruginosa. Thus, NO/GP is a
promising formulation for the treatment of infected wounds.
Keywords: in situ hydrogel-forming powder; nitric oxide-releasing formulation; S-nitrosoglutathione
(GSNO); antibacterial; wound dressing; wound healing
1. Introduction
Cutaneous wound infections are a global problem whose cost of treatment runs into millions
of dollars per year, and these infections can lead to severe complications including sepsis, for which
mortality remains around 30% in the United States [1,2]. Wound healing proceeds spontaneously
through three sequential phases; inflammation, proliferation, and remodeling [3–6]. However,
when wounds are infected, the healing process is delayed during the inflammation phase, since bacteria
induce continuous inflammation at the infected site [7,8]. Thus, eradicating bacteria from the injured
site is essential for the treatment of infected wounds.
In recent years, nitric oxide (NO) has gained attention as a novel agent for the treatment of
infected wounds because it facilitates wound healing processes such as skin cell proliferation and
tissue remodeling, and it also exerts broad-spectrum antibacterial effects [9–12]. NO enhances
re-epithelialization and collagen synthesis during wound healing [5,13]. In addition, NO possesses
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broad-spectrum antibacterial properties through the formation of reactive nitrogen species such as
peroxynitrile, nitrogen dioxide, and dinitrogen trioxide, which can interact with various bacterial
proteins, DNA, and enzymes to result in bacterial cell death [14]. Since NO exerts bactericidal effects
via multiple biochemical pathways, it exhibits antibacterial effects against drug-resistant bacteria,
including methicillin resistant Staphylococcus aureus (MRSA) [15]. Moreover, NO does not develop
drug resistance due to its diverse antibacterial mechanisms, which require multiple mutations for
resistance to develop [16]. However, despite these beneficial effects of NO, its clinical application
remains challenging because of its short half-life and gaseous nature. Therefore, the development of an
NO-releasing formulation with a sustained NO-release and good storage stability is required.
We hypothesized that a powder dressing that forms a hydrogel in situ maintains a powder
state during storage and converts to hydrogel immediately when applied to wounds could
be an ideal NO-releasing formulation for the treatment of infected wounds. An in situ
hydrogel-forming/NO-releasing powder dressing possesses the benefits of both powders and
hydrogels. Since a water-free powder ensures high storage stability, the stability of easily hydrolyzable
pharmaceutical ingredients can be markedly improved. When applied to the wound site, an in situ
hydrogel-forming powder dressing can fit the irregular surface of the wound without wrinkles or
fluting [17–19]. In addition, in situ hydrogel-forming powders are easy to apply to bendable areas
of the human body, such as elbows, finger joints, ankles, or wide wound beds resulting from burn
and pressure ulcers. Once applied to the wound, they can absorb the wound fluid and form an
adhesive hydrogel, which can protect the wound site from the external environment and maintain a
humid environment to aid wound healing [20,21]. At the same time, a NO release triggered by the
absorbed wound fluid may assist wound healing via the elimination of bacteria and stimulation of
wound-healing processes [22].
In this study, a novel in situ hydrogel-forming/NO-releasing powder dressing (NO/GP) possessing
the benefits of both powders and hydrogels was developed using S-nitrosoglutathione (GSNO),
alginate, pectin, and polyethylene glycol (PEG) for the treatment of infected wounds. GSNO is a
widely used endogenous NO donor that can generate NO over several hours under physiological
conditions, which may be beneficial properties for NO releasing wound dressings [23]. Sodium
alginate was selected to form a bioadhesive hydrogel. In addition, it can absorb wound exudate up to
approximately 20-times its weight [24]. Pectin was used to form a hydrogel structure and accelerate the
powder-to-hydrogel transition [19]. PEG was added to modulate the ability of the formulation to uptake
fluid to prevent potential wound drying caused by the excessive absorption of exudate. Following the
characterization of NO/GP, the storage stability, in situ hydrogel-forming ability, rheological properties,
and NO-release profiles were evaluated in a series of in vitro and in vivo experiments. The antibacterial
effects of NO/GP were examined against MRSA and Pseudomonas aeruginosa, which are drug-resistant
gram-positive and -negative bacteria, respectively. The in vivo therapeutic effects of NO/GP were
evaluated using a bacteria-challenged full-thickness wound mouse model.
2. Materials and Methods
2.1. Materials
Glutathione (reduced form) was purchased from Wako Pure Chemical (Osaka, Japan). Pectin
and agar were purchased from Yakuri Co., Ltd. (Osaka, Japan). Sodium alginate, PEG (average
molecular weight: 8000), sodium nitrite, crystal violet, Lugol’s solution, 2,2,2 tribromoethanol, tert-amyl
alcohol, Mayer’s hematoxylin, and eosin-Y disodium were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Bacto™ tryptic soy broth (TSB) and Difco™ cetrimide-agar media were purchased from
BD Biosciences (San Jose, CA, USA). A Twort’s Gram stain set was purchased from Newcomer
Supply (Middleton, WI, USA). Masson’s trichrome stain kit was purchased from Abcam (Cambridge,
MA, USA). The LIVE/DEAD® BacLight™ bacterial viability kit was purchased from Thermo Fisher
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Scientific (Waltham, MA, USA). All other reagents and solvents were of the highest analytical grade
commercially available.
2.2. GSNO Synthesis
GSNO was synthesized following a previously reported method with some modifications [25].
Briefly, sodium nitrite and reduced glutathione were added to a cold HCl solution with stirring
for 40 min in an ice bath (the final concentration of NaNO2, glutathione, and HCl was 0.625 M).
To precipitate GSNO, acetone was added and stirred for 20 min. The precipitate was collected by
filtration and washed once with 80% acetone, twice with 100% acetone, and three times with diethyl
ether. After drying, GSNO was stored in a −20 ◦C refrigerator for subsequent experiments.
2.3. Preparation and Characterization of the NO-Releasing In Situ Hydrogel-Forming Powder
To prepare the in situ hydrogel-forming agent, sodium alginate, pectin, and PEG were micronized,
sieved (90μm), and blended. The ratio of alginate, pectin, and PEG used for the in situ hydrogel-forming
powder (GP) was optimized with sodium alginate:pectin:PEG at a 2:1:6 ratio in several pilot studies.
To prepare the NO-releasing in situ hydrogel-forming powder (NO/GP), GSNO was added to the GP
(final content of GSNO was 4 wt %). GSNO was sieved before blending with GP to eliminate the GSNO
aggregates, which could induce undesirable effects in the content uniformity. NO/GP was stored in a
−20 ◦C refrigerator.
NO/GP was characterized by determining particle size, GSNO content, content homogeneity,
and powder flowability. Briefly, the particle sizes of NO/GP and the non-micronized mixture were
analyzed by ImageJ software (National Institutes of Health, Bethesda, MA, USA) using microscopic
images. More than 100 particles were used to assess particle size. GSNO contents were determined
using 10 samples of each NO/GP and non-micronized mixture, which were dissolved in distilled water
(DW), and then the absorbance was detected using a UV/Vis spectrophotometer (U-5100, Hitachi,
Tokyo, Japan) at 335 nm. From the absorbance values, GSNO content and relative standard deviation
(RSD) were calculated to investigate GSNO content and content homogeneity, respectively. Powder
flowability was evaluated as previously reported, with some modifications [26]. Briefly, 40 mg of
NP/GP was loaded in a 1 mL syringe and tapped until no change in volume was detected. The bulk
and tapped density were calculated from the tapped and untapped volume of NO/GP, and the Hausner
ratio was calculated based on the tap density/bulk density ratio.
2.4. Rheological Properties of NO/GP in Hydrogel Form
The rheological properties of the hydrogel-form of NO/GP were evaluated as previously reported,
with some modification [27–29]. The steady shear and dynamic viscoelastic properties of the
hydrogel-form of NO/GP were measured using a strain-controlled rheometer (Advanced Rheometric
Expansion System [ARES], Rheometric Scientific, Piscataway, NJ, USA) equipped with a parallel-plate
fixture with a radius of 12.5 mm and a gap size of 1.0 mm. All rheological measurements were
performed at a fixed temperature of 37 ◦C over a wide range of shear rates and strain amplitudes.
In this study, simulated wound fluid (SWF) [30,31] was used to induce NO/GP swelling. The SWF
consisted of 0.64% NaCl, 0.22% KCl, 2.5% NaHCO3, and 0.35% NaH2PO4 in double distilled water
with pH 7.4. Three different conditions of NO/GP in hydrogel form (NO/GP that absorbed 200%, 350%,
and 500% of SWF absorbed per weight) were examined with SWF. Before initiating the experiments,
2, 3.5, or 5 mL of SWF were added to 1 g of NO/GP and mixed well to obtain the homogeneous
hydrogel. In all experiments, a fresh sample was used and rested for 15 min after loading to allow for
material relaxation and temperature equilibration. To evaluate the steady shear flow behaviors of the
hydrogel-form of NO/GP, steady rate-sweep tests were performed over a range of shear rates from 1 to
1000 s−1 with a logarithmically increasing scale. Next, strain-sweep tests were conducted to investigate
both the linear viscoelastic region and nonlinear viscoelastic behavior over a strain amplitude range of
0.0625%–500% at a fixed angular frequency of 10 rad/s.
117
Pharmaceutics 2019, 11, 496
2.5. Storage Stability
The storage stability of NO/GP was evaluated by determining GSNO degradation under two
temperature conditions: 4 and 37 ◦C. Two milligrams of NO/GP were placed in each tube, which were
then stored in either a 4 ◦C refrigerator or a 37 ◦C incubator. At previously set time points, three tubes
from each group were sampled, and the absorbance at 335 nm was measured to determine the GSNO
content following dilution with DW.
2.6. Behavior of NO/GP After Exposure to Wound Fluid
2.6.1. Morphological Changes of NO/GP at the Wound Site
All animal experiments in this study have been reviewed and approved by the Pusan National
University Institutional Animal Care and Use Committee (PNU-IACUC) on 01 February 2018 (Approval
Number: PNU-2018-1800). To investigate the ability of NO/GP to form hydrogel in situ, macroscopic
images of wounds treated with NO/GP were taken at each time point. Briefly, imprinting control
region (ICR) mice (7 weeks old, male, Samtako Bio Korea) were purchased and acclimated for 7 days.
To induce anesthesia, 0.5–0.6 mg/g of avertin (tribromoethanol) were administered intraperitoneally.
Then, hair was removed from the dorsal side of the mouse by electric trimmers and hair removal cream
(Veet for sensitive skin, Reckitt Benckiser, France). After hair removal, a full-thickness wound was
created on the dorsal area of the mouse via an 8 mm diameter disposable biopsy punch (Kai medical,
Japan). Macroscopic images were taken at each time point following treatment of the wound with
28.5 mg NO/GP.
2.6.2. Fluid Uptake Ability
The ability of NO/GP to uptake fluid was measured as previously described, with some
modifications [26,32]. A three-station Franz diffusion cell apparatus (PermeGear, Inc., Hellertown,
PA, USA) was used to measure the water uptake ability. A regenerated cellulose membrane
(pore size = 0.45 μm) was placed between the donor and receiver compartments. In the receiver
compartment, SWF was filled and thermostated at 37 ◦C. After SWF was loaded into the receiver
compartment, 40 mg of NO/GP were placed on the regenerated cellulose membrane (donor
compartment). The amount of SWF was maintained at 8 mL. At each time point, the weight of
the donor compartment was measured to calculate the amount of absorbed fluid.
2.6.3. NO Release from NO/GP
The NO release from NO/GP was calculated by measuring the GSNO decomposition. The amount
of GSNO remaining was determined using a UV/Vis spectrophotometer at a wavelength of 335 nm.
Fifty milligrams of NO/GP powder were placed in a 2 mL microtube, and different amounts of SWF
were added to mimic swelling (NO/GP that absorbed 200%, 350%, and 500% of SWF per weight).
All microtubes were placed in a 37 ◦C incubator. At the set time points, the remaining GSNO was
measured by determining the absorbance of the supernatant at 335 nm after dilution and centrifugation.
The NO released from NO/GP at each time point ([NO]t) was calculated using an Equation (1) ([GSNO]0:
Initial GSNO concentration; [GSNO]t: GSNO concentration at each time point) [25,33].
[NO]t = [GSNO]0 − [GSNO]t (1)
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2.7. Antibacterial Assay
The bactericidal effect of NO/GP was evaluated against P. aeruginosa PAO1 (wild-type
prototroph) [34] and MRSA (USA 300) [35]. Each pathogen was incubated overnight in TSB at
37 ◦C, and the bacterial suspension was adjusted with TSB media to approximately 108 colony forming
unit (CFU)/mL until the optical density at 600 nm reached 0.15–0.2 (0.5 of the McFarland scale) [36].
The adjusted bacterial suspension (100 μL) was inoculated into each tube. Then, 28.5 mg of NO/GP and
GP were added to each well and incubated for 24 h at 37 ◦C. To calculate the number of living bacterial
cells, tubes were diluted with an additional 1.9 mL of the TSB medium. After serial dilution, 100 μL of
each aliquot were plated on the TSB agar and incubated for 24 h at 37 ◦C. CFUs were determined by
counting the colonies on the agar plates after incubation. To visualize the antibacterial activity of NO/GP,
bacteria treated with or without GP and NO/GP were stained with SYTO9 (Thermo Fisher Scientific,
Waltham, MA, USA) (final concentration was 66.8 μM) for 15 min. After incubation, bacteria were
collected by centrifugation at 3000 g for 10 min. Each sample was washed three times and resuspended
in 5 mL of normal saline. Green fluorescence from stained bacteria was imaged by an in vivo imaging
system (FOBI, Neoscience, Suwon, Korea). For confocal laser scanning microscopy, bacteria were
washed three times with normal saline after 24 h incubation with or without GP and NO/GP. Then,
the bacteria were stained with SYTO 9 dye and propidium iodide (LIVE/DEAD® BacLight™ bacterial
viability kit) according to the manufacturer’s protocol. Images were obtained at 20×magnification
using the LSM 800 (Carl Zeiss, Oberkochen, Germany).
2.8. In Vivo Wound Healing Study in a Bacteria-Challenged Full Thickness Wound Model
2.8.1. Evaluation of Wound Size Reduction
In this study, mouse models of P. aeruginosa- and MRSA-challenged full thickness wounds were
used to evaluate the ability of NO/GP to heal infected wounds. For P. aeruginosa-challenged wound
healing study, 8 mm-sized wounds were created using above-mentioned method. Then, 109 CFU of P.
aeruginosa suspension was inoculated at the wound site. Each wound was covered with Tegaderm
film and fastened by surgical tape (Durapore™, 3M) for protection. Mice were then incubated for
2 days with no treatment for wound infection. Two days after wounding, mice were treated with
28.5 mg of NO/GP and GSNO-free NO/GP every 2 days. Untreated mice were used as a control group
(changing Tegaderm film and surgical tape only). Photographs were obtained every 2 days, and the
size of the wound was analyzed by ImageJ software. For the MRSA-challenged wound healing study,
a 2 × 106 CFU of MRSA suspension was used instead of P. aeruginosa, and the procedure described
above was followed.
2.8.2. Quantification of P. aeruginosa at the Wound Site
In the P. aeruginosa-challenged wound study, bacteria were quantified at the wound as previously
reported, with some modifications [37]. Briefly, wound samples were harvested from representative
mice on predetermined days with an 8 mm diameter biopsy punch. Each sample was placed in 1 mL
of PBS, chopped, and sonicated to detach bacteria from the tissue samples. Then, 100 μL of each
tissue-bacteria suspension was plated on an agar plate after serial dilution (1:10). To quantify the
amount of P. aeruginosa at the wound site, a cetrimide-agar plate was used as a pseudomonas-selective
media [38]. CFUs were determined by counting the colonies on the agar plates after 24 h of incubation.
2.8.3. Histological Examination
In the P. aeruginosa-challenged wound healing study, mice were euthanized 14 days after the
initiation of drug treatment, and each wound site was sampled with an 8 mm diameter biopsy
punch. Each sample was immediately immersed in 10% buffered formalin for fixation. Fixed wound
samples were placed in paraffin blocks, sectioned to obtain 5 μm wound samples, and prepared for
hematoxylin and eosin (H&E) staining, Twort’s Gram staining, and Masson’s trichrome staining. Each
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staining procedure was performed according to the manufacturer’s protocol with some modifications.
After staining, each slide was photographed using a light microscope at 20×magnification for H&E
and Masson’s trichrome staining, as well as 100× for Twort’s gram staining.
2.9. Statistical Analysis
The statistical analysis was performed using a one-way analysis of variance (ANOVA) with a
Bonferroni posttest in GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). p-values less
than 0.05 were considered statistically significant.
3. Results and Discussion
3.1. Powder Characterization
NO/GP was successfully prepared by micronizing, sieving, and blending GSNO, sodium alginate,
pectin, and PEG. To examine the homogeneous fabrication of NO/GP, particle size distribution
was analyzed using more than 100 particles, and GSNO contents were measured from 10 different
samples. As shown in Figure 1A, pink GSNO particles were homogeneously dispersed in NO/GP.
After micronizing, the average particle size and standard deviation decreased (from 85.2 ± 47.3 to
51.5 ± 22 μm, respectively) (Table 1, Figure 1A,B). In addition, the RSD of GSNO contents was reduced
(16.06–4.77) due to the removal of large GSNO particles which interfere with content homogeneity
(Table 1, Figure 1C). Flowability was measured to investigate the movement of NO/GP at the wound
site before conversion to hydrogel. The flowability of in situ hydrogel-forming powders should be
low because highly flowable powders can be easily cleared from the wound site prior to hydrogel
formation. In this experiment, the flowability of NO/GP was expressed by the Hausner ratio. After the
blending and micronizing process, the Hausner ratio of NO/GP increased from 1.34 to 1.97 (Table 1).
Due to the decreased particle size, flowability decreased after micronization. In general, powders with
a Hausner ratio exceeding 1.6 possess extremely poor flowability [39]. Low flowability can prevent the
removal of the powder and is essential for the in situ hydrogel-forming powder system; the powder
should remain on the wound site until it is converted to a hydrogel. For this reason, the Hausner ratios
of previously developed powder dressings are around 1.7 [18,19,26], as this ratio allows the powders
to resist the flow. Therefore, NO/GPs with a Hausner ratio of 1.97 could also resist flow away from the
wound site before hydrogel formation.










85.2 ± 47.3 4 ± 0.64 16.06 1.34 ± 0.04
NO/GP 51.5 ± 22 4 ± 0.19 4.77 1.97 ± 0.06
Particle size was analyzed by ImageJ software from microscopic images (n > 100). S-nitrosoglutathione (GSNO)
contents and relative standard deviation (RSD) were calculated from 10 samples of NO/GP. The Hausner ratio was
calculated from the tap/bulk density ratio (n = 3).
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Figure 1. Characterization of NO/GP in powder form. Microscopic images (A), particle size distribution
(n > 100) (B), and S-nitrosoglutathione (GSNO) contents of non-micronized mixture and NO/GP (n = 10)
(C). Red arrows indicate GSNO particles (pink particles).
3.2. Rheological Properties of NO/GP in Hydrogel Form
Rheological properties, including viscosity, storage modulus, and loss modulus, were evaluated
to investigate the adhesiveness of NO/GP in hydrogel form against various steady shear strains or
oscillatory shear strains. Adhesiveness is an important factor of hydrogel dressings because hydrogels
should adhere to the damaged site to protect the wound and maintain humid conditions, which is an
essential role of hydrogel dressings. Figure 2A,B show the dependence of shear stress and steady shear
viscosity on shear rate for NO/GP following the absorption of 200%, 350%, and 500% SWF per weight.
In all steady rate-sweep tests, the shear stress tended to level off and approach a limiting constant
value (usually referred to as “yield stress”) as the shear rate approached zero. Yield stress plays an
important role in predicting the adhesiveness of semi-solid formulations because stress is related to the
level of internal structures that can exhibit resistance to flow. Steady shear viscosity decreased sharply
as the shear rate increased, indicating that NO/GP exhibited a marked non-Newtonian shear-thinning
flow behavior. In a previous study, petroleum jelly, which is a widely used and marketed product,
demonstrated similar behavior in the 350% swollen condition, and the values of shear stress and steady
shear viscosity were also similar to those of the swollen condition [40]. These results indicate that the
NO/GP hydrogel could maintain a gel-like structure and resist small shear stress such as gravitational
force or brushing against clothes. Figure 2C,D,E indicate the storage modulus, G’, and loss modulus, G”,
as a function of strain amplitude under three different swelling conditions of NO/GP hydrogels with a
fixed angular frequency of 10 rad/s. The storage modulus was found to be larger than the loss modulus
within a relatively smaller strain amplitude, indicating that the rheological behavior in this region
is dominated by an elastic (solid-like) rather than a viscous (liquid-like) property. However, as the
strain amplitude gradually increased, viscous behavior became superior to elastic behavior because the
storage modulus demonstrated a sharper decrease with increasing strain amplitude compared with
the loss modulus. These results indicate that adhesiveness to a relatively large imposed deformation
(such as scrubbing motion) is weakened; therefore, the NO/GP hydrogels could easily flow and be
removed from the wound site.
121
Pharmaceutics 2019, 11, 496
Figure 2. Rheological properties of NO/GP in hydrogel form. Shear stress and viscosity (A and B,
respectively) of NO/GP following absorption of 200%, 350%, and 500% of simulated wound fluid (SWF)
per weight as a function of shear rate. Storage modulus (G’) and loss modulus (G”) of each swollen
condition as a function of strain amplitude (C and D, respectively). G’ and G” of 350% swollen NO/GP
hydrogel as a function of strain amplitude (E). Strain-sweep tests were performed at a fixed angular
frequency of 10 rad/s.
3.3. Storage Stability
The storage stability of NO/GP was evaluated by detecting GSNO decomposition under two
temperature conditions (4 and 37 ◦C). Since GSNO can be easily degraded by hydrolysis, storage
stability is an important factor in the development of GSNO-containing formulations. Though several
GSNO-containing hydrogel dressings have been developed to accelerate wound healing [41–44],
those formulations did not present long-term stability because GSNO hydrolysis is inevitable in
water-containing formulations. Conversely, no significant GSNO decomposition was noted in NO/GP
up to 140 days under both the 4 and 37 ◦C conditions (Figure 3). Since GSNO in the NO/GP remained
in a powder state, which was a water-free condition during storage, the hydrolysis of GSNO was
prevented. Thus, NO/GP could remain stable whilst in storage without any concerns relating to
GSNO degradation. In addition, there were no significant changes in particle size, Hausner ration and
rheological properties during the storage period (data not shown).
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Figure 3. Storage stability of NO/GP at 4 (blue) and 37 ◦C (red). Remaining GSNO percentage compared
with that of initial NO/GP was calculated to evaluate storage stability. Each point represents the mean
± standard deviation (n = 3).
3.4. Behavior of NO/GP After Exposure to Wound Fluid
3.4.1. Morphological Changes in NO/GP at the Wound Site
To investigate the ability of NO/GP to form hydrogel in situ, morphological changes in NO/GP
were observed following application of 28.5 mg of NO/GP to the full-thickness wounds in mice.
The amount of NO/GP was sufficient to cover 1 cm3 of a full-thickness wound. As shown in Figure 4A,
following its application to the wound, the NO/GP powder was immediately converted to a glittering
hydrogel, and more than 50% of the NO/GP powders converted to a hydrogel within 1 min. All of the
NO/GP applied was converted to hydrogel within 10 min. After 10 min, no morphological changes in
NO/GP were observed due to the completion of the hydrogel structure.
Figure 4. Behavior of NO/GP following exposure to wound fluid. Morphological changes in NO/GP
applied to the mouse full-thickness wound model (A). Fluid uptake profile of NO/GP (amount of
absorbed SWF is presented as the percent per initial NO/GP powder weight) (B). NO release profiles of
NO/GP under different swelling conditions and the GSNO solution at the equivalent concentration to
350% swollen NO/GP (C). Each point represents the mean ± standard deviation (n = 3).
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3.4.2. Fluid Uptake Ability
Since hydrogel formation is initiated by the absorption of wound fluid, an investigation of fluid
uptake ability is essential for evaluation of powder dressings that form hydrogels in situ. To evaluate
the fluid uptake ability of NO/GP, the dressings were exposed to SWF at 37 ◦C, and the amount of
absorbed fluid was calculated by measuring the change in weight of NO/GP. The amount of absorbed
fluid was presented as a percentage of weight gained by fluid uptake per initial NO/GP. As shown in
Figure 4B, NO/GP absorbed SWF rapidly, and around 200% of SWF was absorbed within 20 min. After
the initial rapid absorption of the SWF, the rate of fluid uptake by NO/GP was decreased, and NO/GP
absorbed up to 375% of SWF in 270 min. After that, no further significant fluid absorption was observed
during the experiment. In the initial state, the swellable polymers in NO/GP (pectin and alginate)
absorbed SWF and rapidly formed a hydrogel structure. Following hydrogel formation, SWF was
slowly captured in the intermolecular space of the hydrogel structure, because hydrophilic polymers
in NO/GP are able to trap SWF by hydrogen bonding between polymers and water molecules. Finally,
since the intermolecular space was filled with SWF, no more fluid could be absorbed. Since NO/GP
could efficiently absorb fluid, hydrogel formation and subsequent NO release was initiated rapidly.
3.4.3. NO Release from NO/GP
Since NO released from GSNO in NO/GP exerts therapeutic effects, the NO release profiles of
NO/GP were investigated by exposing NO/GP to SWF at 37 ◦C. The NO release from NO/GP was
investigated under three swollen conditions (200%, 350%, and 500% of SWF per initial NO/GP weight)
that represented an amount of low, medium and high wound exudate, respectively. As GSNO generates
NO via hydrolytic cleavage of the S–N bond, the NO release from NO/GP is initiated by wound fluid.
Thus, the amount of NO released from NO/GP was calculated by measuring GSNO degradation
(released NO = initial GSNO − remaining GSNO). Regardless of swelling, NO/GP exhibited a linear
NO release without a burst release (Figure 4C). In addition, lower levels of NO/GP swelling resulted in
a slightly faster NO release rate compared with higher levels of swelling, and NO was released up to
18, 22, and 26 h in the 200%, 350%, and 500% conditions, respectively. Due to the presence of polymeric
compounds (alginate, pectin, and PEG) in the NO/GP hydrogel structure, GSNO molecules or NO
radicals were surrounded by polymeric molecules which restrict the diffusion of radicals in what is
termed the “cage effect” [45,46]. Compared with the GSNO solution, NO/GP presented a prolonged
NO-release profile, which was due to the restricted diffusion of radicals over the cage (NO was released
100% within 12 h at the GSNO concentration equivalent to 350% swollen NO/GP). The release profiles
different under different levels of swelling because the rate of NO release from GSNO was affected by
its initial concentration; thus, the higher initial concentration resulted in faster NO release due to the
increased amount of radicals contributing to the degradation of GSNO molecules [47]. Therefore, 200%
SWF added to the NO/GP group (high GSNO concentration) resulted in a faster NO release compared
with the 350% and 500% groups. In addition, since NO/GP exhibited a linear NO release under all
levels of swelling, this indicates that dressings can be changed any time without concerns of toxicity
caused by burst-released NO.
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3.5. In Vitro Antibacterial Assay
Antibacterial efficacy is the most important characteristic of a dressing for the treatment of
infected wounds. To investigate the antibacterial activity of NO/GP, an in vitro antibacterial assay
was performed using the CFU method against MRSA and P. aeruginosa, which are representative
drug-resistant gram-positive and -negative bacteria. Following incubation for 24 h with or without
NO/GP in TSB media, a 6-log reduction in bacterial CFUs was observed in the NO/GP-treated group
compared to the GP-treated group against both MRSA and P. aeruginosa (Figure 5A). After CFU
examination, the antibacterial activity of NO/GP was visualized by staining with SYTO 9, which is
a green fluorescence dye that can stain bacterial DNA. Since only living bacteria were collected by
centrifugation, green fluorescence indicated the presence of live bacteria. As shown in Figure 5B,
distinct green fluorescence was detected in the untreated and GP-treated groups for both MRSA and P.
aeruginosa. Furthermore, signals from the NO/GP-treated group were significantly reduced, owing to
the high number of bacteria killed by NO in both the MRSA and P. aeruginosa groups. The antibacterial
effect of NO/GP was also examined via confocal microscopy using the LIVE/DEAD® BacLight™
bacterial viability kit. Since propidium iodide can only penetrate damaged bacterial membranes,
living bacteria were stained with SYTO 9 (green fluorescence) and damaged bacteria were stained
with propidium iodide (red fluorescence). As shown in Figure 5C, confocal images of the GP-treated
and untreated groups exhibited distinct green fluorescence, while those of the NO/GP-treated group
exhibited strong red fluorescence. This indicates that most of the bacteria survived in the GP-treated
and untreated groups, while few bacteria survived in the NO/GP-treated group. Since NO possesses
broad-spectrum antibacterial effects and NO/GP can release NO in a sustained manner, these results
indicate that NO/GP exhibited significant bactericidal activity against both gram-negative P. aeruginosa
and gram-positive MRSA without bacterial re-growth for 24 h. Broad-spectrum antibacterial and
potent bactericidal effects against drug-resistant bacteria are essential for the treatment of infected
wounds, since the infection of cutaneous wounds by drug-resistant bacteria is increasing and it is hard
to immediately distinguish bacterial species. Moreover, the multiple antibacterial mechanisms of NO
may prevent the emergence of NO-resistant bacteria [16]. Thus, these findings indicate that NO/GP
possesses desirable antibacterial properties and may be beneficial for the treatment of infected wounds.
3.6. In Vivo Wound Healing Study
3.6.1. Evaluation of Wound Size Reduction Effect
The therapeutic effects of NO/GP were evaluated in mice using the bacteria-challenged
full-thickness wound model. The acceleration of infected wound recovery with NO/GP was evaluated
by observing morphological changes in the wound and measuring wound size change every 2 days.
In both P. aeruginosa- and MRSA-challenged full-thickness wound models, the NO/GP treatment
resulted in a significant reduction in wound size compared with GP treatment and no treatment after
4 days (Figure 6). In NO/GP-treated groups, wound size was reduced to less than 20% of the initial size
14 and 8 days after treatment initiation in the P. aeruginosa- and MRSA-challenged models, respectively.
Conversely, in the GP treated groups, no significant acceleration of wound healing was observed in
either the P. aeruginosa- or MRSA-challenged models compared to the untreated groups. Accelerated
wound healing in the NO/GP groups can be attributed to the action of NO released from GSNO in
NO/GP [22]. In particular, broad and potent antibacterial effects could effectively eradicate infection
with gram-positive or -negative bacteria [48,49]. Moreover, NO facilitates wound healing by promoting
fibroblast proliferation, collagen formation, and tissue remodeling [13,50]. Therefore, NO/GP may
facilitate wound healing in P. aeruginosa- and MRSA-challenged full-thickness wounds in mice.
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Figure 5. Antibacterial effects of NO/GP. Antibacterial effects of NO/GP against Pseudomonas aeruginosa
and methicillin-resistant Staphylococcus aureus (MRSA) by the colony forming unit (CFU) method.
The results are presented as the mean ± standard deviation (n = 3) (A). Visualization of bacteria by
SYTO9 staining. Green fluorescence indicates the presence of live bacteria (B). Confocal laser scanning
microscopic images of cells treated and untreated with GP and NO/GP. Green fluorescence indicates
live bacteria and red fluorescence indicates dead bacteria. Images were taken at 20× magnification.
Scale bar represents 50 μm (C).
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Figure 6. Representative macroscopic images of P. aeruginosa-challenged full-thickness wounds in mice 0,
6, and 14 days after treatment initiation (A). Changes in wound size in mice with P. aeruginosa-challenged
full-thickness wounds (B). Representative macroscopic images of MRSA-challenged full-thickness
wounds in mice 0, 6, and 14 days after treatment initiation (C). Changes in wound size in mice with
MRSA-challenged full-thickness wounds (D). Values are presented as the mean ± standard deviation
(n = 4).
3.6.2. Quantification of P. aeruginosa at the Wound Site
To investigate the in vivo antibacterial effects of NO/GP, wound samples were harvested 2, 8,
and 14 days after treatment initiation, and CFUs were assessed with Pseudomonas-selective agar plates,
which exclude other bacterial species. As shown in Figure 7A, there was no decrease in the number
of P. aeruginosa 2 days after treatment initiation; however, on day 8, significant bactericidal effects
were observed in the NO/GP-treated group (around 3-log CFU reduction). Only 4.1 and 4.8 CFU/cm2
P. aeruginosa were observed in the NO/GP-treated group, while 6.7 and 7.6 CFU/cm2 and 6.4 and
6.5 CFU/cm2 P. aeruginosa were observed in untreated and GP-treated groups 8 and 14 days after
treatment initiation, respectively. To visualize the antibacterial effects in vivo, Twort’s Gram-staining
was performed. Because P. aeruginosa is a rod-shaped gram-negative bacteria 1–2 μm in size, it can
be detected by Twort’s gram staining in tissue samples containing more than 105 CFU (low levels
of bacteria are hard to detect by Gram staining) [51,52]. Fourteen days after treatment initiation,
rod-shaped, brown-colored bacteria (P. aeruginosa) were observed in GP-treated and -untreated groups
in the damaged epidermal region, indicating that at least 105 CFU P. aeruginosa was present in the
samples (Figure 7B). Conversely, no bacteria were observed in the NO/GP-treated group or in the
healthy control. Since NO released from NO/GP was able to efficiently eradicate P. aeruginosa from
infected wound sites, wound healing may have occurred subsequent to inflammation. Furthermore,
high numbers of P. aeruginosa in GP-treated and untreated groups resulted in consistent inflammation
and, consequently, in impaired re-epithelization.
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Figure 7. Bacterial quantification at the wound site (n = 3) (A). Twort’s gram staining of wound samples
from mice treated with or without GP or NO/GP. The epidermal region of the tissue samples was
imaged with a microscope at a magnification of 100×. Arrows indicate P. aeruginosa (1–2 μm sized,
rod-shaped, and brown). Scale bar represents 10 μm (B).
3.6.3. Histological Examination
Tissue regeneration and collagen synthesis in full thickness wounds challenged with P. aeruginosa
were evaluated by H&E and Masson’s trichrome staining. Fourteen days after the initiation of
drug treatment, more organized skin morphology and higher collagen abundance were observed
in the NO/GP-treated group compared with the GP-treated and untreated groups (Figure 8).
Well-differentiated epidermis was observed in the NO/GP-treated group, whilst damaged epidermis
was observed in the GP-treated and untreated groups following H&E staining. In addition, skin cells,
such as keratinocytes and fibroblasts, were abundant in the NO/GP-treated group. Conversely,
granulation and large numbers of immune cells were observed in GP-treated and untreated groups.
The amount of collagen in wound samples was visualized by Masson’s trichrome staining (blue color
indicates collagen). As shown in Figure 8, samples from the NO/GP-treated group exhibited a prominent
blue color similar to that of healthy skin tissue. However, GP-treated and untreated groups exhibited
less collagen in the dermis region. Since inflammation was ongoing in these groups, the collagen
synthesis and tissue remodeling processes were inhibited, resulting in delayed wound healing.
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Figure 8. H&E (hematoxylin and eosin) and Masson’s trichrome straining of wound tissues from
P. aeruginosa-challenged full-thickness wound mice threated with or without GP or NO/GP for 14 days.
A: Adipose tissue; C: Cell debris; E: Epidermis; F: Fibrous tissue; G: Granulation tissue; H: Hair follicle;
I: Immune cells; M: Muscle. Scale bar represents 200 and 100 μm for the H&E and Masson’s trichrome
images, respectively.
4. Conclusions
In this study, we successfully developed an in situ hydrogel-forming/NO-releasing wound dressing
(NO/GP) composed of alginate, pectin, PEG, and GSNO, with a controlled NO release property and
good storage stability for the effective treatment of infected wounds (Figure 9). Since NO/GP maintained
a water-free powder form until use on the wound, the degradation of GSNO in NO/GP was prevented
for more than 3 months when stored at 4 and 37 ◦C. When applied to wounds, NO/GP absorbed up
to 350% of wound fluid and was quickly transformed from a dry powder to an adhesive hydrogel.
Simultaneously, a NO release was triggered by absorbed wound exudates, followed by a sustained
NO release over 24 h without an initial burst release. Rheological studies indicated that the hydrogel
structure of NO/GP exhibited sufficient adhesiveness to remain stable on the wound surface. The results
of an in vitro antibacterial study demonstrated that NO/GP leads to a 6-log reduction in MRSA and
P. aeruginosa over 24 h. Finally, in vivo antibacterial effects and accelerated wound healing were
observed in mice with infected wounds treated with NO/GP. These results suggest that the in situ
hydrogel-forming/NO releasing formulation presented in this study can be fabricated by a simple and
cost-effective manufacturing process and thus would be a promising alternative to dressings for the
treatment of infected wounds.
Figure 9. Schematic illustration of NO/GP for the treatment of infected wounds.
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Abstract: Polyglycerol-based thermoresponsive nanogels (tNGs) have been shown to have excellent
skin hydration properties and to be valuable delivery systems for sustained release of drugs into
skin. In this study, we compared the skin penetration of tacrolimus formulated in tNGs with a
commercial 0.1% tacrolimus ointment. The penetration of the drug was investigated in ex vivo
abdominal and breast skin, while different methods for skin barrier disruption were investigated
to improve skin permeability or simulate inflammatory conditions with compromised skin barrier.
The amount of penetrated tacrolimus was measured in skin extracts by liquid chromatography
tandem-mass spectrometry (LC-MS/MS), whereas the inflammatory markers IL-6 and IL-8 were
detected by enzyme-linked immunosorbent assay (ELISA). Higher amounts of tacrolimus penetrated
in breast as compared to abdominal skin or in barrier-disrupted as compared to intact skin, confirming
that the stratum corneum is the main barrier for tacrolimus skin penetration. The anti-proliferative
effect of the penetrated drug was measured in skin tissue/Jurkat cells co-cultures. Interestingly,
tNGs exhibited similar anti-proliferative effects as the 0.1% tacrolimus ointment. We conclude that
polyglycerol-based nanogels represent an interesting alternative to paraffin-based formulations for
the treatment of inflammatory skin conditions.
Keywords: tacrolimus formulation; nanogels; skin penetration; drug delivery; human excised skin;
Jurkat cells
1. Introduction
Tacrolimus, also known as FK 506, is an immunosuppressive drug acting predominantly via
inhibition of T cell proliferation. This macrolide molecule builds a complex with the FK binding
protein, which in turn binds to calcineurin and inhibits the dephosphorylation of the nuclear factor of
activated T cells (NFATs) and its translocation to the nucleus [1–3]. As a consequence, the expression of
IL-2, which is required for T cell proliferation, is inhibited. Tacrolimus also binds to isoforms of the FK
binding protein, which have a cell type-specific expression pattern. This results in inhibitory or toxic
effects towards other types of cells, e.g., mast and Langerhans cells [4–6]. In addition, induction of T cell
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apoptosis was found by Hashimoto and co-workers [7] and confirmed by Chung et al., who showed
that tacrolimus induced apoptosis in Jurkat cells via activation of caspases 3 and 12 [8]. Furthermore,
interference with the activation of the mitogen-activated protein kinase (MAPK) signaling pathways in
primary human T lymphocytes was described by Matsuda et al. [9].
While the compound is widely used as topical agent to treat certain inflammatory skin diseases,
its limited penetration across the skin barrier is a major limitation for a wider clinical use. Because
of the poor solubility, the marketed formulation (Protopic®) consists of a paraffin-based ointment
containing 0.03% or 0.1% tacrolimus in hard, liquid and white soft paraffin. In addition to insufficient
drug penetration rates, mis-sensations such as skin stinging, burning and pruritus at the application site
frequently lead to treatment discontinuation [10]. These side effects probably result from drug-induced
chemical irritation and release of pro-inflammatory cytokines such as IL-6, as demonstrated for
UVB-activated keratinocytes [11] and fibroblasts [12].
The hydrophobic paraffins in the ointment can reduce skin water loss and have therefore
moisturizing properties. However, besides the fact that greasy excipients may be unpleasant for
daily skin care, increasing concerns have been expressed because of symptom exacerbation in eczema
sufferers. Furthermore, paraffin is a flammable excipient and consumers are often not aware of this
fact [13]. Thus, several aspects indicate that new alternative formulations could result in significant
improvements of current therapeutic strategies. Consequently, new formulations for the delivery of
tacrolimus into the skin have been investigated in the last years, including lipid-based nanocarriers [14],
liposomes [15], micelles [16–18], or transferosomes [19]. In all these works, the investigated nanocarrier
formulation improved skin penetration of tacrolimus with respect to the marketed formulation.
Almost all studies used lipid-based carriers or delivery systems formulated with surfactants or
permeabilizing components like ethanol that may cause side effects when applied on inflamed skin.
In contrast, in this study, we investigated an alternative formulations based on thermoresponsive
nanogels (tNGs) made of dendritic polyglycerol, which is cross-linked with thermoresponsive polymers,
namely poly(glycidyl methyl ether-co-ethyl glycidyl ether) (tPG) and poly(N-isopropylacrylamide)
(pNIPAM). During inflammatory skin diseases, skin temperature is slightly enhanced compared to
unaffected skin. The concept of thermoresponsive nanogels implies sensing of such temperature
differences with preferential release of drug in diseased skin. In fact, the progressive temperature
increment after topical application has been shown to influence nanogel softness and the release of the
drug [20]. More specifically, nanogels are soft when applied on skin surface and can penetrate deep in
the stratum corneum (SC), where local temperature increase induces a change of conformation that
results in the release of the incorporated active compound. The investigated nanogels were shown to
enhance SC hydration [21–23] and exhibited promising drug delivery properties [24] along with low
cytotoxicity [25,26].
In most previous studies, tacrolimus penetration was investigated using animal skin [18,27],
which is anatomically and immunologically different from human skin, with little consideration of
skin barrier impairment or skin inflammatory status. In this study, we used excised human skin from
two distinct anatomical regions, breast as well as abdomen, and different methods to induce barrier
disruption and inflammatory reactions. In this way, we could monitor the effects of barrier-disruption
on tacrolimus skin penetration and release of inflammatory markers like IL-6 and IL-8. The additional
use of a trans-well set up to co-culture ex vivo human skin and Jurkat cells enabled the assessment of
tacrolimus anti-proliferative effects.
2. Materials and Methods
2.1. Nanogel Preparation and Characterization
Commercially available chemicals from standardized sources were used as delivered. Solvents
were purchased as reagent grade and distilled if necessary. Anhydrous solvents were either purchased
as ultra-dry solvent (Acros Organics®, Geel, Belgium) or received from solvent purification system.
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For the tPG polymerization reactions, dry toluene was obtained from MBRAUN SPS 800 solvent
purification system (Garching, Germany). Water was purified by Millipore water purification system.
Dendritic polyglycerol with average molecular weight of 10 kDa (PDI = 1.27) was purchased from
Nanopartica GmbH (Berlin, Germany). Glycidyl methyl ether (85%) and ethyl glycidyl ether (98%;
both TCI Europe, Eschborn, Germany) were dried over CaH2, distilled, and stored over molecular
sieves (5 Å). The crosslinking reagent (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl)
carbonate was purchased from Synaffix (Oss, the Netherlands). The cyanine dye indodicarbocyanine
(IDCC) was purchased from Lumiprobe GmbH (Hannover, Germany).
The tNGs were synthesized according to previously reported methods. For detailed synthesis and
characterization description, refer to the following publications [22,26,28]. Briefly, for the synthesis of
poly(N-isopropylacrylamide) (pNIPAM)-based nanogels (NG-pNIPAM), NIPAM (66 mg), acrylated
dendritic polyglycerol (dPG-Ac10%) (33 mg), sodium dodecyl sulfate (SDS) (1.8 mg), and ammonium
persulfate (APS) (2.8 mg) were dissolved in 5 mL of distilled water. Argon was bubbled into the reaction
mixture for 15 min, which was followed by stirring under argon atmosphere for another 15 min. The
reaction mixture was transferred into a hot bath at 68 ◦C and polymerization was activated after 5 min
with the addition of a catalytic amount of N,N,N′,N′-tetramethylethane-1,2-diamine (TEMED; 120 μL).
The mixture was stirred at 500 rpm for at least 4 h, prior to purification by dialysis. For the synthesis of
fluorescently labeled nanogels, a mixture of unlabeled dPG-Ac10% (30 mg) and indodicarbocyanine
(IDCC)-labelled dPG-Ac10% (3 mg) was used.
For the synthesis of tPG-based nanogels (NG-tPG), dPG functionalized with (1R,8S,9s)-
bicyclo[6.1.0]non-4-yn-9-ylmethyl carbonate (dPG-BCN8%) (10 mg) and di-azide functionalized tPG
(tPG-(N3)2) (20 mg) were mixed in 1 mL of dimethylformamide (DMF), cooled in an ice bath and
injected with a syringe into 20 mL of water at 45 ◦C. The mixture was stirred for 3 h and the unreacted
alkynes were quenched with azidopropanol or alternatively with IDCC-N3.
For loading tacrolimus, highly concentrated tNGs (10 mg) were added to a suspension of tacrolimus
(5 mg) in 2 mL of MilliQ water. The nanogels were let to swell, followed by sonication in an ice water
bath for 30 min. The suspension was stirred overnight at 25 ◦C and the encapsulated fraction was
separated from the free drug by filtration with a 0.45 μm regenerated cellulose syringe filter. Following,
100 μL of the encapsulated fraction were lyophilized for determination of the total concentration,
while the encapsulation capacity was determined by LC-MS/MS measurements. The nanogels with the
encapsulated drugs were stored at 4 ◦C. The characterization of the investigated nanogels is reported
in Table 1.
Table 1. Properties and drug loading of the investigated nanogels.
Nanogel Size (PDI) a Cloud Point Temperature b Tacrolimus Loading c ζ Potential [mV] d
NG-pNIPAM 110.5 nm (0.194) 34.6 ◦C 0.9 wt.% −1.07
NG-tPG 132.9 nm (0.073) 28.9 ◦C 2.5 wt.% 0.332
a Size and polydispersity index (PDI) by dynamic light scattering (DLS) in water at 25 ◦C. Measurements were
performed in triplicates; intensity average mean value presented; b Cloud point temperature determined as
the temperature at 50% transmittance by UV-Vis (λ = 500 nm); c Refer to Gerecke, et al., Nanotoxicology 2017, 11,
267–277 [26] for detailed information; d ζ potential determined by Zeta-sizer in phosphate buffer. Measurements were
performed in triplicates; intensity average mean value presented. NG-pNIPAM: poly(N-isopropylacrylamide-based
nanogels; NG-tPG: poly(glycidyl methyl ether-co-ethyl glycidyl ether)-based nanogels.
2.2. Skin Samples
Breast and abdominal skin were obtained after informed consent from healthy donors
undergoing plastic surgery. The study was conducted after approval by the Ethics Committee
of the Charité–Universitätsmedizin Berlin (approval EA1/135/06, renewed on January 2018) and in
accordance with the Declaration of Helsinki guidelines. The excised skin was used between 3 and
6 h after surgery and was examined to exclude injured parts, including macroscopic skin surface
damages but also deeper structural defects like stretch marks. Subcutaneous fat tissue was partially
removed (approximately 0.5 cm was kept) and skin was stretched and fixed on a Styrofoam block
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using needles. Skin areas of 2 cm2 were marked. In order to induce skin barrier disruption, three
methods were used: tape stripping 50 times (50 × TS), laser poration (LP), and sodium lauryl sulfate
(SLS). TS was performed with adhesive, polyethylene tape (19-mm diameter, TESA film no. 5529,
Beiersdorf, Hamburg, Germany). For LP, a P.L.E.A.S.E® Professional system (Pantec Biosolutions,
Ruggell, Lichtenstein) was used with the following setting: delivered energy 73.1 J/cm2, pulse length
125 μs, repetition rate 300 Hz, 10 pulses per pore, treated surface 10 × 10 mm, pore density 8%. For SLS
treatment, 20 μL/cm2 of 5 % SLS (w/v) in deionized distilled water were applied on a filter paper disc
(12 mm2 diameter for Finn Chambers®, SmartPractice, Hillerød, Denmark) and incubated for 4 h at
37 ◦C. Thereafter, skin was carefully cleaned with a paper towel.
A total amount of 5 μg tacrolimus per square centimeter was applied either incorporated in an
aqueous suspension of nanogels or as 0.1% marketed formulation (Protopic®, manufactured by LEO
Laboratories Ltd., Dublin, Ireland). Safety margins of at least 0.5 cm were left. Controls consisted
of skin treated with 20 μL/cm2 of sterile 0.9% NaCl solution. Samples and controls were placed in
humid chambers (plastic boxes with lid filled with humidified towels) and incubated for 24 h at 37 ◦C,
5% CO2 and 100% humidity. After incubation, non-penetrated material was removed with a paper
towel, the untreated safety margins were cut and the treated tissue blocks were plunge frozen in liquid
nitrogen and stored at −80◦C for further processing.
2.3. Preparation of Skin Extracts
In order to separate epidermis from dermis and prepare extracts for tacrolimus and cytokine
analyses, skin samples were cut horizontally (thickness 50 μm) with a microtome (Frigocut 2800 N,
Leica, Bensheim, Germany): the first 100 μm corresponding roughly to epidermis and the remaining
900 μm to dermis. The sections were put in 500 μL of extraction buffer (100 mM Tris-HCl; 150 mM
NaCl; 1 mM EDTA; 1 g Triton-X-100; 10% EtOH), homogenized (GLH OMNI homogenizer, Kennesaw,
GA, USA) for 10 s, and incubated on ice for 45 min. Then, samples were sonicated at 4 ◦C for 10 min,
vortexed and centrifuged for 5 min at 450× g. The pellets were then added of 500 μL of extraction
buffer and the above described procedure was repeated once more. The supernatants were pooled and
stored at −80◦C.
2.4. Determination of Tacrolimus in Skin Extracts by Isotope-Dilution Liquid Chromatography Tandem-Mass
Spectrometry (LC-MS/MS)
Skin extracts were thawed at room temperature, spiked with stable-isotope labeled internal
standard [13C1,D4]tacrolimus (Alsachim, Illkirch-Graffenstaden, France), vortexed, and centrifuged at
9300× g for 3 min (4 ◦C). Analyses were conducted with an Agilent 1260 Infinity LC system coupled to
an Agilent 6490 triple quadrupole-mass spectrometer (both from Waldbronn, Germany) interfaced
with an electrospray ion source operating in the positive ion mode (ESI+). Chromatographic separation
was carried out using an Agilent Zorbax SB-C18 column (1.8 μm, 2.1 × 50 mm). Aqueous ammonium
formate (20 mM, pH 3.5) and methanol (VWR, Darmstadt, Germany) were used as eluents A and B,
respectively. Samples (5 μL) were injected into a mobile phase consisting of 90% eluent A. Tacrolimus
and its internal standard [13C1,D4]tacrolimus were eluted from the column, which was tempered at
30 ◦C, with a 4-min linear gradient to and a subsequent isocratic stage for 5 min at 2:98 (v:v) eluent
A/B at a flow rate of 0.35 mL/min. Tacrolimus and [13C1,D4]tacrolimus co-eluted from the separation
column at 5.3 min. The total run time for one analysis was 13 min, including re-equilibration of
the LC system. The following ion source parameters were taken from Koster et al. [29], who used a
comparable mass spectrometric configuration for detection of four immunosuppressants including
tacrolimus: drying gas temperature = 200 ◦C, drying gas flow = 13 L/min of nitrogen, sheath gas
temperature = 200 ◦C, sheath gas flow = 12 L/min of nitrogen, nebulizer pressure = 18 psi, capillary
voltage = 4500 V, and nozzle voltage = 0 V. The ion funnel parameters were: high pressure RF voltage
= 150 V and low pressure RF voltage = 60 V. Quantification of tacrolimus in relation to the internal
standard [13C1,D4]tacrolimus was carried out using the multiple reaction monitoring (MRM) approach.
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Ammonium adducts [M+NH4]+ were selected as precursor ions by the first quadrupole. The following
mass transitions were recorded (optimized collision energies in parentheses): tacrolimus: m/z 821.5→
786.5 (16 eV), m/z 821.5→ 768.5 (20 eV), m/z 821.5→ 576.2 (24 eV); [13C1,D4]tacrolimus: m/z 826.5→
791.5 (16 eV), m/z 826.5→ 773.6 (20 eV), m/z 826.5→ 581.4 (24 eV). Thereby, the loss of two hydroxyl
groups and ammonium from the precursor ion, represented by m/z 821.5→ 768.5 for tacrolimus and
m/z 826.5→ 773.6 for [13C1,D4]tacrolimus, was used for quantification. The dwell time for each of the
six mass transitions recorded was 150 ms.
2.5. Enzyme-linked Immunosorbent Assay (ELISA)
Human IL-6 and IL-8 were investigated using ELISA kits (Human IL-6 and IL-8 CytoSetTM
(CHC1263, CHC1303) Invitrogen Corporation, Carlsbad, CA, USA) following the manufacturer
instructions. The amounts of cytokines were normalized to total protein content measured with Pierce
660 nm Protein Assay (Thermo Fisher Scientific Inc., Rockford, IL, USA). Absorbance was measured
with EnSpire® Multimode plate reader (Perkin Elmer, Akron, OH, USA).
2.6. Preparation of Cryosections and Fluorescence Microscopy
Skin samples treated with fluorescent nanogels were placed in tissue freezing medium (Leica
Microsystems, Wetzlar, Germany) and plunge-frozen in liquid nitrogen. Cryosections of 5 μm thickness
were prepared and observed by means of a fluorescence microscope (Olympus BX60F3, Olympus,
Hamburg, Germany). The following filter combinations were used: bright pass = 545–580 nm, long
pass > 610 nm for IDCC (red) and bright pass = 470–490 nm, long pass > 550 nm for FL. Pictures
(magnification of 200×) of at least 20 randomly chosen skin sections per donor and skin sample were
taken, and the mean fluorescence intensity of areas in the SC, viable epidermis, and dermis was
calculated using the ImageJ software (Version 1.47).
2.7. Isolation of Cells, Flow Cytometry, and Confocal Fluorescence Microscopy
After incubation with nanogels, skin samples were cut in small pieces (0.2 × 0.2 cm) and incubated
overnight at 4 ◦C in 2.4 U/mL dispase (Roche Applied Science, Penzberg, Germany) in order to detach
epidermis from dermis. The epidermis sheets were incubated for 10 min at 37 ◦C in 5 mL of trypsin
solution (0.025% trypsin and 1.5 mM CaCl2 in PBS). Dermis tissue was digested by incubation for
2 h at 37 ◦C with an enzyme cocktail made of 0.6 g/mL collagenase II (Biochrom, Berlin, Germany),
0.3 g/mL hyaluronidase (Sigma-Aldrich, Hamburg, Germany), and 1 μg/mL DNase (Roche Diagnostics,
Berlin, Germany). Enzymes were stopped with RPMI-1640 cell culture medium (PAA, Heidelberg,
Germany) containing 10% fetal calf serum (PAA, Heidelberg, Germany) and cells were harvested by
repeated pipetting, filtering through a 70 μm cell strainer (FalconTM, Becton Dickinson, Heidelberg,
Germany) and washing twice with PBS (PAA, Heidelberg, Germany). After centrifugation at 300× g for
10 min, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich, Taufkirchen, Germany) and stored
at 4 ◦C until analysis by flow cytometry (FACS Calibur, BD, Heidelberg, Germany). At least 20,000
events were collected in the selected gate. The software FCS Express (De Novo Software, Version 3.1,
Glendale, CA, USA) was used for data analysis. Pictures of isolated cells were taken by means of a
confocal laser microscope (LSM Exciter, Zeiss, Jena, Germany).
2.8. Isolation and Culture of T cells
T cells were isolated from dermis after digestion as described above. Dermis cell suspension was
cultured overnight in RPMI 1640 medium (Gibco, Darmstadt, Germany) supplemented with 10% fetal
calf serum, 100 μg/mL streptomycin, and 100 I.E./mL penicillin. Non-adherent cells were collected and
red blood cells were lysed with 1% Triton X-100 in PBS for 10 min on ice. Cells were then washed with
PBS and incubated with carboxyfluorescein succinimide ester (CFSE, CellTraceTM, Life Technologies,
Darmstadt, Germany) for 20 min at room temperature. Cells were washed with 1% bovine serum
albumin and re-suspended in supplemented RPMI 1640 medium. Cells were left untreated, incubated
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with IL-2 (2.5 μg/mL) only, or incubated with IL-2 and tacrolimus in 10% ethanol or tacrolimus-loaded
NG-tPG nanogels (final tacrolimus concentration of 5 μg/mL). Cell proliferation was measured after
5 days by flow cytometry. T cells were gated in forward vs. side scatter dot plots and at least 10,000
events were collected.
2.9. Co-culture of Full-Thickness Human Skin and Jurkat Cells
After topical application of tacrolimus formulations, skin samples were transferred on 8 μm-pore
inserts (Cell Culture Inserts, BD Falcon™, Corning, New York, NY, USA). These were placed in a 6-well
plate with 2 mL supplemented RPMI 1640 medium and 106 Jurkat cells (clone E6.1) per well. Jurkat
cells had previously been stained with CFSE as described above. Skin was maintained at the air-liquid
interface and co-cultured with Jurkat cells for 2 or 5 days (37 ◦C, 5% CO2). 500 μL of fresh medium
were replaced every 2 days. Jurkat cells were collected and analyzed by flow cytometry.
3. Results and Discussion
3.1. Tacrolimus Penetration and Inflammatory Reaction in Ex Vivo Human Skin with Intact or
Disrupted Barrier
In order to compare the new nanogel-based tacrolimus formulations to the commercially available
0.1% tacrolimus ointment, we measured the amounts of penetrated drug and released inflammatory
markers (IL-6 and IL-8) in ex vivo human skin. Different methods (TS, LP, and SLS) were applied to
simulate a barrier dysfunction and improve drug penetration. Laser poration (at the used energy)
induces a local removal of stratum corneum (micropores), whereas tape stripping reduces the thickness
of the stratum corneum. Both methods result in a partial removal of both lipids and corneocytes [30,31].
On the other hand, the surfactant SLS acts predominantly on the lipid layers disrupting their
structure [32]. Skin from eight donors and two different areas was used: abdomen (see Appendix A,
Figure A1(D1–D3)) and breast (Figure 1(D4–D6), and Figure 2(D7,D8). After incubation, skin samples
were processed as described in Material and Methods and the amounts of drug as well as cytokines
were quantified by means of LC-MS/MS and ELISA, respectively. In general, the ointment formulation
resulted in higher concentrations of penetrated tacrolimus. This better performance might be due to
the permeabilizing effects of some of the excipients in the ointment formulation. However, it has to
be considered that the detection of tacrolimus in epidermis extracts does not provide any spatially
resolved information, i.e., the distribution of the drug between the SC and the viable epidermis
remains unknown.
Low penetration of tacrolimus was measured in intact abdominal skin. Pretreatment with TS had
no significant effects on drug penetration, independently on the tested formulation (Figure A1). Little
effect was measured also with regard of the inflammatory markers IL-6 and IL-8. On the contrary,
higher tacrolimus concentrations were detected in intact breast skin as compared to intact abdominal
skin (Figure 1). In addition, slightly increased drug penetration and cytokine production were found
after barrier disruption by LP.
These results suggest that breast skin is more permeable than abdominal skin, probably due to
a thinner SC and a higher density of hair follicles, which have been shown to contribute to the skin
permeation of topically applied substances [33–35]. The fact that skin from breast areas expressed
also much more IL-6 and IL-8 than skin from abdominal region might be due to a higher number of
immune active cells.
With regard to tacrolimus penetration in breast skin, TS pretreatment resulted in a marked
increase of tacrolimus penetration for both ointment and nanogel formulations (Figure 2(D7,D8)),
while application of 5% SLS, a standard procedure for chemical barrier disruption, had no effects. The
results obtained after different time points (Figure 2(D8)) show that the penetration of tacrolimus in
barrier disrupted skin treated with the ointment increased exponentially with time. On the contrary,
the amount of drug penetrated in nanogel-treated samples after 100 min of incubation were similar
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to that measured after 24 h of incubation (Figure 2(D7)), suggesting a slower but constant delivery
of drug by the nanogel formulations. Thus, the lower amounts of penetrated drug observed for the
nanogel formulations after 24 h of incubation may also be a result of the slower drug delivery rate of
the nanogel formulations.
 
Figure 1. Tacrolimus skin penetration and expression of the inflammatory cytokines IL-6 and IL-8 after
topical application of tacrolimus ointment or nanogel formulation (tacrolimus final dosage 5 μg/cm2)
on breast skin from three different donors (D4–6). Skin barrier was left intact or treated with LP prior
to the application of the test formulations. Control skin was treated with 0.9% NaCl solution. TAC:
tacrolimus; LP: laser poration; NG-tPG: nanogels based on thermoresponsive polyglycerol.
When considering cytokine release, a clear increase of both inflammatory markers was observed
in control skin after LP or TS especially in the experiments performed on breast skin (Figures 1 and 2).
An additional increase of IL-8 and IL-6 was registered in tacrolimus-treated barrier disrupted skin. This
reaction might be attributed to activating or irritating effects of the nanogels themselves or of tacrolimus.
While in previous experiments no toxicity was detected for the investigated nanogels [25,26], it is
known that tacrolimus may have irritating effects [12]. Our findings point towards the fact that
enhanced penetration, while beneficial for therapeutic effects, may pose new challenges with regard to
tolerability, especially when the applied substances are capable of reaching cells of the viable epidermis
that might be in an activated state as observed in inflammatory skin [36,37].
Overall, these results indicate that breast skin is more permeable to tacrolimus than abdominal
skin, regardless of whether skin barrier was disrupted or not. After 24 h of incubation, higher amounts
of tacrolimus were measured in ointment-treated samples. Nevertheless, biological effects, like the
release of IL-6 and IL-8, were detected also in response to tacrolimus-loaded nanogel formulations.
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Figure 2. Effects of tape stripping (TS) on tacrolimus penetration and release of IL-6 and IL-8 in breast
skin. The amounts of tacrolimus, IL-6, and IL-8 were measured in the epidermis and dermis of breast
skin pre-treated to disrupt the skin barrier and incubated with the investigated tacrolimus formulations.
(D7) Breast skin was treated with 50 × TS or with 5% SLS previous topical application of 0.1% tacrolimus
ointment and tacrolimus-loaded NG-tPG (tacrolimus end concentration 5 μg/cm2) after 24 h. (D8)
Tacrolimus penetration and cytokine release in breast skin pre-treated with 50 × TS after 10, 100, and
1000 min of incubation with tacrolimus ointment and comparison with skin pre-treated with 50 × TS or
LP and incubation for 100 min with NG-tPG or ointment formulations. Control skin was treated with
0.9% NaCl solution. 50 × TS: tape stripping 50 times; TAC: tacrolimus; LP: laser poration; 5% SLS: 5%
sodium lauryl sulfate; NG-tPG: nanogels based on thermoresponsive polyglycerol.
3.2. Nanogel Skin Penetration and Cellular Uptake after Different Degrees of Barrier Disruption by TS
The SC is a key barrier which hinders the penetration of topically applied compounds. Especially
size is one of the major determinants of penetration. With regard to nanoparticulate drug delivery
systems, deformability and elasticity further contribute to their penetration properties. Large amounts
of carrier material typically remain on the skin surface or in superficial SC compartments. However,
the question as to how deep single nanogel particles are capable to penetrate is important with regard
to the likelihood of exposure of viable cells to nanogels. Thus, possible translocation of small amounts
of nanogel particles to the viable skin layers after skin barrier disruption by TS was investigated using
IDCC-tagged nanogels loaded with fluorescein (FL) (Figure 3).
The degree of skin barrier disruption was assessed by measuring the SC thickness in images
of skin sections from different regions of the sample. In Figure 3a,d, representative images and the
average of at least 15 measurements from three different donors (D9–11) are shown. After 50 TS,
a mild skin barrier disruption was achieved for one donor (Figure 3a(D9)), whereas a more severe
skin barrier disruption with a stronger reduction of SC thickness was obtained in skin from two other
donors (Figure 3d, D10 and D11). Such a different extent of barrier disruption reflects the individual
variability of SC thickness and strength. The spatially resolved skin penetration of nanogels (IDCC,
red fluorescence) and delivered model dye (fluorescein, FL, green fluorescence) served to clarify the
drug delivery mechanism of nanogels. In the representative fluorescence images (Figure 3b,e), it is
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to recognize that the two fluorophores co-localized in the SC, which resulted in yellow fluorescence,
whereas the released FL penetrated deeper in the viable epidermis, especially in the skin with severe
barrier disruption. To quantify the extent of FL penetration, the mean fluorescence intensity (MFI) in
the green channel was calculated for different skin areas of at least 20 skin sections per sample. For D9
(Figure 3b), a higher fluorescence signal was detected in the SC for the tNG sample as compared to free
FL, confirming the ability of NG-tPG to create a depot in the outermost layer of the epidermis [22].
In skin from donors 10 and 11, where TS procedure had induced a severe skin barrier disruption, a
better skin penetration of the released dye was observed not only in the SC but also in the viable
epidermis and dermis (Figure 3e). The analysis of NG-tPG penetration (IDCC signal) by fluorescence
microscopy showed penetration only in the SC for donor 9 and also in the viable epidermis for
donors 10 and 11 (Figure 3c,f). To detect possible cellular association with penetrated nanogels, part
of the treated skin was processed to isolate cells and analyze them by flow cytometry and confocal
fluorescence microscopy. While after mild skin disruption (D9) only a small percent of cells had high
fluorescent signal, over 50% of epidermis cells and 10% of dermis cells were associated with nanogels
after severe barrier perturbation (D10 and D11). Especially in the two donors with severe skin barrier
disruption, NG-tPG were found to be associated also with Langerhans cells.
Figure 3. Skin penetration of topically applied nanogels and released dye depends on the degree of
barrier disruption. Mild (a–c) and severe (d–f) skin barrier disruption was induced in breast skin by TS
previous application of free fluorescein (green) or NG-tPG tagged with IDCC (red) and loaded with FL.
After 16 h of incubation, skin was processed to prepare cryosections and isolate cells. (a,d) Representative
transmission light microscopy images of skin sections showing the different degrees of barrier disruption
and diagrams showing the average SC thickness; (b,e) analysis of FL penetration in SC, viable epidermis
and dermis of skin sections by measurement of mean fluorescence intensity; (c,f) analysis of IDCC
fluorescence on skin sections (diagrams) and in cells (flow cytometry, dot plots, and images of single
cells) isolated from NG-tPG-treated skin and stained with anti-CD1a antibody (Langerhans cells). FL:
fluorescein; SC: stratum corneum; VE: viable epidermis; D: dermis; MFI: mean fluorescence intensity;
NG-tPG: nanogels based on thermoresponsive polyglycerol; IDCC: indodicarbocyanine.
These results clearly show that, when skin barrier is compromised, nanogels can penetrate to
viable skin layers, be taken-up by epidermal and dermal cells and that uptake in dendritic cells is
favored in pro-inflammatory environment. This observation may be of special advantage for the
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treatment of inflammatory skin diseases where, besides T cells, dendritic cells are key targets of
therapeutics like tacrolimus. [5,6].
3.3. Effects of Tacrolimus Nanogels and Ointment on T Cells and Skin/Jurkat Cell Co-Cultures.
As outlined in the previous sections, assessment of a potential benefit of enhanced tacrolimus
penetration on the cellular level is limited by its irritative effects on keratinocytes and fibroblasts. Given
that immune cells are main therapeutic targets, we created an experimental set-up of skin tissue/T
cell co-cultures to measure the effects of penetrated tacrolimus on T cell proliferation [3,10]. First,
tacrolimus anti-proliferative effects was measured in vitro on T cells isolated from human excised skin
and stimulated with recombinant human IL-2 (Figure 4a–c).
Figure 4. Effects of tacrolimus in solution or formulated in nanogels on Jurkat and T-cell proliferation
in vitro. (a–c) Preliminary experiments on isolated dermal T-cells stimulated with IL-2 showed the
inhibitory effects of tacrolimus (5 μg/mL) both in solution and in nanogels. Different cell populations
were detected by flow cytometry (a) and the percentage of cells in each gate at day 5 of culture are
plotted (b). Values in gates D and E are reported in (c) using a different axis scale. (d–f) Effects of
tacrolimus were also detected in Jurkat cells after incubation with 5 and 10 μg/mL tacrolimus solution
for 4 days. Cells were gated according to fluorescence intensity (d). The percentages of cells in each
gate (e) as well as the normalized mean fluorescence intensity of all cells (f) showed a decrease of
proliferation after treatment with tacrolimus. MFI: mean fluorescence intensity.
Approximately 20% of cells were stimulated to proliferate after addition of IL-2. Both tacrolimus in
solution and loaded on NG-tPG reproducibly reduced the percentage of proliferating cells (Figure 4b,c).
Tacrolimus was also reported to exert anti-proliferative effects on T cells and Jurkat cells via induction
of apoptosis [7,8]. Accordingly, when Jurkat cells were incubated with tacrolimus, a concentration
dependent anti-proliferative effect could be measured (Figure 4d–f). These results show the ability of
nanogels to deliver tacrolimus to T cells in vitro and induce anti-proliferative effects in a degree similar
to that of the free drug. In addition, it was shown that the pro-apoptotic effects of tacrolimus on Jurkat
cells were measurable by CFSE assay (Figure 4e,f).
As next step, we cultured ex vivo skin at the air/liquid interface with Jurkat cells using a trans-well
set-up (Figure 5a).
We hypothesized that, when tacrolimus is applied topically on skin, the penetrated drug would
reach the medium compartment and affect the proliferation of Jurkat cells. In fact, all treated samples
had higher MFI than the controls, as shown in the representative histogram in Figure 5b, confirming
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the anti-proliferative effects of the penetrated drug. A concentration-dependent effect was visible
when Jurkat cells were co-cultured for 4 days with skin topically treated with 10 and 20 mg/cm2 of
0.1% tacrolimus ointment, corresponding to 10 and 20 μg/cm2 of tacrolimus, respectively (Figure 5c).
When the ointment was compared to the NG-tPG tacrolimus formulation using a final tacrolimus
concentration of 5 μg/cm2 (Figure 5d,e), a clear reduction of proliferation was visible at day 5 (Figure 5e).
Interestingly, at day 5, ointment and nanogels had similar effects for donors D14 and D15, while for
donor D13 nanogels had even a higher anti-proliferative activity than the ointment. Thus, even if in
the 24 h penetration experiments, low tacrolimus amounts were measured in the skin treated with
nanogels, after longer incubation time in the skin/cell co-culture set up, nanogel formulations could
exert anti-proliferative effects comparable to that of tacrolimus ointment.
Figure 5. Penetration of tacrolimus across full thickness skin and inhibition of Jurkat cell proliferation.
(a) Typical experimental procedure. Tacrolimus ointment or nanogels were applied topically on ex
vivo skin with disrupted barrier (tape stripping 50 times) that was co-cultured with CFSE-labelled
Jurkat cells in a trans-well set up. (b) Flow cytometry histogram of cells after treatment with tacrolimus
ointment. (c) Normalized mean fluorescence intensity of cells cocultured with skin treated with 10 and
20 mg/cm2 of ointment. (d,e) Normalized mean fluorescence intensity of Jurkat cells co-cultured for 2
(d) or 5 days (e) with skin treated with 5 μg/cm2 of tacrolimus formulated as ointment or nanogel. Both
ointment and tacrolimus-loaded NG showed inhibitory effects on Jurkat cell proliferation after topical
application on co-cultured ex vivo skin. TAC: tacrolimus; CFSE: carboxyfluorescein succinimide ester;
MFI: mean fluorescence intensity; tNGs: thermoresponsive nanogels.
4. Conclusions
This In this work, we show that tacrolimus formulated as ointment or nanogel suspension
penetrates skin with different efficiency in dependence on SC thickness and integrity. Irritation effects
of tacrolimus ointment and nanogel formulations, reflected by the released inflammatory cytokines
IL-6 and IL-8, were more pronounced in barrier-disrupted and immuno-activated skin. Extensive
barrier disruption by mechanical removal of SC resulted also in enhanced penetration of topically
applied materials, including deformable macromolecules like nanogels, with consequent interaction
and uptake by skin immune active cells. These results support the key role of the SC as barrier for
drug and nanocarrier penetration. Our results further demonstrate the critical balance of penetration
enhancement and potential increase of side effects. Slow release systems as observed herein already
addresses this aspect. The slow drug release and delivery combined with SC hydration and special
interaction with skin cells in inflamed skin may explain the good performance of nanogels with
respect to tacrolimus ointment. Thus, we conclude that tNGs represent an attractive alternative
143
Pharmaceutics 2019, 11, 394
water-based formulation for the topical delivery of high molecular weight, poorly water-soluble drugs
like tacrolimus.
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Appendix A
Tacrolimus penetration and inflammatory reaction in abdominal skin with or without barrier
disruption. Tape stripping had no significant effects on drug penetration in abdominal skin. Only
in skin from one donor and only for the ointment a high amount of tacrolimus, approximately 6 ng
per μg of total extracted proteins, was detected after tape stripping (Figure A1, Donor 3). Little effect
was measured also with regard of the inflammatory markers IL-6 and IL-8, with values around 0.2 pg
per μg of total proteins and maximal of 4 pg/μg for NG-tPG in donor 3. While a moderate increase
of IL-6 could be observed in tape-stripped skin controls, almost no IL-8 increase was measured in
controls after barrier disruption, indicating that IL-6 might be a more sensitive marker for measuring
the effect of mechanical damage to the SC. A moderate increase of IL-6 with respect to controls was
observed only in the samples treated with the nanogel formulations, whereas a slight decrease of IL-6
with respect to control was measured in skin treated with 0.1% tacrolimus ointment.
Figure A1. Tacrolimus penetration after topical application on abdominal skin with or without barrier
disruption. Abdominal skin from three different donors (D1-3) was left intact or treated with tape
stripping times (50 × TS). NG-pNIPAM (0.9 wt.% tacrolimus), NG-tPG (2.5 wt.% tacrolimus), and 0.1%
tacrolimus ointment were applied for 24 h at a final tacrolimus concentration of 5 μg/cm2. Tacrolimus
as well as the inflammatory markers IL-6 and IL-8 were detected in skin extracts. TAC: tacrolimus.
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Abstract: Topical formulations are an important pillar in the therapy of skin diseases. Nevertheless,
after application the formulation will be exposed to environmental effects. Contact with other surfaces
will reduce the available amount of formulation and drug substance. The resulting consequences
for therapy range from reduced effects to therapeutic failure. The removed active ingredient also
contaminates patients’ environment. The aim of this work was to develop preparations that remain at
the application site. These will enhance safety and efficiency and thus improve of skin disease therapies.
Therefore, we developed polymer-stabilised emulsions that show thermogelling properties. Emulsions
with different methyl cellulose concentrations and macrogols of different molecular weights were
investigated. The dispersed phase consisted of nonivamide as the active pharmaceutical ingredient,
dissolved in medium-chain triglycerides. Rheological properties, droplet size, substantivity and
ex vivo penetration experiments were performed to characterise the developed formulations. Droplet
size and rheological parameters were affected by the composition of the preparations. The tested
formulations showed benefits in their substantivity compared to a conventional semi-solid cream.
We found a residual amount of up to 100% at the application site. The drug levels in viable epidermis
were in a therapeutic range. The developed emulsions are a promising vehicle to improve therapy for
chronic skin diseases.
Keywords: nonivamide; methyl cellulose; skin penetration; substantivity; thermogel
1. Introduction
The vehicle of a topical formulation plays an important role with respect to disease control and
therapeutic outcome. It controls the penetration profile of the preparation [1–5] and has an effect on the
skin barrier function [6,7]. This can improve or worsen the healing process of diseased skin. However,
the applied formulation is partly removed, e.g., by touching skin surfaces or clothing. As a result,
the drug and vehicle can be removed from the application site and thus cannot achieve the desired
outcome. Higher drug concentration or repeated application will conceal this problem but will not
solve it. Additionally, active pharmaceutical ingredients (API) can pollute the patients’ environment.
Consequently, other people can come into contact with the drug substance, resulting in irritations or
undesired effects. Topical formulations that are more resistant to contact with the environment and
remain at the application site are a promising approach to improve patients’ compliance and reduce
the consumption of such formulations. Safety aspects are another benefit. If the preparation stays at
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the application site, unintentional contact will be minimised. Furthermore, formulations that remain
on the skin surface are possible drug reservoirs for topical preparations that exhibit sustained release.
The ability of a topical formulation to remain on the skin surface is called substantivity [8].
It has been shown that different types of formulations show notable differences in their substantivity.
A substantial amount of semi-solid formulations and liquid preparations are removed from the skin
surface by contact with other surfaces, whereas film-forming formulations are not affected [9,10]. These
preparations differ in their rheological properties. Thus, it is a promising approach to tune the rheological
behaviour of a topical formulation to increase its substantivity. We hypothesise that formulations
that change their rheological behaviour to a more elastic character upon application to the skin, e.g.,
by thermogelation, will show enhanced substantivity. We thus developed emulsions that are stabilised
with methyl cellulose (MC). Cellulose derivates, such as hydroxypropyl methylcellulose or methyl
cellulose, are known to be suitable for preparing oil-in-water emulsions and show thermogelation [11–15].
In this work, we focus on nonivamide as a drug substance for chronic skin diseases. The compound
is an agonist on the transient receptor vanilloid type 1 ion channel (TRPV1) [16]. This non-specific ion
channel is present in human skin, especially in sensory nerve fibres [17]. The short-term activation
of TRPV1 results in different symptoms. Most pronounced are warming and burning, in addition
to stinging and itching [18,19]. With long-term use, the intracellular amount of calcium increases
due to calcium influx and after a certain time the cellular processes modify. As a result, neurons
are defunctionalised and the stimulus of itch is not conducted. Therefore, nonivamide and other
capsaicinoids have a certain analgesic and antipruritic potential. They are thus agents used to treat
neuralgic pain or chronic pruritus [20,21], which presents in many skin diseases. Their use in clinical
practise is limited due to the necessity of multiple dosing and thus impaired patient compliance.
Formulations with enhanced substantivity might therefore offer a beneficial approach to promote the
use of capsaicinoids.
The substantivity of dermal preparations is less investigated and little is known about the
influencing factors. A further aim of this work was thus to understand the rheological factors that
influence substantivity and to employ this knowledge in the development of a topical formulation that
remains at the application site due to optimised rheological properties.
2. Material and Methods
2.1. Materials
Methyl cellulose (Metolose SM-25) was kindly donated by Shin-Etsu Chemical Co., Tokyo,
Japan. Avobenzone was provided by Symrise AG, Holzminden, Germany. All other materials were
obtained from the named supplier: sodium citrate (Carl Roth GmbH + Co. KG, Karlsruhe, Germany),
nonivamide (Sigma Aldrich Chemie GmbH, Steinheim, Germany), white soft paraffin (Hansen and
Rosenthal KG, Hamburg, Germany), medium-chain triglycerides (Myritol® 312), propylene glycole
and macrogol 200 and 4000 (BASF SE, Ludwigshafen, Germany) and cetyl alcohol (Ceasar and Loretz,
Hilden, Germany). PEG-20-glyceryl stearate (Tagat S2®) and glycerol stearate (Fagron GmbH and
Co. KG, Barsbüttel, Germany). Solvents methanol and acetonitril were HPLC gradient grade. Sodium
chloride, disodium phosphate, potassium dihydrogen phosphate, magnesium sulphate and phosphoric
acid were of European Pharmacopeia grade.
2.2. Preparation of Oil-in-Water Emulsions
The formulation was prepared by a syringe-to-syringe technique. Methyl cellulose, long-chain
macrogol and sodium citrate were weighed into a syringe. Water was heated up to boiling and
then weighed into a second syringe of the same size. The water had a temperature of 85–90 ◦C.
Water-miscible liquids such as ethanol or liquid (short-chain) macrogol were added to the hot water.
The two syringes were connected by an adapter and then mixed until no solid particles were visible.
A white dispersion was the result. To avoid the incorporation of air in the formulation, the syringes
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were disconnected and the air in the headspace was removed. Subsequently, the syringes were
connected again and the dispersion was mixed 100 times by transferring the mixture from one syringe
to the other. The formulation was stored at 5 ◦C for 24 h. The preparation of such aqueous methyl
cellulose preparations has already been described by Takeuchi et al. [22]. As a final step, nonivamide
was dissolved in medium-chain triglycerides. The oily solution was weighed into a syringe and
connected to the prepared aqueous phase. For a preparation with 0.9% API, the concentration of
the oily solution was 3.6% nonivamide in medium-chain triglycerides. For an emulsion with 0.3%
nonivamide, the concentration of API in the lipophilic phase was 1.2%. The two phases were mixed
100 times. As a result, a white oil-in-water emulsion was formed. The percentage composition of the
emulsions is given in Table 1. The liquid formulation was filled into a glass vial and tightly sealed.
Due to the preparation in a closed system, it was not necessary to add evaporated water.
Table 1. Percentage composition of thermogelling emulsions. The amount of nonivamide varied
between 0.3 and 0.9% with regard to the final mass of the formulation.
A B C
Substance Amount (% m/m)
Methyl cellulose 0.5 1.0 4.8
Sodium citrate 2.1 2.1 2.1
Macrogol 200 or 4000 6.0 6.0 6.0
Ethanol 9.0 9.0 9.0
Medium-chain triglycerides with nonivamide 25.0 25.0 25.0
Purified water to 100 to 100 to 100
The composition and preparation of Hydrophilic Nonivamide Cream (HNC) is described in “Neues
Rezeptur-Formularium”. The cream was prepared as described in the monograph [23]. Capsaicin was replaced
by nonivamide.
Formulations used in the in vivo substantivity measurements contained avobenzone instead of
nonivamide. Formulations were prepared as described above.
2.3. Rheoloigcal Measurements
A rotational viscometer (Physica MCR 501, Anton Paar, Graz, Austria) with a plate/plate measuring
arrangement (d = 25 mm) was used to characterise the rheological behaviour of the formulations.
Oscillatory tests were performed at 5 ◦C and 32 ◦C. A temperature of 5 ◦C ensured that the measurement
was below the gelling point. The rheological behaviour on skin surface was determined at 32 ◦C.
The frequency was 1 Hz and the deformation was increased from 0.01 to 1000%. The gap size was
set to 0.2 mm. Storage modulus G’ and loss modulus G” were determined in the linear viscoelastic
region. The dissipation factor was calculated as shown in Equation (1). All formulations contained
0.9% nonivamide. Experiments were performed in triplicate.
Dissipation f actor =
G′′
G′ (1)
2.4. Preparation of Dermatomed Pig Ear Skin
For ex vivo substantivity tests and penetration experiments, we used porcine ear skin. Porcine
skin is frequently used as a model for human skin [24–26]. Ears of German Land Race pigs with an
age between 15 and 30 weeks and a weight of 40–65 kg were used. Pig ears were donated from the
Department of Experimental Medicine, University Hospital of Tübingen. The ears were removed right
after the death of the animals. Afterwards, the ears were washed with isotonic saline and postauricular
skin was removed. The obtained skin sample was cleaned with cotton swabs and isotonic saline.
Afterwards the surface was patted dry and packed in aluminium foil. Porcine skin was stored at
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−30 ◦C. Before use, the skin was thawed at room temperature. Strips with adequate width were cut
and attached onto a styrofoam block. A dermatom (Dermatom GA 630, Aesculap AG and Co. KG,
Tuttlingen, Germany) was used to obtain skin samples with a defined thickness of 1 mm. This method
is described in previous work of our group [1,2,9,10,27]. For ex vivo substantivity tests pieces with a
diameter of 30 mm, and for penetration experiments discs with a diameter of 25 mm were punched
out of the skin.
2.5. Ex Vivo Substantivity Test
To test the substantivity of the formulations, a method of Herrmann et al. [10] was used. Two heatable
steel cylinders were fixed to a texture analyser (Type BDO-FB0.5TS, Zwick Roell GmbH and Co. KG, Ulm,
Germany). Both parts were heated to 32 ◦C (skin surface temperature). The lower part was rigid, while
the second cylinder was placed above the other and was movable. A piece of dermatomed pig ear
skin was fixed to the lower cylinder and about 4 mg of formulation was applied to the skin surface.
To this end, approximately 8 mg of the formulation was put on a plastic cylinder and weighed exactly.
By pressing down and rotating, the formulation was transferred to the skin. Afterwards the application
aid was weighed again. The mass difference gave the applied mass of formulation. Subsequently,
the formulation had 10 min to dry. Another piece of skin or a piece of cloth was fixed to the upper steel
cylinder. Then, the two devices were pressed together with a defined force of 10 N for 50 s. The skin
surface was cleaned twice with a cotton swab, then soaked with 2 mL of phosphate-buffered saline
(PBS) with pH 7.4. The swabs were collected in a 50 mL centrifuge tube and 4 mL of methanol was
added to extract the API. Clothing was extracted in a mixture of methanol and PBS in equal parts.
Nonivamide was quantified by HPLC. Experiments were performed in triplicate.
2.6. In Vivo Substantivity Test
A square of 9 cm2 was marked on the upper right arm of female Caucasian volunteers. All subjects
(aged 29 ± 6 years) gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved
by the local Ethics Committee on Human Research (University of Belgrade, Faculty of Pharmacy,
Serbia; approval number: 2298/2, issued on December 2017). Approximately 18 mg of formulation was
applied and the exact mass was obtained by difference weighing. After 10 min drying time, a piece of
cloth (6 × 6 cm) was fixed in the inner side of the clothing item with safety pins, such that the applied
formulation was covered. Afterwards the participants had 3 h at their disposal, to return to their
normal physical activities. Then the formulation was washed away twice with a cotton swab soaked
with 2 mL of purified water. The two swabs were collected in a centrifuge tube and 10 mL of methanol
was added to extract the API. The piece of cloth was put into a second centrifuge tube and 10 mL of
methanol and 4 mL of purified water were added. Subsequently, the centrifuge tubes were shaken for
1 min and then put into an ultrasonic bath for 60 min. The amount of formulation was analysed using
a UV/Vis spectrometer. All formulations contained 0.9% of avobenzone. This sun protection factor
remained on the skin surface and the penetrated amount was negligible [28]. Only volunteers with a
recovery within 65–125% of the applied amount of avobenzone were included. The actual determined
amount of avobenzone was set as 100%.
2.7. Ex Vivo Penetration Experiments
The dermatomed pig ear skin with a thickness of 1 mm was placed on the top of the acceptor
compartment of a Franz diffusion cell with 2 cm2 penetration area (Gauer Glas, Puettlingen, Germany).
The acceptor compartment was filled with a solution of 4% bovine serum albumin in phosphate-buffered
saline with pH 7.4. This acceptor medium is equivalent to whole blood with regard to the permeation
rate for lipophilic compounds [29]. The diffusion cells were placed in a water bath and heated to
32 ◦C for 30 min before the formulation was applied. The acceptor medium was stirred at 500 rpm
during the incubation time. The experiments were performed under finite dose conditions. To this
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end, about 4 mg of formulation was applied to the skin surface in the same way as described for
substantivity testing (Section 2.5). After 4 h the skin was removed from the diffusion cell. To remove the
remaining formulation, skin surface was washed twice with a cotton swab soaked with 2 mL saturated
magnesium sulphate solution. The actual penetration area was punched out, directly weighed and
frozen in liquid nitrogen. The skin was sectioned horizontally with a cryo-microtome (HM 560
Cryo-Star; Thermo Fisher Scientific, Inc., Waltham, MA, USA) into thin sections with a thickness of
16 μm. The first incomplete cuts and the first complete cut were collected in a 2 mL tube, representing
the stratum corneum. The next 14 sections were collected in a second container, representing the viable
epidermis. The last fraction, the dermis, was also cut in 16 μm thin sections and put in a third vial. This
method has been described in detail by Lunter and Daniels [2]. To extract the API from the skin tissue,
1 mL saturated solution of magnesium sulphate was added. This aqueous phase was covered with
200 μL acetonitrile. The organic liquid contained avobenzone as an internal standard. The tubes were
shaken for 60 min at 1000 rpm (BioShake iQ, Analytik Jena AG, Jena, Germany). To achieve complete
phase separation, the samples were centrifuged for 15 min at 13,400 rpm (MiniSpin, Eppendorf AG,
Hamburg, Germany). Afterwards, 80 μL of the upper organic phase was transferred into a HPLC vial.
Nonivamide was quantified by HPLC. This procedure was performed to concentrate nonivamide in
the organic phase in order to improve quantification. Experiments were performed in triplicate.
2.8. UV/Vis Detection of Avobenzone
The concentration of avobenzone was quantified using a UV/Vis Spectrophotometer Evolution 300
in combination with Visionpro Software (Thermo Scientific, Waltham, MA, USA). The solution was
filled in a quartz cuvette. The detection wavelength was 360 nm. If the signal was outside the
calibration range, the stock solution was diluted with fresh solvent. The coefficient of determination
was >0.999, the limit of detection was 0.009 μg/mL and the limit of quantification 0.033 μg/mL.
2.9. HPLC Analytics
The used HPLC system had the following components: Dionex P680 HPLC Pump, Dionex
Autosampler ASI-100 Automated Sample Injector, Gynkotek UVD170U Detector (Dionex Corporation,
Sunnyvale, CA, USA) and the column-oven SunTherm 5-100 (SunChrom Wissenschaftliche Geräte
GmbH, Friedrichsdorf, Germany). For nonivamide quantification in methanol 50% (substantivity
measurements), a multistep gradient with acetonitrile and phosphoric acid (pH 3.0) was performed.
The amount of acetonitrile was raised from 30 to 75% within 8 min and was then held constant for
2 min. Afterwards the amount was reduced to 30% within 2 min and equilibrated for 3 min. The flow
rate was set to 1.15 mL/min, the injection volume was 200 μL and the oven temperature was 40 ◦C.
The retention time of nonivamide was approximately 5.6 min. The HPLC column Nucleosil 100-5
C8 EC 125/4 (Macherey-Nagel GmbH and Co. KG, Dueren, Germany) was used together with the
HPLC-precolumn EC 4/3 Universal RP (Macherey-Nagel GmbH and Co. KG, Dueren, Germany).
Avobenzone was used as an internal standard. Calibration data are given in Table 2.










Methanol 50% 0.01–0.10 0.9868 0.014 0.042
Methanol 50% 0.1–1.0 0.9953 0.029 0.103
Methanol 50% 1.0–10.0 0.9949 0.304 1.066
Acetonitrile 0.05–0.50 0.9878 0.023 0.079
Acetonitrile 0.1–1.0 0.9911 0.042 0.146
Acetonitrile 1.0–10.0 0.9994 0.109 0.390
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To separate and quantify nonivamide and avobenzone in acetonitrile (penetration experiments)
the HPLC column Nucleosil 100-5 C18 EC 125/4 (Macherey-Nagel GmbH and Co. KG, Dueren,
Germany) was used together with the HPLC-precolumn EC 4/3 Universal RP (Macherey-Nagel GmbH
and Co. KG, Dueren, Germany). A multistep gradient with methanol and phosphoric acid (pH 3.0)
was performed. At the beginning, the organic amount was set to 45%, reaching 99% after 15 min,
and it was then held constant for 2 min. The gradient returned within 2 min to initial conditions and
was equilibrated for 5 min. The pump was set to 1.0 mL/min, the injection volume was 60 μL and
the oven temperature was 30 ◦C. The retention time was approximately 8.6 min for nonivamide and
approximately 15.1 min for avobenzone. Calibration data are given in Tables 2 and 3.










Acetonitrile 0.05–0.50 0.9971 0.011 0.040
Acetonitrile 0.1–1.0 0.9954 0.031 0.109
Acetonitrile 1.0–10.0 0.9975 0.230 0.816
2.10. Droplet Size Measurements
Droplet size was measured by laser diffraction using Mastersizer® 2000 with Hydro 2000s
(Malvern Panalytical Ltd., Malvern, UK). Therefore, 200 μL of the emulsion was added to about 10 mL
of purified water and mixed manually. The mixture was put in Hydro 2000s under stirring (2000 rpm)
until an obscuration between 10% and 20% was reached. After 60 s the measurement was started.
One measurement cycle recorded the signal three times for 30 s. For each emulsion three aliquots were
measured. For each aliquot three repetitions were performed.
2.11. Statistical Analysis
The data were obtained from repeated measurements (n ≥ 3). The diagrams show mean ± standard
deviation (SD). The data were analysed by unpaired t-test (p < 0.05) or, if multiple groups were to
be compared, by one-sided one factorial analysis of variance (ANOVA) (p < 0.05) followed by the
Student–Newman–Keuls test.
3. Results and Discussion
The aim of this work was to develop methyl cellulose-stabilised emulsions that show enhanced
substantivity due to thermogelation. We thus investigated the effect of different methyl cellulose
concentrations and different macrogol types on rheological properties and substantivity. The semi-solid
Hydrophilic Nonivamide Cream (HNC) that is used as a therapy for chronic itch was used for
comparison. To determine loss and storage modulus, oscillatory experiments were performed.
The results gave information on the viscoelastic properties of the formulation. Figure 1 exemplarily
shows the results of the oscillatory experiments at 5 and at 32 ◦C, which are equivalent to storage
temperature and skin surface temperature, respectively. At 5 ◦C the presented emulsion has a higher
loss modulus compared to its storage modulus and thus the formulation is a liquid preparation at
this temperature. By increasing the temperature to 32 ◦C, the rheological parameters change. Storage
and loss modulus reach higher values. Here, the storage modulus is higher than the loss modulus.
This means that the preparation has semi-solid properties at skin surface temperature. Therefore,
it can be concluded that the developed formulations show thermogelling properties. The emulsion has
a dissipation factor of about 0.1 and thus, compared to HNC, it is approximately six times smaller.
Therefore, the elastic properties of the emulsion are more pronounced compared to those of HNC.
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Figure 1. Oscillatory measurements of HNC at 32 ◦C (black icons) and the emulsion containing 4.8%
methyl cellulose at 5 ◦C (grey icons) and 32 ◦C (open icons), mean ± SD, n = 3.
In Table 4, the rheological parameters of different emulsions are listed (for more detailed
information the reader is kindly referred to supplementary material Figures S1–S5). With increasing
methyl cellulose concentration, the storage and loss modulus increase, but no effect on the dissipation
factor appears. The emulsions have a dissipation factor of about 0.1. Apart from different methyl
cellulose concentrations, we also investigated the impact of short-chain versus long-chain macrogols.
The emulsions with an amount of 0.5% or 1.0% of methyl cellulose but different types of macrogol
did not differ in their rheological properties. The emulsion with 4.8% methyl cellulose and macrogol
200 had a higher storage and loss modulus than the emulsion containing macrogol 4000. The latter
finding is somewhat contrary to our expectation that the long-chain macrogol that is solid at skin
surface temperature might also lead to a more solid gel character. Presumably the short-chain macrogol
interacts more strongly with methyl cellulose and thus exhibits a stronger impact on the rheological
properties of the emulsion.
Table 4. Rheological parameters of thermogelling emulsions and HNC at 32 ◦C, mean ± SD, n ≥ 3.
Formulation Storage Modulus (Pa) Loss Modulus (Pa) Dissipation Factor
HNC 396.73 (±32.32) 233.37 (±16.95) 0.59 (±0.01)
4.8% Methyl cellulose, macrogol 4000 284.00 (±147.55) 25.43 (±8.96) 0.09 (±0.01)
1.0% Methyl cellulose, macrogol 4000 5.64 (±1.11) 0.61 (±0.27) 0.10 (±0.04)
0.5% Methyl cellulose, macrogol 4000 4.28 (±2.07) 0.44 (±0.23) 0.14 (±0.12)
4.8% Methyl cellulose, macrogol 200 2123.33 (±51.32) 200.00 (±6.24) 0.09 (±0.00)
1.0% Methyl cellulose, macrogol 200 3.52 (±0.62) 0.42 (±0.08) 0.12 (±0.04)
0.5% Methyl cellulose, macrogol 200 2.00 (±0.31) 0.44 (±0.23) 0.23 (±0.12)
The droplet size of the emulsions was determined directly after preparation. The results are
shown in Table 5. The emulsions with high methyl cellulose concentrations showed the smallest
droplet size. Upon decreasing the polymer concentration, the values for d10, d50 and d90 rose. Methyl
cellulose is the emulsifying agent and a direct correlation between droplet size and methyl cellulose
concentration was expected. Our results do not show any effect of the macrogol chain length on the
droplet size. The emulsions with the same amount of methyl cellulose but different macrogol types
were comparable with respect to their droplet size. The macroscopic and microscopic appearances of
the emulsions are shown in supplementary Figure S6.
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Table 5. Droplet size of the emulsions with different methyl cellulose concentrations and different
macrogol types. Formulations were prepared without nonivamide, mean ± SD, n = 3.
Formulation d10 d50 d90
4.8% Methyl cellulose, macrogol 4000 1.34 (±0.01) 2.37 (±0.00) 3.82 (±0.01)
1.0% Methyl cellulose, macrogol 4000 1.93 (±0.01) 4.88 (±0.01) 9.33 (±0.03)
0.5% Methyl cellulose, macrogol 4000 3.32 (±0.04) 6.70 (±0.07) 12.37 (±0.16)
4.8% Methyl cellulose, macrogol 200 1.40 (±0.00) 2.26 (±0.01) 3.45 (±0.02)
1.0% Methyl cellulose, macrogol 200 2.74 (±0.06) 5.95 (±0.08) 11.14 (±0.21)
0.5% Methyl cellulose, macrogol 200 3.09 (±0.11) 6.49 (±0.11) 11.99 (±0.21)
Furthermore, the effect of different methyl cellulose concentrations and macrogols on substantivity
was investigated. The results of the ex vivo substantivity test are shown in Figure 2. It can be
seen that skin-to-formulation or clothing-to-formulation contact removes about one third of HNC.
Formulations with 0.5% or 1.0% methyl cellulose showed comparable results. About 70% of the
applied emulsion remained at skin surface after simulated contact. The two emulsions with a methyl
cellulose concentration of 4.8% showed residual amounts of 86% and 100%. This shows that neither
skin-to-formulation nor clothing-to-formulation removed a substantial share of the applied emulsion.
Figure 2. Ex vivo substantivity tests simulating skin-to-formulation and clothing-to-formulation contact.
Results of HNC and developed emulsions, mean ± SD, n = 3.
The results of the ex vivo substantivity tests show that with a methyl cellulose concentration of
4.8% and macrogol 4000 or 200, high residual fractions were obtained—i.e., the withdrawn amount
was not more than 14% when skin-to-formulation contact was simulated. Moreover, a residual amount
up to 100% was obtained, when clothing-to-formulation was simulated. A lower methyl cellulose
concentration resulted in higher withdrawn amounts. Emulsions with the same amount of methyl
cellulose but different types of macrogol were comparable. The emulsions with a high methyl cellulose
concentration were neither affected by simulating skin-to-formulation nor clothing-to-formulation
contact. Statistical results of the ex vivo substantivity test are given in the supplementary material
(Tables S1 and S2). These results can be explained by the rheological behaviour of the formulations.
Emulsions that showed similar rheological behaviour also showed similar substantivity. Emulsions
with high methyl cellulose concentration were characterised by their high storage modulus and a low
dissipation factor and thus showed high substantivity. On the other hand, emulsions with low methyl
cellulose concentration showed low storage modulus and a higher dissipation factor, resulting in
lower substantivity. The substantivity of the developed emulsions is comparable to that of previously
developed film-forming formulations [9,10]. This finding is remarkable, as the emulsions do not form
a deductible, cohesive film.
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The droplet size plays a minor role in resistance against contact with other surfaces. Formulations
with 4.8%, 1.0% and 0.5% methyl cellulose showed differences in their droplet size, though we could
not find a clear trend in their substantivity.
The next step was to investigate the skin penetration of nonivamide from the developed emulsions.
The nonivamide site of action is located in the viable epidermis. Thus, ex vivo permeation experiments
were not informative in this case as they reflect transdermal absorption. We thus focused on ex-vivo
penetration experiments that enabled the measurement of the nonivamide concentration in the different
strata of the skin. Penetration from the emulsion was compared to penetration from HNC, which
contained nonivamide in a concentration that is clinically used (0.05%). The aim was to achieve
drug levels at the site of action that were comparable to this reference. The emulsion contained 0.9%
nonivamide, as this concentration had been found to give similar drug concentrations in skin to HNC
0.05% in earlier work by our group [2,3,27].
Figure 3 shows the penetrated amount of nonivamide from HNC 0.05% and an emulsion with
0.9% in the different skin layers. From HNC 0.05%, about 70 ng/cm2 penetrated in the stratum corneum
after 4 h incubation time. In both the viable epidermis and dermis we could find about 25 ng/cm2.
The new emulsion with an API concentration of 0.9% resulted in a mean of 250 ng/cm2 nonivamide in
the stratum corneum, 100 ng/cm2 in the viable epidermis and 60 ng/cm2 in the dermis. The penetrated
amount in the stratum corneum and viable epidermis was about three to four times higher compared
to that achieved using HNC 0.05%. Therefore, the drug concentration was set to 0.3% in a subsequent
experiment. A reduced API concentration of 0.3% led to a reduced penetrated amount (Figure 4). Drug
concentration in the viable epidermis, the site of action, was about 14 ng/cm2 from the emulsion and
12 ng/cm2 from HNC, and was thus comparable to HNC 0.05%. Although the emulsion contained
a higher concentration of API, the penetrated amount was almost the same. This can be explained
by the composition of the two formulations. HNC contained 15% of propylene glycol and 9% of
ethanol, which are both known as penetration enhancers [30–32], whereas the emulsion did not contain
propylene glycol. Differences in penetrated amount from HNC 0.05% between the two experiments
were related to the use of skin from different donors. It can thus be concluded that the emulsion
delivers an amount of the active ingredient to the skin that is suitable for therapy. The penetrated
amount can be tuned by adjusting the drug concentration in the emulsion.
Figure 3. Penetrated amount of nonivamide after 4 h from HNC 0.05% and a developed emulsion
containing 0.9% nonivamide, mean ± SD, n ≥ 3.
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Figure 4. Penetrated amount of nonivamide after 4 h from HNC 0.05% and a developed emulsion
containing 0.3% nonivamide, mean ± SD, n = 3.
Finally, the in vivo substantivity of the thermogelling emulsion was compared to that of HNC.
The results are given in Figure 5. It can clearly be seen that from HNC, 67% of the formulation was
transferred to the clothing, whereas from the emulsion only 37% was removed. This is in accordance
with the ex vivo substantivity test, which had already shown that the emulsion was superior to HNC.
Nevertheless, the SDs were higher and the differences between the two formulations were slightly
less evident in the in vivo experiment. We believe that this was to be expected as a higher degree of
variability is typical for in vivo experiments. As our study group was very homogeneous regarding age,
gender and ethnicity, we believe that the variability manly reflects different physical activity among
the volunteers, who were not given any restriction on to how to behave during the application interval.
Therefore, the in vivo experiment better reflects real life conditions compared to the ex vivo experiment.
As we could still find a significant difference between substantivity in the in vivo experiment, we are
convinced that the emulsion will be superior to HNC under real-life conditions.
 
Figure 5. In vivo substantivity tests simulating clothing-to-formulation contact. Results of HNC and
the developed emulsion, mean ± SD, n = 5 or 6.
4. Conclusions
Thermogels or formulations that form a gel in situ are promising dosage forms for different
applications. Ophthalmic, injectable as well as dermal preparations are described in the literature. Lin et al.
investigated thermogels containing mixtures of alginate and pluronics for ophthalmic application [33].
Zhang et al. used PLGA-PEG_PLGA-block-copolymers as injectable and biodegradable delivery
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systems [34]. In the context of dermal application, Hemelrijk et al. employed poloxamer to form
thermogels for the enhanced delivery of 5-ALA into keratotic skin [35]. Takeuchi et al. investigated
methyl cellulose-based thermogels and characterised the impact of different excipients on rheological
parameters [22]. Their gels contained no oil phase and no studies concerning the dermal uptake of
pharmaceutical actives from the gels were conducted. Further, the question of substantivity has not
been investigated in publications dealing with methyl cellulose thermogels. Although researchers and
practitioners are aware of the fact that a substantial amount of formulations is removed from the skin
after application, research on the rational development of formulations with enhanced substantivity
is scarce.
The presented work illustrates that the developed thermogelling emulsions are more substantive
than the tested conventional semi-solid cream. With a high methyl cellulose concentration, almost the
entire applied formulation stays at the application site. The results suggest that a connection between
rheological characteristics and substantivity exists. High storage modulus and low dissipation factor
increase the residual amount of topical formulations. Thus, it is possible to combine the advantages of
the high substantivity of film-forming formulations and the beneficial characteristics of conventional
semi-solid creams with regard to skin care. While in film-forming formulations the oil is immobilised in
mesoporous silica particle [1], in the presented emulsions the medium-chain triglycerides are available
for skin care. The penetrated amount of nonivamide is comparable to the monographed HNC 0.05%.
The thermogelling emulsions may therefore provide an alternative to conventional creams in the
therapy of chronic skin diseases. With enhanced substantivity, they may reduce application frequency
and the contamination of patients’ environment with the active ingredients. They may also be used as
a formulation platform for other pharmaceutical actives. Future research will focus on the impact of
further excipients on thermogelation and on the selection of optimal additives for the enhancement of
in vivo substantivity. As differences were found between ex vivo and in vivo substantivity, we will
further improve the ex vivo method of substantivity determination to better reflect the in vivo situation.
Furthermore, the optimisation of drug delivery properties will be investigated.
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Figure S1: Oscillatory measurements methyl cellulose stabilised emulsion at 5 ◦C (grey icons) and 32 ◦C (open
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Abstract: The aim of this research was to investigate the stability of a lidocaine-loaded nanostructured
lipid carrier dispersion at different temperatures, formulate a nanostructured lipid carrier gel, and test
the penetration profile of lidocaine from the nanostructured lipid carrier gel using different skin
penetration modeling methods. The formulations were characterized by laser diffraction, rheological
measurements and microscopic examinations. Various in vitro methods were used to study drug
release, diffusion and penetration. Two types of vertical Franz diffusion cells with three different
membranes, including cellulose, Strat-M®, and heat separated human epidermis were used and
compared to the Skin-parallel artificial membrane permeability assay (PAMPA) method. Results
indicated that the nanostructured lipid carrier dispersion had to be gelified as soon as possible for
proper stability. Both the Skin-PAMPA model and Strat-M® membranes correlated favorably with
heat separated human epidermis in this research, with the Strat-M® membranes sharing the most
similar drug permeability profile to an ex vivo human skin model. Our experimental findings suggest
that even when the best available in vitro experiment is selected for modeling human skin penetration
to study nanostructured lipid carrier gel systems, relevant in vitro/in vivo correlation should be made
to calculate the drug release/permeation in vivo. Future investigations in this field are still needed to
demonstrate the influence of membranes and equipment from other classes on other drug candidates.
Keywords: dermal drug delivery; diffusion cell; Franz diffusion; Skin-PAMPA; Strat-M® membrane;
nanocarrier
1. Introduction
Topical and transdermal formulations are widely used for delivering drugs to the skin and
underlying tissue, or through the skin for systemic action. The vast majority of topically applied
formulations are semisolids, including creams, ointments and gels, which offer suitable residence time
on the skin, and are usually well accepted by the patients. Topical formulations deliver the active
pharmaceutical ingredients (APIs) into different layers of the skin, thus enabling several diseases to
be prevented and/or cured. The beginning, duration and strength of the therapeutic effect depend
on the efficacy of three consecutive processes: (1) The release of the API from the carrier system;
(2) penetration/diffusion of the API into the stratum corneum or other skin layers; (3) exertion of
a pharmacological effect at the target point. All these effects determine the safety-efficacy profile
of a product [1–3]. For most skin problems or diseases, the target point is the stratum corneum,
viable epidermis or dermis.
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Modeling of penetration through the skin is discussed by numerous directives [4–8]. The in vitro
method for skin penetration modeling is included in OECD Guideline 428 [5]. Advantages of the
in vitro method are that measurements can be carried out on human skin samples among other
potential membranes; multiple tests can be performed on a skin sample from the same donor; several
formulations can be tested at the same time; there is no need for radio-labelling the test material;
and there are no ethical issues.
Topical semisolid products are complex formulations with a complex structure. Physical properties
of the composition depend on several factors, including particle size of dispersed particles, surface
tension between the phases, fractional distribution of the drug between the phases, and rheological
behavior of the product. These properties collectively determine the in vitro dissolution profile, together
with other characteristics. The amount of API released in vitro is an important quality characteristic
of a product. Modeling of penetration through the skin is a complex challenge. The device and the
membrane, along with the properties of the product influence how the system can be tested most
effectively. There are various types of equipment with which the diffusion and penetration of drug
carrier systems can be studied. Human skin tests give the most relevant information; however, because
of the high cost, it is a generally accepted approach to choose simpler methods in the early stages of
formulation development. Previously, several simple, reliable, reproducible and validated methods
were described for drug liberation by a vertical diffusion cell (VDC) using a synthetic membrane [9–11].
In vitro drug release testing is a widely used and reliable tool for evaluating products.
The use of Franz diffusion cells to evaluate skin permeability has developed into a major research
methodology. With Franz diffusion studies, diffusion and penetration of an API through the skin and
the relationships among the skin, drug and formulation can be investigated [12–19]. Franz diffusion
cells are available with multiple types of automatic sampler systems. A lot of different membranes,
including artificial and biological membranes can be applied on the Franz cells. Artificial membranes
provide a simple and reproducible alternative way to study the basic physicochemical mechanisms of
the drug diffusion, including interactions between the carrier and the membrane. They are suitable for
early-stage drug development studies [13]. The Strat-M® membrane, built by two polyether sulfone
layers, was specifically designed for skin penetration studies. The layers are impregnated with a
mixture of synthetic lipids, and a polyolefin layer is located underneath. Moving downwards into
the membrane layers, the size of the pores increases [20]. Transdermal diffusion and safety of APIs,
excipients, functional cosmetic ingredients, cosmetic active substances, and finished products can be
tested using the Strat-M® membrane. Advantages include that its diffusion properties are highly
correlated with human diffusion studies, and it is characterized by minimal variability. It is also
long-lasting and requires no special storage conditions or preparation for its use [20–24]. In addition
to synthetic membranes, human skin membranes can also be used to model skin penetration. In the
development of dermal preparations, it is not sufficient to perform membrane diffusion studies. It is
necessary to do permeation studies through the biological membrane since the interaction of the API
and carrier system with the skin can also be investigated, and it can be determined whether and to
what extent the skin acts as a reservoir for the API. Usually, skin sections are obtained from plastic
surgery, and a heat-separated epidermis is used as a membrane [13,25,26].
The parallel artificial membrane permeability assay (PAMPA) is a device that is adapted to
simulate penetration of a product into the skin. For Skin-PAMPA, the bottom part of the PAMPA
sandwich is substituted by a special donor plate, which was designed to study semi-solid products.
It contains synthetic ceramides and has similar penetration properties to full-thickness skin. Synthetic
lipids are easier to store, and their stability is more favorable [27–30]. The biomimetic model is able to
determine in vitro human skin data based on the tests and can be a good alternative to skin permeability
testing [17,28,31].
Lidocaine is a commonly used numbing agent before local interventions. Delivering lidocaine
to the skin from a specific vehicle provides a numbing/pain relief effect to that area. It is possible to
localize the numbing effect onto a smaller skin area without reaching the muscle. By concentrating
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the numbing effect to the skin, the patient is able to retain full motor function of the area to which
lidocaine is applied.
Our research group previously formulated and compared different drug carrier systems for
the dermal delivery of lidocaine, including a conventional hydrogel, an oleogel, a lyotropic liquid
crystalline gel and nanostructured lipid carrier (NLC) gel. It was concluded that the penetration of
lidocaine from the NLC gel was the most significant, and the skin hydrating and occlusive effect made it
a favorable carrier system [25,32]. In addition, several articles in the literature featured lidocaine-filled
NLCs or NLC gels [33–37]. Therefore, a lidocaine-loaded NLC and NLC gel was selected for the
current investigations.
In this study, our aims were to investigate the stability of a lidocaine-loaded NLC dispersion at
various storage temperatures, formulate an NLC gel, and evaluate the penetration profile of lidocaine
from the NLC gel. Two types of vertical Franz diffusion cells with three different membranes, including
a cellulose membrane, Strat-M® membrane, and heat separated human epidermis were used to study
the drug release and permeation. Additionally, the NLC gels were evaluated using the Skin-PAMPA
method, and the three methods were compared.
2. Materials and Methods
2.1. Materials
Lidocaine base and glycerol were obtained from Hungaropharma Ltd. (Budapest, Hungary).
Miglyol® 812 N (caprylic/capric triglyceride) was a gift from Sasol GmbH (Hamburg, Germany).
Cremophor® RH 60 (PEG-60 Hydrogenated Castor Oil; HLB value: 15–17) was kindly supplied by
BASF SE Chemtrade GmbH (Ludwigshafen, Germany). Apifil® (PEG-8 Beeswax) was a gift from
Gattefossé (St. Priest, France). Methocel™ E4M (hydroxypropyl methylcellulose) was from Colorcon
(Budapest, Hungary). The water used was purified and deionized with the Milli-Q system from
Millipore (Milford, MA, USA). The cellulose acetate filter (Porafil membrane filter, cellulose acetate,
pore diameter: 0.45 μm) was obtained from Macherey-Nagel GmbH & Co. KG (Düren, Germany).
The Strat-M® membrane (Strat-M® Membrane, Transdermal Diffusion Test Model, 25 mm) was from
Merck KGaA (Darmstadt, Germany). Excised human skin was obtained from a Caucasian female
patient by routine plastic surgery procedure in the Department of Dermatology and Allergology,
University of Szeged. The ex vivo skin penetration test does not need ethical permission, and patient’s
consent according to the Act CLIV of 1997 on health, Section 210/A in Hungary. The local ethical
committee (Ethical Committee of the University of Szeged, Albert Szent-Györgyi Clinical Center)
was informed about the ex vivo skin penetration studies (Human Investigation Review Board license
number: 83/2008). The Skin-PAMPA sandwiches (P/N: 120657), hydration solution (P/N: 120706) and
stirring bars (P/N: 110066) were purchased from Pion, Inc (Woburn, MA, USA). The UV plates (UV-star
micro plate, clear, flat bottom, half area) were from Greiner Bio-one (Kremsmünster, Austria).
2.2. Methods
2.2.1. Preparation of the NLC
NLCs are colloidal carriers which were introduced in the early 1990s. They are derived from o/w
emulsions by replacing the liquid lipid with a solid lipid at room temperature. The lipophlic phase
of NLC included Apifil, Cremophor RH 60 and Miglyol 812 N, which were melted at 60 ◦C under
controlled stirring. Then lidocaine was added to the melted lipid phase under similar conditions.
Then purified water was added to the lipid phase to form the pre-emulsion. The pre-emulsion was
ultrasonicated using a Hielscher UP200S compact ultrasonic homogenizer (Hielscher Ultrasonics
GmbH, Teltow, Germany) for 10 min at 70% amplitude. At the end, the sample was cooled in ice to
obtain the solid lipid particles (LID-NLC) [38]. For dermal application, a gel was formed at room
temperature with glycerol and Methocel E4M. In the last step, the NLC dispersion was added to the
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gel (LID-NLC gel). A blank-NLC and blank-NLC gel were also prepared using the same procedure,
but without adding lidocaine. Table 1 summarizes the formulations. The NLC formulations were
stored at different temperatures 7 ◦C (cold) and 25 ◦C (room temperature).
Table 1. Compositions of the test preparations.
LID-NLC Blank NLC LID-NLC Gel Blank NLC-Gel
Apifil 11.8% Apifil 11.8% LID-NLC 89% Blank NLC 89%
Cremophor RH 60.8% Cremophor RH 60.8% Glycerin 8% Glycerin 8%
Miglyol 812 N 5% Miglyol 812 N 5% Methocel E4M 3% Methocel E4M 3%
Purified water 69.2% Purified water 75.2%
Lidocaine 6%
2.2.2. Laser Diffraction
Laser diffraction analysis was performed with a Malvern Mastersizer 2000 particle size analyzer
provided with the Hydro SM wet dispersion unit (Malvern Instruments, Worcestershire, UK) to
determine the particle size and stability of the NLC formulation at different temperatures (cold
and room temperature). A few drops of the sample were placed inside the Hydro SM loaded with
purified water, and the speed of the stirrer was set to 2000 rpm. Three values, namely d(0.1), d(0.5),
and d(0.9), were evaluated, indicating that 10%, 50%, and 90% of the analyzed particles were below a
certain size (diameter). The span value describing the width of the particle size distribution curve
((d(0.9) − d(0.1))/d(0.5)) was calculated as well.
2.2.3. Rheological Measurements
Rheological measurements were performed with a Physica MCR101 rheometer (Anton Paar
GmbH, Graz, Austria), employing a parallel plate geometry PP25 with a measuring gap of 0.1 mm to
verify the proper consistency of the LID-NLC gel system for topical application. The blank-NLC gel
was studied as well. Flow curves, viscosity curves and frequency sweep tests were obtained. The shear
rate was increased from 0.1 to 100 1/s (up-curve) and then decreased from 100 to 0.1 1/s (down-curve)
in CR mode. The shearing time in was 300 s. The measurements were carried out at 25 ◦C [39].
2.2.4. Microscopic Examinations
The structure of the NLC samples was examined with a microscope (LEICA DM6 B, Leica
Microsystems GmbH, Wetzlar, Germany) at room temperature. Magnifications were 100× and 200×.
2.2.5. pH Measurements
For pH measurement, 10 g of each sample (NLC dispersion and NLC gel) was placed in a beaker,
and the surface pH was measured using a Testo 206 pH meter (Testo SE & Co. KGaA, Lenzkirch,
Germany) with a pH2 probe. Three parallel measurements were carried out at room temperature.
2.2.6. Drug Diffusion and Penetration Studies
Three different methods were used to model and compare drug release and diffusion through
the membrane and penetration into the skin from the LID-NLC gel (Table 2). The methods included
two types of vertical Franz diffusion cells, namely Hanson Microette TM Topical & Transdermal
Diffusion Cell System, and Logan Automated Dry heat sampling system. The third method used
was the Skin-PAMPA method. On the Franz cells, the donor and acceptor phases were separated
by either a synthetic cellulose acetate membrane, a Strat-M® membrane or heat-separated human
epidermis (HSE). A 0.3 g portion of sample was placed in the donor chamber on the membrane.
The human skin was placed in a water bath (60 ± 0.5 ◦C), and the epidermis was separated from
the dermis. Thermostated phosphate buffer solution (PBS pH 7.4 ± 0.15), made in-house, kept at
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32 ± 0.5 ◦C was used as the acceptor phase. Membrane diffusion and skin penetration experiments
lasted 24 h (sampling times: 0.5; 1; 2; 3; 4; 5; 6; 8; 10; 12; 16; 20; and 24 h). The stirring speed was
400 rpm. The concentration of the drug was measured spectrophotometrically with a Thermo Scientific
Evolution 201 spectrometer with Thermo Insight v1.4.40 software package (Thermo Fisher Scientific,
Waltham, MA, USA) at a wavelength of 262 nm (analytical parameters: Slope: 0.001738 ± 0.000016; SE:
4.554 × 10−5; SD: 0.0001205; LOD: 0.2339 μg/mL; LOQ: 0.7088 μg/mL). The Skin-PAMPA sandwiches
were used after a 24-hour hydration period (Hydration Solution, Pion, Inc., Billerica, MA, USA). 70 μL
of the NLC gels were applied to the well of the formulation plate as the donor phase. Phosphate buffer
solution (PBS pH 7.4 ± 0.15), made in-house, was used as the acceptor phase. The top plate was filled
with 250 μL of fresh acceptor solution, and a stirring bar was also used in each well. The Gut-Box™
from Pion, Inc. was used for stirring; the resultant sandwich was incubated at 32 ◦C for six hours.
The Skin-PAMPA membrane is not designed for 24-h measurements, the membrane can provide
relevant values for a shorter time. Therefore, the acceptor solution was examined after 0.5, 1, 2, 3,
4, 5 and 6 h of incubation. The quantity of the API was determined by UV spectroscopy at 262 nm
using a Synergy HT UV plate reader by KC4 (BIO-TEK Instruments, Inc., Winooski, VT, USA) software.
The quantity of the permeated API was expressed as μg/cm2 units.
Table 2. The experimental design of drug diffusion and penetration studies.
Device Hanson Logan Skin-PAMPA




Two-way ANOVA analysis of variance (Bonferroni post-test), working with Prism for Windows
software (GraphPad Software Inc., La Jolla, CA, USA), was used to analyze the statistical difference
between the samples. Results are shown as average of six parallel experiments and standard deviation
(SD). Variations were considered significant if p < 0.05 *, p < 0.01 ** and p < 0.001 *** versus the control.
3. Results and Discussion
3.1. Particle Size Analysis
Usually light scattering methods, such as photon correlation spectroscopy and/or laser diffraction
(LD) are used for particle size determination of lipid nanoparticles. LD is a powerful method that has a
wider detection spectrum (20 nm–2.000 μm), and it is considered a better option for lipid nanoparticles
in the upper nanometer and micrometer size ranges.
All NLC dispersions were in the nanosize range, between 97 and 163 nm (d(0.5)). The particle
size of LID-NLC stored at room temperature was the smallest (97 nm), and it was stable for three days
(the values of d(0.5) and d(0.9) were below 200 nm). On the fourth day, the d(0.9) values showed a
significant increase (41.749 μm). The particle size of the NLC dispersion stored in the refrigerator
increased after one day. The reason for this instability was that lidocaine crystallized in the refrigerator,
and the formulation was not stable under these conditions. The exact parameters are summarized in
Table 3. According to the particle size analysis, the holding time of the preparation was three days at
room temperature.
165
Pharmaceutics 2019, 11, 310
Table 3. Particle size of nanostructured lipid carrier (NLC) dispersions stored at different conditions.
Day NLC Dispersion d(0.1) μm d(0.5) μm d(0.9) μm Span
1st day Blank-NLC, room temperature 0.066 0.131 0.320 1.950
Blank-NLC, cooled 0.066 0.130 0.302 1.821
LID-NLC, room temperature 0.069 0.098 0.145 0.787
LID-NLC, cooled 0.069 0.098 0.146 0.790
2nd day Blank-NLC, room temperature 0.065 0.127 0.266 1.584
Blank-NLC, cooled 0.065 0.127 0.266 1.587
LID-NLC, room temperature 0.068 0.097 0.144 0.782
LID-NLC, cooled 0.073 0.114 0.259 1.625
3rd day Blank-NLC, room temperature 0.065 0.126 0.258 1.542
Blank-NLC, cooled 0.065 0.126 0.262 1.564
LID-NLC, room temperature 0.069 0.098 0.146 0.791
LID-NLC, cooled 0.079 0.130 0.300 1.698
4th day Blank-NLC, room temperature 0.065 0.128 0.289 1.746
Blank-NLC, cooled 0.065 0.128 0.298 1.814
LID-NLC, room temperature 0.090 0.163 41.749 255.201
LID-NLC, cooled - - - -
3.2. Microscopic Study
Parallel to the particle size analysis, microscopic studies were performed as well on the NLC
dispersions. As it can be seen in Figure 1, in cooled circumstances lidocaine crystals appeared on the
second day, while at room temperature they appeared on the third day. Based on the microscopic
examination, the holding time of the NLC dispersion was two days at room temperature.
The structure of the LID-NLC gel was examined with a polarized light microscope as well.
The formula had a homogenous structure after two weeks, no API crystals were detected (Figure 2).
It can be concluded based on these results that it is very important to gelify the NLC dispersion as
soon as possible for proper stability.
 
Figure 1. The NLC dispersions’ stability over the course of three days at different storage conditions.
(The magnification was 200×).
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Figure 2. The solid lipid particles (LID-NLC) gel in polarized light at week two. (The magnification
was 100×).
3.3. Rheological Studies
The LID-NLC gel had a shear thinning behavior (Figure 3A), which means the shear stress
increased continuously with the shear rate, but the rate of the increase decreased. Slight thixotropy
was observed, meaning that structure regeneration was time-dependent. The viscosity value of
the LID-NLC gel at the shear rate of 100 1/s was 6.72 Pa·s at 25 ◦C. According to the rheological
measurements, the consistency of the formulation was suitable for dermal use. The viscosity value of
the blank-NLC gel at the shear rate of 100 1/s was 5.58 Pa·s at 25 ◦C. Based on the rheological curves,
it can be stated that incorporation of the API into the formulation made the system more viscous.
Viscosity values increased and consistency improved. The frequency sweep test (Figure 3B) showed a
viscoelastic behavior, where the elastic characteristic dominated (G′ higher than G”); with a relatively
large frequency dependence of the moduli (G′ and G”) which is a typical feature of a so-called weak gel.
Figure 3. Rheological behavior of the NLC gel. (A): flow curves; (B): frequency sweep test.
3.4. pH Measurement
pH of the blank-NLC dispersion was 5.2 ± 0.2 and the blank-NLC gel 5.3 ± 0.3. pH of the LID-NLC
dispersion was 8.0 ± 0.3 and the LID-NLC gel 7.9 ± 0.4. Due to its basic characteristics, the active
ingredient increased the pH value of the preparation.
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3.5. Drug Release, Diffusion and Penetration Studies
The in vitro diffusion/penetration of lidocaine from the LID-NLC gel through the two synthetic
and one biological membranes and the Skin-PAMPA membrane were calculated in terms of the mean
cumulative amount and percentage diffused/penetrated ± SD by 6 or 24 h (Table 4).
The cellulose acetate membrane is a non-barrier, non-skin like membrane, which was used to
measure the in vitro release of lidocaine from the NLC gel. As expected, a high amount of lidocaine
released through this membrane over the course of 24 h from both Franz cell types (Figure 4A).
Differences between the Logan and Hanson Franz cell results were not significant, however, a lower
standard deviation was observed with the Hanson method.





Hanson Logan Hanson Logan Hanson Logan
6 h (μg/cm2) 3808.82 ± 448.91 3355.40 ± 320.70 304.20 ± 113.40 514.89 ± 209.69 1778.25 ± 483.81 670.85 ± 189.05 696.32 ± 20.50
6 h (%) 41.35 ± 18.8 27.73 ± 0.83 3.45 ± 1.21 7.72 ± 2.89 11.61 ± 2.95 8.785 ± 2.03 13.93 ± 0.41
24 h (μg/cm2) 8014.05 ± 471.89 6878.13 ± 1172.21 1079.27 ± 304.36 1847.08 ± 335.19 3094.60 ± 829.73 1222.69 ± 358.70 -
24 h (%) 70.40 ± 13.72 58.66 ± 4.28 12.96 ± 3.52 27.89 ± 5.17 19.44 ± 5.05 16.00 ± 3.81 -
Figure 4. In vitro drug diffusion and ex vivo skin penetration studies. (A): In vitro release of lidocaine
through cellulose acetate membrane (24 h); (B): In vitro penetration of lidocaine through Strat-M®
membrane (24 h); (C): Ex vivo penetration of lidocaine through HSE (24 h); (D): Comparison of various
penetration methods with various membranes (6 h). p < 0.05 *, p < 0.01 ** and p < 0.001 *** compared to
each other within each one figure.
The Strat-M® membrane and HSE were skin-like and acted as barriers to API penetration.
Figure 4B shows the penetration of lidocaine via the synthetic Strat-M® membrane, which Figure 4C
shows the penetration via HSE. As for the Strat-M® membrane, differences between the Logan and
Hanson Franz cells were significant after eight hours. Penetration via the HSE was higher than via
168
Pharmaceutics 2019, 11, 310
the Strat-M® membrane, especially on Hanson device over the 24 h. In the case of HSE, differences
between the Logan and Hanson Franz cells were significant from two hours. This significant difference
between the two types of Franz cells can be explained by the difference in structure of the two devices.
The Logan cell was open from above, therefore the measurement runs on atmospheric pressure.
However, the cell of the Hanson device was closed from the top and the pressure is higher leading to
significantly higher penetration. The standard deviation was similar with the two methods. Figure 4D
presents the diffusion/penetration data via the three different membranes (Strat-M®, Skin-PAMPA,
HSE) tested on the Franz cells and Skin-PAMPA system. A lower standard deviation was observed
with the PAMPA model than with the Franz cell method. This may be caused by the diversity in the
membrane structure of the two methods. However, the penetration profiles of the Skin PAMPA and
in vitro and ex vivo Franz cell methods were in good balance. If comparing the results at 6 h, the values
obtained with Logan cells and Skin-PAMPA method were close to each other. Our results demonstrated
that a novel Strat-M® synthetic membrane and the Skin-PAMPA method have the potential to be used
as an early screening tool to select the best dermal lidocaine-loaded nanoformulation.
4. Conclusions
A lidocaine-loaded NLC dispersion and a lidocaine-loaded, NLC gel were formulated to study
their stability at various temperatures and evaluate their in vitro release as well as in vitro and ex vivo
skin penetration. The NLC dispersions were found to be stable at room temperature, with acceptable
changes in particle characteristics, for two days. Microscopic evaluations further verified the stability
of the NLC dispersion at room temperature. It can be concluded that two days is a reasonable time
period to create a gel from this NLC dispersion. The microscopic and rheological measurements
verified that the consistency of the formulation was well suitable for dermal use, and the gel was stable
for at least two weeks at room temperature.
Synthetic membranes are useful tools to examine and determine which formulation is the most
promising for in vivo human skin studies. There are numerous commercial membranes available,
all of which may have different drug diffusion properties. Cellulose membranes were used to study
in vitro drug release, while the Skin-PAMPA membranes and Strat-M® membranes were used for
modeling in vitro skin penetration. Both the Skin-PAMPA and Strat-M® membranes correlated well
with HSE in this study, but the Strat-M® membranes shared the most similar drug permeability
profile to an ex vivo human skin model. Our results can be used to guide formulators in selecting
vehicles in early development in the pharmaceutical, personal care and cosmetic industries. Overall,
researchers must carefully select the most suitable membrane to be used with Franz cells for topical
quality control testing.
Modeling of penetration through the skin is a complex challenge. The drug release profiles of
the LID-NLC gel obtained with the different techniques were not fully equivalent. The device and
the membrane, along with the properties of the product itself, influence how the system can be tested
most effectively. Based on our results, we can select the best in vitro test for modeling human skin
penetration of NLC gel systems, but appropriate in vitro/in vivo correlation should be performed to
calculate the drug release in vivo. Future studies in this field are still needed to explain the influence of
membranes and equipment from other classes on other drug candidates.
Author Contributions: Conceptualization, S.Z. and S.B.; methodology, S.Z. and S.B.; software, M.B.-S.; validation,
A.K.; formal analysis, S.Z. and K.C.; investigation, S.Z. and K.C.; writing—original draft preparation, S.Z.;
writing—review and editing, G.B., E.C.; visualization, A.G.; supervision, S.B. and E.C.
Funding: This research received no external funding.
Acknowledgments: The authors would like to thank Sasol GmbH, Gattefossé and BASF SE for the gift samples.
We are grateful for the financial support of the “GINOP 2.2.1-15-2016-00023” as they have made this article possible.
Conflicts of Interest: The authors declare no conflicts of interest.
169
Pharmaceutics 2019, 11, 310
References
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tool in optimization of drug formulation. Eur. J. Pharm. Sci. 2015, 75, 10–24. [CrossRef]
14. Intarakumhaeng, R.; Alsheddi, L.; Wanasathop, A.; Shi, Z.; Li, S.K. Skin Permeation of Urea Under Finite
Dose Condition. J. Pharm. Sci. 2019, 108, 987–995. [CrossRef]
15. Trombino, S.; Russo, R.; Mellace, S.; Varano, G.P.; Laganà, A.S.; Marcucci, F.; Cassano, R. Solid lipid
nanoparticles made of trehalose monooleate for cyclosporin-A topic release. J. Drug Deliv. Sci. Technol. 2019,
49, 563–569. [CrossRef]
16. Soriano-Ruiz, J.L.; Suñer-Carbó, J.; Calpena-Campmany, A.C.; Bozal-de Febrer, N.; Halbaut-Bellowa, L.;
Boix-Montañés, A.; Souto, E.B.; Clares-Naveros, B. Clotrimazole multiple W/O/W emulsion as anticandidal
agent: Characterization and evaluation on skin and mucosae. Coll. Surf. B Biointerfaces 2019, 175, 166–174.
[CrossRef] [PubMed]
17. Zhang, Y.; Lane, M.E.; Hadgraft, J.; Heinrich, M.; Chen, T.; Lian, G.; Sinko, B. A comparison of the in vitro
permeation of niacinamide in mammalian skin and in the Parallel Artificial Membrane Permeation Assay
(PAMPA) model. Int. J. Pharm. 2019, 556, 142–149. [CrossRef] [PubMed]
18. Montenegro, L.; Castelli, F.; Sarpietro, M. Differential Scanning Calorimetry Analyses of Idebenone-Loaded
Solid Lipid Nanoparticles Interactions with a Model of Bio-Membrane: A Comparison with In Vitro Skin
Permeation Data. Pharmaceuticals 2018, 11, 138. [CrossRef] [PubMed]
19. Dahlizar, S.; Futaki, M.; Okada, A.; Yatomi, C.; Todo, H.; Sugibayashi, K. Combined Use of
N-Palmitoyl-Glycine-Histidine Gel and Several Penetration Enhancers on the Skin Permeation and
Concentration of Metronidazole. Pharmaceutics 2018, 10, 163. [CrossRef] [PubMed]
20. Haq, A.; Goodyear, B.; Ameen, D.; Joshi, V.; Michniak-Kohn, B. Strat-M® synthetic membrane: Permeability
comparison to human cadaver skin. Int. J. Pharm. 2018, 547, 432–437. [CrossRef] [PubMed]
21. Balázs, B. Investigation of the Skin Barrier Function and Transdermal Drug Delivery Techniques. Ph.D. Thesis,
Unviersity of Szeged, Szeged, Hungary, 2016.
22. Simon, A.; Amaro, M.I.; Healy, A.M.; Cabral, L.M.; de Sousa, V.P. Comparative evaluation of rivastigmine
permeation from a transdermal system in the Franz cell using synthetic membranes and pig ear skin with
in vivo-in vitro correlation. Int. J. Pharm. 2016, 512, 234–241. [CrossRef] [PubMed]
170
Pharmaceutics 2019, 11, 310
23. Uchida, T.; Kadhum, W.R.; Kanai, S.; Todo, H.; Oshizaka, T.; Sugibayashi, K. Prediction of skin permeation
by chemical compounds using the artificial membrane, Strat-MTM. Eur. J. Pharm. Sci. 2015, 67, 113–118.
[CrossRef] [PubMed]
24. Kim, K.-T.; Kim, M.-H.; Park, J.-H.; Lee, J.-Y.; Cho, H.-J.; Yoon, I.-S.; Kim, D.-D. Microemulsion-based
hydrogels for enhancing epidermal/dermal deposition of topically administered 20(S)-protopanaxadiol:
In vitro and in vivo evaluation studies. J. Ginseng Res. 2018, 42, 512–523. [CrossRef] [PubMed]
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